-
1
-
-
33947375647
-
Molecular basis of antifolate resistance
-
Assaraf, Y. G. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007, 26, 153-181
-
(2007)
Cancer Metastasis Rev.
, vol.26
, pp. 153-181
-
-
Assaraf, Y.G.1
-
2
-
-
33845691987
-
The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil
-
DOI 10.1002/ijc.22318
-
Jensen, S. A.; Vainer, B.; Sorensen, J. B. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int. J. Cancer 2007, 120, 694-701. (Pubitemid 44969043)
-
(2007)
International Journal of Cancer
, vol.120
, Issue.3
, pp. 694-701
-
-
Jensen, S.A.1
Vainer, B.2
Sorensen, J.B.3
-
3
-
-
0034048729
-
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
-
Salonga, D.; Danenberg, K. D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D. D.; Lenz, H. J.; Leichman, C. G.; Leichman, L.; Diasio, R. B.; Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000, 6, 1322-1327.
-
(2000)
Clin. Cancer Res.
, vol.6
, pp. 1322-1327
-
-
Salonga, D.1
Danenberg, K.D.2
Johnson, M.3
Metzger, R.4
Groshen, S.5
Tsao-Wei, D.D.6
Lenz, H.J.7
Leichman, C.G.8
Leichman, L.9
Diasio, R.B.10
Danenberg, P.V.11
-
4
-
-
0035057872
-
Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan
-
Innocenti, F.; Iyer, L.; Ratain, M. J. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab. Dispos. 2001, 29, 596-600.
-
(2001)
Drug Metab. Dispos.
, vol.29
, pp. 596-600
-
-
Innocenti, F.1
Iyer, L.2
Ratain, M.J.3
-
5
-
-
33847244929
-
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
-
DOI 10.1016/j.bbcan.2006.08.001, PII S0304419X06000503
-
Longley, D. B.; Allen, W. L.; Johnston, P. G. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta. 2006, 1766, 184-196. (Pubitemid 46321456)
-
(2006)
Biochimica et Biophysica Acta - Reviews on Cancer
, vol.1766
, Issue.2
, pp. 184-196
-
-
Longley, D.B.1
Allen, W.L.2
Johnston, P.G.3
-
6
-
-
33745915849
-
Reversal of resistance to oxazaphosphorines
-
Zhang, J.; Tian, Q.; Zhu, Y. Z.; Xu, A. L.; Zhou, S. F. Reversal of resistance to oxazaphosphorines. Curr. Cancer Drug Targets 2006, 6, 385-407.
-
(2006)
Curr. Cancer Drug Targets
, vol.6
, pp. 385-407
-
-
Zhang, J.1
Tian, Q.2
Zhu, Y.Z.3
Xu, A.L.4
Zhou, S.F.5
-
7
-
-
39749098413
-
Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells
-
DOI 10.1080/10428190701824569, PII 790365665
-
Fotoohi, A. K.; Albertioni, F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk. Lymphoma. 2008, 49, 410-426. (Pubitemid 351298325)
-
(2008)
Leukemia and Lymphoma
, vol.49
, Issue.3
, pp. 410-426
-
-
Fotoohi, A.K.1
Albertioni, F.2
-
8
-
-
35448967331
-
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
-
DOI 10.1016/S1470-2045(07)70342-X, PII S147020450770342X
-
Apperley, J. F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8, 1018-1029. (Pubitemid 47629897)
-
(2007)
Lancet Oncology
, vol.8
, Issue.11
, pp. 1018-1029
-
-
Apperley, J.F.1
-
9
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
-
DOI 10.1038/sj.leu.2402741
-
Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosée, P.; Müller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16, 2190-2196. (Pubitemid 35331833)
-
(2002)
Leukemia
, vol.16
, Issue.11
, pp. 2190-2196
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
La Rosee, P.4
Muller, M.C.5
Lahaye, T.6
Hanfstein, B.7
Schoch, C.8
Cross, N.C.P.9
Berger, U.10
Gschaidmeier, H.11
Druker, B.J.12
Hehlmann, R.13
-
10
-
-
18644380835
-
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: Focus on tamoxifen, paclitaxel and imatinib metabolism
-
DOI 10.2165/00003088-200544040-00002
-
Rochat, B. Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, Paclitaxel and imatinib metabolism. Clin. Pharmacokinet. 2005, 44, 349-366. (Pubitemid 40663682)
-
(2005)
Clinical Pharmacokinetics
, vol.44
, Issue.4
, pp. 349-366
-
-
Rochat, B.1
-
11
-
-
0037238805
-
Lessons learned from the irinotecan metabolic pathway
-
Ma, M. K.; McLeod, H. L. Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem. 2003, 10, 41-49
-
(2003)
Curr. Med. Chem.
, vol.10
, pp. 41-49
-
-
Ma, M.K.1
McLeod, H.L.2
-
12
-
-
0034254368
-
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571, diverse mechanisms of resistance
-
Mahon, F. X.; Deininger, M. W.; Schultheis, B.; Chabrol, J.; Reiffers, J.; Goldman, J. M.; Melo, J. V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571, diverse mechanisms of resistance. Blood 2000, 96, 1070-1079.
-
(2000)
Blood
, vol.96
, pp. 1070-1079
-
-
Mahon, F.X.1
Deininger, M.W.2
Schultheis, B.3
Chabrol, J.4
Reiffers, J.5
Goldman, J.M.6
Melo, J.V.7
-
13
-
-
0037130294
-
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1
-
DOI 10.1016/S0925-4439(02)00095-9, PII S0925443902000959
-
Hegedus, T.; Orfi, L.; Seprodi, A.; Váradi, A.; Sarkadi, B.; Kéri, G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 2002, 1587, 318-325. (Pubitemid 34655800)
-
(2002)
Biochimica et Biophysica Acta - Molecular Basis of Disease
, vol.1587
, Issue.2-3
, pp. 318-325
-
-
Hegedus, T.1
Orfi, L.2
Seprodi, A.3
Varadi, A.4
Sarkadi, B.5
Keri, G.6
-
14
-
-
1542713480
-
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate
-
DOI 10.1038/sj.leu.2403257
-
Illmer, T.; Schaich, M.; Platzbecker, U.; Freiberg-Richter, J.; Oelschlagel, U.; von Bonin, M.; Pursche, S.; Bergemann, T.; Ehninger, G.; Schleyer, E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004, 18, 401-408. (Pubitemid 38425851)
-
(2004)
Leukemia
, vol.18
, Issue.3
, pp. 401-408
-
-
Illmer, T.1
Schaich, M.2
Platzbecker, U.3
Freiberg-Richter, J.4
Oelschlagel, U.5
Von Bonin, M.6
Pursche, S.7
Bergemann, T.8
Ehninger, G.9
Schleyer, E.10
-
15
-
-
2442638937
-
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
-
DOI 10.1124/mol.65.6.1485
-
Ozvegy-Laczka, C.; Hegedus, T.; Várady, G.; Ujhelly, O.; Schuetz, J. D.; Váradi, A.; Kéri, G.; Orfi, L.; Német, K.; Sarkadi, B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 2004, 65, 1485-1495. (Pubitemid 38668306)
-
(2004)
Molecular Pharmacology
, vol.65
, Issue.6
, pp. 1485-1495
-
-
Ozvegy-Laczka, C.1
Hegedus, T.2
Varady, G.3
Ujhelly, O.4
Schuetz, J.D.5
Varadi, A.6
Keri, G.7
Orfi, L.8
Nemet, K.9
Sarkadi, B.10
-
16
-
-
18344396578
-
Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571
-
Le Coutre, P.; Kreuzer, K. A.; Il-Kang, N. A. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cell Mol. 2002, 28, 75-85.
-
(2002)
Blood Cell Mol.
, vol.28
, pp. 75-85
-
-
Le Coutre, P.1
Kreuzer, K.A.2
Il-Kang, N.A.3
-
17
-
-
0034684075
-
+ leukemic cells to the Abl inhibitor STI571
-
Gambacorti-Passerini, C.; Barni, R.; le Coutre, P.; Zucchetti, M.; Cabrita, G.; Cleris, L.; Rossi, F.; Gianazza, E.; Brueggen, J.; Cozens, R.; Pioltelli, P.; Pogliani, E.; Corneo, G.; Formelli, F.; D'Incalci, M. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J. Natl. Cancer Inst. 2000, 92, 1641-1650. (Pubitemid 30807644)
-
(2000)
Journal of the National Cancer Institute
, vol.92
, Issue.20
, pp. 1641-1650
-
-
Gambacorti-Passerini, C.1
Barni, R.2
Le Coutre, P.3
Zucchetti, M.4
Cabrita, G.5
Cleris, L.6
Rossi, F.7
Gianazza, E.8
Brueggen, J.9
Cozens, R.10
Pioltelli, P.11
Pogliani, E.12
Corneo, G.13
Formelli, F.14
D'Incalci, M.15
-
18
-
-
10744232038
-
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo
-
DOI 10.1016/S0006-2952(03)00469-6
-
Larghero, J.; Leguay, T.; Mourah, S.; Madelaine-Chambrin, I.; Taksin, A.L.; Raffoux, E.; Bastie, J. N.; Degos, L.; Berthaud, P.; Marolleau, J. P.; Calvo, F.; Chomienne, C.; Mahon, F. X.; Rousselot, P. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem. Pharmacol. 2003, 66, 1907-1913. (Pubitemid 37352853)
-
(2003)
Biochemical Pharmacology
, vol.66
, Issue.10
, pp. 1907-1913
-
-
Larghero, J.1
Leguay, T.2
Mourah, S.3
Madelaine-Chambrin, I.4
Taksin, A.-L.5
Raffoux, E.6
Bastie, J.-N.7
Degos, L.8
Berthaud, P.9
Marolleau, J.-P.10
Calvo, F.11
Chomienne, C.12
Mahon, F.-X.13
Rousselot, P.14
-
19
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002, 2, 117-125.
-
(2002)
Cancer Cell.
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
Gorre, M.E.4
Paquette, R.L.5
Kuriyan, J.6
Sawyers, C.L.7
-
20
-
-
0036678472
-
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
-
Roumiantsev, S.; Shah, N. P.; Gorre, M. E.; Nicoll, J.; Brasher, B. B.; Sawyers, C. L.; Van Etten, R. A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA 2002, 99, 10700-10705.
-
(2002)
Proc. Natl. Acad. Sci. USA
, vol.99
, pp. 10700-10705
-
-
Roumiantsev, S.1
Shah, N.P.2
Gorre, M.E.3
Nicoll, J.4
Brasher, B.B.5
Sawyers, C.L.6
Van Etten, R.A.7
-
21
-
-
0036493544
-
+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
-
DOI 10.1182/blood.V99.5.1860
-
Hofmann, W. K.; Jones, L. C.; Lemp, N. A.; de Vos, S.; Gschaidmeier, H.; Hoelzer, D.; Ottmann, O. G.; Koeffler, H. P. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99, 1860-1862. (Pubitemid 34533064)
-
(2002)
Blood
, vol.99
, Issue.5
, pp. 1860-1862
-
-
Hofmann, W.-K.1
Jones, L.C.2
Lemp, N.A.3
De Vos, S.4
Gschaidmeier, H.5
Hoelzer, D.6
Ottmann, O.G.7
Phillip Koeffler, H.8
-
22
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293, 876-880.
-
(2001)
Science
, vol.293
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
Hsu, N.4
Paquette, R.5
Rao, P.N.6
Sawyers, C.L.7
-
23
-
-
0037045583
-
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study
-
DOI 10.1016/S0140-6736(02)07679-1
-
von Bubnoff, N.; Schneller, F.; Peschel, C.; Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002, 359, 487-491. (Pubitemid 34164296)
-
(2002)
Lancet
, vol.359
, Issue.9305
, pp. 487-491
-
-
Von Bubnoff, N.1
Schneller, F.2
Peschel, C.3
Duyster, J.4
-
24
-
-
0036566540
-
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
-
DOI 10.1182/blood.V99.9.3472
-
Branford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K. P.; Hughes, T. P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99, 3472-3475. (Pubitemid 34525335)
-
(2002)
Blood
, vol.99
, Issue.9
, pp. 3472-3475
-
-
Branford, S.1
Rudzki, Z.2
Walsh, S.3
Grigg, A.4
Arthur, C.5
Taylor, K.6
Herrmann, R.7
Lynch, K.P.8
Hughes, T.P.9
-
25
-
-
33750344192
-
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib [10]
-
DOI 10.1038/sj.leu.2404400, PII 2404400
-
Gruber, F. X.; Hjorth-Hansen, H.; Mikkola, I.; Stenke, L.; Johansen, T. A novel BCR-ABL splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia 2006, 20, 2057-2060. (Pubitemid 44614904)
-
(2006)
Leukemia
, vol.20
, Issue.11
, pp. 2057-2060
-
-
Gruber, F.X.1
Hjorth-Hansen, H.2
Mikkola, I.3
Stenke, L.4
Johansen, T.5
-
26
-
-
34247644944
-
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
-
DOI 10.3324/haematol.10822
-
Soverini, S.; Colarossi, S.; Gnani, A.; Castagnetti, F.; Rosti, G.; Bosi, C.; Paolini, S.; Rondoni, M.; Piccaluga, P. P.; Palandri, F.; Giannoulia, P.; Marzocchi, G.; Luatti, S.; Testoni, N.; Iacobucci, I.; Cilloni, D.; Saglio, G.; Baccarani, M.; Martinelli, G. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007, 92, 401-404. (Pubitemid 350143551)
-
(2007)
Haematologica
, vol.92
, Issue.3
, pp. 401-404
-
-
Soverini, S.1
Colarossi, S.2
Gnani, A.3
Castagnetti, F.4
Rosti, G.5
Bosi, C.6
Paolini, S.7
Rondoni, M.8
Piccaluga, P.P.9
Palandri, F.10
Giannoulia, P.11
Marzocchi, G.12
Luatti, S.13
Testoni, N.14
Iacobucci, I.15
Cilloni, D.16
Saglio, G.17
Baccarani, M.18
Martinelli, G.19
-
27
-
-
34548830437
-
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia [28] Burchert, A. Roots of imatinib resistance: A question of selfrenewal?
-
Donato, N. J.; Wu, J. Y.; Stapley, J.; Gallick, G.; Lin, H.; Arlinghaus, R.; Talpaz, M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia [28] Burchert, A. Roots of imatinib resistance: A question of selfrenewal? Drug Resist. Updat. 2007, 10, 152-161.
-
(2007)
Drug Resist. Updat.
, vol.10
, pp. 152-161
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
Gallick, G.4
Lin, H.5
Arlinghaus, R.6
Talpaz, M.7
-
28
-
-
0035949485
-
Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy
-
DOI 10.1073/pnas.201398998
-
Duesberg, P.; Stindl, R.; Hehlmann, R. Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc. Natl. Acad. Sci. USA 2001, 98, 11283-11288. (Pubitemid 32928720)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.20
, pp. 11283-11288
-
-
Duesberg, P.1
Stindl, R.2
Hehlmann, R.3
-
29
-
-
2342647429
-
Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene
-
Janssen, J. J.; Hochhaus, A.; van Oostveen, J. W.; Waisfisz, Q.; Schuurhuis, G. J.; Ossenkoppele, G. J. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene. Leukemia 2004, 18, 1020-1021.
-
(2004)
Leukemia
, vol.18
, pp. 1020-1021
-
-
Janssen, J.J.1
Hochhaus, A.2
Van Oostveen, J.W.3
Waisfisz, Q.4
Schuurhuis, G.J.5
Ossenkoppele, G.J.6
-
30
-
-
34547433234
-
Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations
-
DOI 10.1073/pnas.0700631104
-
Gao, C.; Furge, K.; Koeman, J.; Dykema, K.; Su, Y.; Cutler, M. L.; Werts, A.; Haak, P.; Vande Woude, G. F. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc. Natl. Acad. Sci. USA 2007, 104, 8995-9000. (Pubitemid 47175425)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.21
, pp. 8995-9000
-
-
Gao, C.1
Furge, K.2
Koeman, J.3
Dykema, K.4
Su, Y.5
Cutler, M.L.6
Werts, A.7
Haak, P.8
Vande Woude, G.F.9
-
31
-
-
2442551051
-
Chromosomal instability
-
Gollin, S. M. Chromosomal instability. Curr. Opin. Oncol. 2004, 16, 25-31.
-
(2004)
Curr. Opin. Oncol.
, vol.16
, pp. 25-31
-
-
Gollin, S.M.1
-
32
-
-
43049183136
-
Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia
-
DOI 10.1016/j.cancergencyto.2008.01.024, PII S0165460808001404
-
Yamamoto, K.; Yakushijin, K.; Nishikawa, S.; Minagawa, K.; Katayama, Y.; Shimoyama, M.; Matsui, T. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia. Cancer Genet. Cytogenet. 2008, 183, 77-81. (Pubitemid 351636130)
-
(2008)
Cancer Genetics and Cytogenetics
, vol.183
, Issue.1
, pp. 77-81
-
-
Yamamoto, K.1
Yakushijin, K.2
Nishikawa, S.3
Minagawa, K.4
Katayama, Y.5
Shimoyama, M.6
Matsui, T.7
-
33
-
-
35648999534
-
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies
-
Mimeault, M.; Hauke, R.; Batra, S. K. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther. 2007, 11, 981-1011.
-
(2007)
Clin. Pharmacol. Ther.
, vol.11
, pp. 981-1011
-
-
Mimeault, M.1
Hauke, R.2
Batra, S.K.3
-
34
-
-
35748981505
-
Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells
-
DOI 10.1080/10245330701384179, PII 779749476
-
Baran, Y.; Ural, A. U.; Gunduz, U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007, 12, 497-503. (Pubitemid 350048059)
-
(2007)
Hematology
, vol.12
, Issue.6
, pp. 497-503
-
-
Baran, Y.1
Ural, A.U.2
Gunduz, U.3
-
35
-
-
43749123266
-
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells
-
DOI 10.1038/leu.2008.95, PII LEU200895
-
Bonhoure, E.; Lauret, A.; Barnes, D. J.; Martin, C.; Malavaud, B.; Kohama, T.; Melo, J. V.; Cuvillier O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008, 2, 971-979. (Pubitemid 351689879)
-
(2008)
Leukemia
, vol.22
, Issue.5
, pp. 971-979
-
-
Bonhoure, E.1
Lauret, A.2
Barnes, D.J.3
Martin, C.4
Malavaud, B.5
Kohama, T.6
Melo, J.V.7
Cuvillier, O.8
-
36
-
-
46749095012
-
A role for ceramide in driving cancer cell resistance to doxorubicin
-
Liu, Y. Y.; Yu, J. Y.; Yin, D.; Patwardhan, G. A.; Gupta, V.; Hirabayashi, Y.; Holleran, W. M.; Giuliano, A. E.; Jazwinski, S. M.; Gouaze-Andersson, V.; Consoli, D. P.; Cabot, M. C. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 2008, 22, 2541-2551.
-
(2008)
FASEB J.
, vol.22
, pp. 2541-2551
-
-
Liu, Y.Y.1
Yu, J.Y.2
Yin, D.3
Patwardhan, G.A.4
Gupta, V.5
Hirabayashi, Y.6
Holleran, W.M.7
Giuliano, A.E.8
Jazwinski, S.M.9
Gouaze-Andersson, V.10
Consoli, D.P.11
Cabot, M.C.12
-
37
-
-
34248166041
-
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
-
Nam, S.; Williams, A.; Vultur, A.; List, A.; Bhalla, K.; Smith, D.; Lee, F. Y.; Jove, R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 2007, 6, 1400-1405.
-
(2007)
Mol. Cancer Ther.
, vol.6
, pp. 1400-1405
-
-
Nam, S.1
Williams, A.2
Vultur, A.3
List, A.4
Bhalla, K.5
Smith, D.6
Lee, F.Y.7
Jove, R.8
-
38
-
-
34548412863
-
+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation
-
DOI 10.1124/mol.106.033308
-
Rahmani, M.; Nguyen, T. K.; Dent, P.; Grant, S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol. Pharmacol. 2007, 72, 788-795. (Pubitemid 47351213)
-
(2007)
Molecular Pharmacology
, vol.72
, Issue.3
, pp. 788-795
-
-
Rahmani, M.1
Nguyen, T.K.2
Dent, P.3
Grant, S.4
-
39
-
-
21144459060
-
Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors
-
Jiang, J. G.; Chen, C. L.; Card, J. W.; Yang, S.; Chen, J. X.; Fu, X. N.; Ning, Y. G.; Xiao, X.; Zeldin, D. C.; Wang, D.W. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005, 65, 4707-4715.
-
(2005)
Cancer Res.
, vol.65
, pp. 4707-4715
-
-
Jiang, J.G.1
Chen, C.L.2
Card, J.W.3
Yang, S.4
Chen, J.X.5
Fu, X.N.6
Ning, Y.G.7
Xiao, X.8
Zeldin, D.C.9
Wang, D.W.10
-
40
-
-
34547092185
-
Cytochrome p450 epoxygenase promotes human cancer metastasis
-
Jiang, J. G.; Ning, Y. G.; Chen, C.; Ma, D.; Liu, Z. J.; Yang, S.; Zhou, J.; Xiao, X.; Zhang, X. A.; Edin, M. L.; Card, J.W.; Wang, J.; Zeldin, D.C.; Wang, D.W. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 2007, 67, 6665-6674.
-
(2007)
Cancer Res.
, vol.67
, pp. 6665-6674
-
-
Jiang, J.G.1
Ning, Y.G.2
Chen, C.3
Ma, D.4
Liu, Z.J.5
Yang, S.6
Zhou, J.7
Xiao, X.8
Zhang, X.A.9
Edin, M.L.10
Card, J.W.11
Wang, J.12
Zeldin, D.C.13
Wang, D.W.14
-
41
-
-
0142227047
-
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate
-
Tipping, A. J.; Deininger, M. W.; Goldman, J. M.; Melo, J. V. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp. Hematol. 2003, 31, 1073-1080.
-
(2003)
Exp. Hematol.
, vol.31
, pp. 1073-1080
-
-
Tipping, A.J.1
Deininger, M.W.2
Goldman, J.M.3
Melo, J.V.4
-
42
-
-
34249737950
-
Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells
-
DOI 10.1074/jbc.M610157200
-
Baran, Y.; Salas, A.; Senkal, C. E.; Gunduz, U.; Bielawski, J.; Obeid, L. M.; Ogretmen, B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem. 2007, 282, 10922-10934. (Pubitemid 47100788)
-
(2007)
Journal of Biological Chemistry
, vol.282
, Issue.15
, pp. 10922-10934
-
-
Baran, Y.1
Salas, A.2
Senkal, C.E.3
Gunduz, U.4
Bielawski, J.5
Obeid, L.M.6
Ogretmen, B.7
-
43
-
-
40849126769
-
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells
-
Sugimoto, Y.; Nakamura, S.; Okinaka, K.; Hirano, I.; Ono, T.; Shigeno, K.; Shinjo, K.; Ohnishi, K. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. Leuk. Res. 2008, 32, 962-971
-
(2008)
Leuk. Res.
, vol.32
, pp. 962-971
-
-
Sugimoto, Y.1
Nakamura, S.2
Okinaka, K.3
Hirano, I.4
Ono, T.5
Shigeno, K.6
Shinjo, K.7
Ohnishi, K.8
-
44
-
-
4344715880
-
Prognostic and predictive markers in cancer
-
Conley, B. A.; Taube, S. E. Prognostic and predictive markers in cancer. Dis. Markers. 2004, 20, 35-43. (Pubitemid 39149913)
-
(2004)
Disease Markers
, vol.20
, Issue.2
, pp. 35-43
-
-
Conley, B.A.1
Taube, S.E.2
-
45
-
-
12144289310
-
Changes Associated with the Development of Resistance to Imatinib (STI571) in Two Leukemia Cell Lines Expressing p210 Bcr/Abl Protein
-
DOI 10.1002/cncr.20131
-
Scappini, B.; Gatto, S.; Onida, F.; Ricci, C.; Divoky, V.; Wierda, W. G.; Andreeff, M.; Dong, L.; Hayes, K.; Verstovsek, S.; Kantarjian, H. M.; Beran, M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 2004, 100, 1459-1471. (Pubitemid 38366849)
-
(2004)
Cancer
, vol.100
, Issue.7
, pp. 1459-1471
-
-
Scappini, B.1
Gatto, S.2
Onida, F.3
Ricci, C.4
Divoky, V.5
Wierda, W.G.6
Andreeff, M.7
Dong, L.8
Hayes, K.9
Verstovsek, S.10
Kantarjian, H.M.11
Beran, M.12
-
46
-
-
33750577939
-
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
-
Shanafelt, T. D.; Witzig, T. E.; Fink, S. R.; Jenkins, R. B.; Paternoster, S. F.; Smoley, S. A.; Stockero, K. J.; Nast, D. M.; Flynn, H. C.; Tschumper, R. C.; Geyer, S.; Zent, C. S.; Call, T. G.; Jelinek, D. F.; Kay, N. E.; Dewald, G. W. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J. Clin. Oncol. 2006, 24, 4634-4641.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 4634-4641
-
-
Shanafelt, T.D.1
Witzig, T.E.2
Fink, S.R.3
Jenkins, R.B.4
Paternoster, S.F.5
Smoley, S.A.6
Stockero, K.J.7
Nast, D.M.8
Flynn, H.C.9
Tschumper, R.C.10
Geyer, S.11
Zent, C.S.12
Call, T.G.13
Jelinek, D.F.14
Kay, N.E.15
Dewald, G.W.16
-
47
-
-
0037108879
-
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin
-
Nimmanapalli, R.; O'Bryan, E.; Huang, M.; Bali, P.; Burnette, P. K.; Loughran, T.; Tepperberg, J.; Jove, R.; Bhalla, K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002, 60, 5761-5769. (Pubitemid 35204733)
-
(2002)
Cancer Research
, vol.62
, Issue.20
, pp. 5761-5769
-
-
Nimmanapalli, R.1
O'Bryan, E.2
Huang, M.3
Bali, P.4
Burnette, P.K.5
Loughran, T.6
Tepperberg, J.7
Jove, R.8
Bhalla, K.9
-
48
-
-
9144234689
-
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
-
DOI 10.1158/0008-5472.CAN-03-1484
-
Donato, N. J.; Wu, J. Y.; Stapley, J.; Lin, H.; Arlinghaus, R.; Aggarwal, B. B.; Shishodia, S.; Albitar, M.; Hayes, K.; Kantarjian, H.; Talpaz, M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64, 672-677. (Pubitemid 38120909)
-
(2004)
Cancer Research
, vol.64
, Issue.2
, pp. 672-677
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
Lin, H.4
Arlinghaus, R.5
Aggarwal, B.6
Shishodin, S.7
Albitar, M.8
Hayes, K.9
Kantarjian, H.10
Talpaz, M.11
-
49
-
-
33845311843
-
Human cancers express a mutator phenotype
-
Bielas, J. H.; Loeb, K. R.; Rubin, B. P.; True, L. D.; Loeb, L. A. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. USA 2006, 103, 18238-18242.
-
(2006)
Proc. Natl. Acad. Sci. USA
, vol.103
, pp. 18238-18242
-
-
Bielas, J.H.1
Loeb, K.R.2
Rubin, B.P.3
True, L.D.4
Loeb, L.A.5
-
50
-
-
33846168450
-
Genomic mechanisms and measurement of structural and numerical instability in cancer cells
-
Bayani, J.; Selvarajah, S.; Maire, G.; Vukovic, B.; Al-Romaih, K.; Zielenska, M.; Squire, J. A. Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin. Cancer Biol. 2007, 17, 5-18.
-
(2007)
Semin. Cancer Biol.
, vol.17
, pp. 5-18
-
-
Bayani, J.1
Selvarajah, S.2
Maire, G.3
Vukovic, B.4
Al-Romaih, K.5
Zielenska, M.6
Squire, J.A.7
-
51
-
-
34247387973
-
Cancer drug resistance: The central role of the karyotype
-
DOI 10.1016/j.drup.2007.02.003, PII S1368764607000076
-
Duesberg, P.; Li, R.; Sachs, R.; Fabarius, A.; Upender, M. B.; Hehlmann, R. Cancer drug resistance, the central role of the karyotype. Drug Resist. Updat. 2007, 10, 51-58. (Pubitemid 46636382)
-
(2007)
Drug Resistance Updates
, vol.10
, Issue.1-2
, pp. 51-58
-
-
Duesberg, P.1
Li, R.2
Sachs, R.3
Fabarius, A.4
Upender, M.B.5
Hehlmann, R.6
-
52
-
-
34247391483
-
Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs
-
DOI 10.1016/j.drup.2007.02.002, PII S1368764607000064
-
Fojo, T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist. Updat. 2007, 10, 59-67. (Pubitemid 46656478)
-
(2007)
Drug Resistance Updates
, vol.10
, Issue.1-2
, pp. 59-67
-
-
Fojo, T.1
-
53
-
-
33749993417
-
The consensus coding sequences of human breast and colorectal cancers
-
DOI 10.1126/science.1133427
-
Sjöblom, T.; Jones, S.; Wood, L. D.; Parsons, D. W.; Lin, J.; Barber, T. D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N.; Szabo, S.; Buckhaults, P.; Farrell, C.; Meeh, P.; Markowitz, S.D.; Willis, J.; Dawson, D.; Willson, J. K.; Gazdar, A. F.; Hartigan, J.; Wu, L.; Liu, C.; Parmigiani, G.; Park, B. H.; Bachman, K. E.; Papadopoulos, N.; Vogelstein, B.; Kinzler, K. W.; Velculescu, V. E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274. (Pubitemid 44571966)
-
(2006)
Science
, vol.314
, Issue.5797
, pp. 268-274
-
-
Sjoblom, T.1
Jones, S.2
Wood, L.D.3
Parsons, D.W.4
Lin, J.5
Barber, T.D.6
Mandelker, D.7
Leary, R.J.8
Ptak, J.9
Silliman, N.10
Szabo, S.11
Buckhaults, P.12
Farrell, C.13
Meeh, P.14
Markowitz, S.D.15
Willis, J.16
Dawson, D.17
Willson, J.K.V.18
Gazdar, A.F.19
Hartigan, J.20
Wu, L.21
Liu, C.22
Parmigiani, G.23
Park, B.H.24
Bachman, K.E.25
Papadopoulos, N.26
Vogelstein, B.27
Kinzler, K.W.28
Velculescu, V.E.29
more..
-
54
-
-
33748122556
-
Cancer-linked DNA hypomethylation and its relationship to hypermethylation
-
DNA Methylation: Development, Genetic Disease and Cancer
-
Ehrlich, M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr. Top. Microbiol. Immunol. 2006, 310, 251-274. (Pubitemid 47400293)
-
(2006)
Current Topics in Microbiology and Immunology
, vol.310
, pp. 251-274
-
-
Ehrlich, M.1
-
55
-
-
33845237644
-
RNAi, microRNAs, and human disease
-
Hammond, S. M. RNAi, microRNAs, and human disease. Cancer Chemother. Pharmacol. 2006, 58, 63-68.
-
(2006)
Cancer Chemother. Pharmacol.
, vol.58
, pp. 63-68
-
-
Hammond, S.M.1
-
56
-
-
33749487425
-
MicroRNA regulates the expression of human cytochrome P450 1B1
-
DOI 10.1158/0008-5472.CAN-06-1403
-
Tsuchiya, Y.; Nakajima, M.; Takagi, S.; Taniya, T.; Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006, 66, 9090-9098. (Pubitemid 44521128)
-
(2006)
Cancer Research
, vol.66
, Issue.18
, pp. 9090-9098
-
-
Tsuchiya, Y.1
Nakajima, M.2
Takagi, S.3
Taniya, T.4
Yokoi, T.5
-
57
-
-
35348992096
-
Investigation of MicroRNA Alterations in Leukemias and Lymphomas
-
Calin, G. A.; Croce, C. M. Investigation of MicroRNA Alterations in Leukemias and Lymphomas. Methods Enzymol. 2007, 427, 191-213.
-
(2007)
Methods Enzymol.
, vol.427
, pp. 191-213
-
-
Calin, G.A.1
Croce, C.M.2
-
58
-
-
34748887189
-
Epigenetic remodelling of DNA in cancer
-
Lettini, A. A.; Guidoboni, M.; Fonsatti, E.; Anzalone, L.; Cortini, E.; Maio, M. Epigenetic remodelling of DNA in cancer. Histol. Histopathol. 2007, 22, 1413-1424.
-
(2007)
Histol. Histopathol.
, vol.22
, pp. 1413-1424
-
-
Lettini, A.A.1
Guidoboni, M.2
Fonsatti, E.3
Anzalone, L.4
Cortini, E.5
Maio, M.6
-
59
-
-
33846401539
-
Molecular mechanisms of metabolic resistance to synthetic and natural xenobiotics
-
Li, X.; Schuler, M. A.; Berenbaum, M. R. Molecular mechanisms of metabolic resistance to synthetic and natural xenobiotics. Annu. Rev. Entomol. 2007, 52, 231-253.
-
(2007)
Annu. Rev. Entomol.
, vol.52
, pp. 231-253
-
-
Li, X.1
Schuler, M.A.2
Berenbaum, M.R.3
-
60
-
-
21344453004
-
Pharmacogenetics for individualized cancer chemotherapy
-
Efferth, T.; Volm, M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. 2005, 107, 155-176.
-
(2005)
Pharmacol. Ther.
, vol.107
, pp. 155-176
-
-
Efferth, T.1
Volm, M.2
-
61
-
-
18844409128
-
Predicting drug response and toxicity based on gene polymorphisms
-
DOI 10.1016/j.critrevonc.2005.01.005, PII S1040842805000314
-
Robert, J.; Morvan, V. L.; Smith, D.; Pourquier, P.; Bonnet, J. Predicting drug response and toxicity based on gene polymorphisms. Crit. Rev. Oncol. Hematol. 2005, 54, 171-196 (Pubitemid 40693684)
-
(2005)
Critical Reviews in Oncology/Hematology
, vol.54
, Issue.3
, pp. 171-196
-
-
Robert, J.1
Le Morvan, V.2
Smith, D.3
Pourquier, P.4
Bonnet, J.5
-
62
-
-
20144388183
-
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up
-
Lahaye, T.; Riehm, B.; Berger, U.; Paschka, P.; Muller, M. C.; Kreil, S.; Merx, K.; Schwindel, U.; Schoch, C.; Hehlmann, R.; Hochhaus, A. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005, 103, 1659-1669.
-
(2005)
Cancer
, vol.103
, pp. 1659-1669
-
-
Lahaye, T.1
Riehm, B.2
Berger, U.3
Paschka, P.4
Muller, M.C.5
Kreil, S.6
Merx, K.7
Schwindel, U.8
Schoch, C.9
Hehlmann, R.10
Hochhaus, A.11
-
63
-
-
42049122204
-
New therapeutic approaches and prognostic factors in chronic myeloid leukaemia
-
Saglio, G.; Ulisciani, S.; Bosa, M.; Cilloni, D.; Rege-Cambrin, G. New therapeutic approaches and prognostic factors in chronic myeloid leukaemia. Leuk. Lymphoma 2008, 49, 625-628.
-
(2008)
Leuk. Lymphoma
, vol.49
, pp. 625-628
-
-
Saglio, G.1
Ulisciani, S.2
Bosa, M.3
Cilloni, D.4
Rege-Cambrin, G.5
-
64
-
-
42049086836
-
BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts
-
Skorski, T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk. Lymphoma 2008, 49, 610-614.
-
(2008)
Leuk. Lymphoma
, vol.49
, pp. 610-614
-
-
Skorski, T.1
-
65
-
-
40249100997
-
Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation
-
DOI 10.1016/j.leukres.2007.09.005, PII S014521260700344X
-
Montiel-Duarte, C.; Cordeu, L.; Agirre, X.; Román-Gómez, J.; Jiménez-Velasco, A.; José-Eneriz, E. S.; Gárate, L.; Andreu, E. J.; Calasanz, M. J.; Heiniger, A.; Torres, A.; Prósper, F. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk. Res. 2008, 32, 709-716. (Pubitemid 351330173)
-
(2008)
Leukemia Research
, vol.32
, Issue.5
, pp. 709-716
-
-
Montiel-Duarte, C.1
Cordeu, L.2
Agirre, X.3
Roman-Gomez, J.4
Jimenez-Velasco, A.5
Jose-Eneriz, E.S.6
Garate, L.7
Andreu, E.J.8
Calasanz, M.J.9
Heiniger, A.10
Torres, A.11
Prosper, F.12
-
66
-
-
0345688603
-
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias
-
DOI 10.1038/sj.onc.1206942, Drug Resistance
-
Shah, N. P.; Sawyers, C. L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003, 22, 7389-7395. (Pubitemid 37487164)
-
(2003)
Oncogene
, vol.22
, Issue.47 REV. ISS. 6
, pp. 7389-7395
-
-
Shah, N.P.1
Sawyers, C.L.2
-
67
-
-
33750613947
-
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele
-
Anand, M.; Khorashad, J.; Marin, D.; Apperley, J. F.; Goldman, J. M.; Kaeda, J. S. Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele. Blood 2006, 108, 2881-2882.
-
(2006)
Blood
, vol.108
, pp. 2881-2882
-
-
Anand, M.1
Khorashad, J.2
Marin, D.3
Apperley, J.F.4
Goldman, J.M.5
Kaeda, J.S.6
-
68
-
-
41349085814
-
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
-
Khorashad, J. S.; Milojkovic, D.; Mehta, P.; Anand, M.; Ghorashian, S.; Reid, A. G.; De Melo, V.; Babb, A.; de Lavallade, H.; Olavarria, E.; Marin, D.; Goldman, J. M.; Apperley, J. F.; Kaeda, J. S. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008, 111, 2378-2381.
-
(2008)
Blood
, vol.111
, pp. 2378-2381
-
-
Khorashad, J.S.1
Milojkovic, D.2
Mehta, P.3
Anand, M.4
Ghorashian, S.5
Reid, A.G.6
De Melo, V.7
Babb, A.8
De Lavallade, H.9
Olavarria, E.10
Marin, D.11
Goldman, J.M.12
Apperley, J.F.13
Kaeda, J.S.14
-
69
-
-
10744232328
-
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
-
DOI 10.1182/blood-2002-09-2896
-
Branford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Herrmann, R.; Seymour, J.F.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance.; and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102, 276-283. (Pubitemid 36759665)
-
(2003)
Blood
, vol.102
, Issue.1
, pp. 276-283
-
-
Branford, S.1
Rudzki, Z.2
Walsh, S.3
Parkinson, I.4
Grigg, A.5
Szer, J.6
Taylor, K.7
Herrmann, R.8
Seymour, J.F.9
Arthur, C.10
Joske, D.11
Lynch, K.12
Hughes, T.13
-
70
-
-
1342287959
-
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
-
Al-Ali, H. K.; Heinrich, M. C.; Lange, T.; Krahl, R.; Mueller, M.; Muller, C.; Niederwieser, D.; Druker, B. J.; Deininger, M. W. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol. J. 2004, 5, 55-60.
-
(2004)
Hematol. J.
, vol.5
, pp. 55-60
-
-
Al-Ali, H.K.1
Heinrich, M.C.2
Lange, T.3
Krahl, R.4
Mueller, M.5
Muller, C.6
Niederwieser, D.7
Druker, B.J.8
Deininger, M.W.9
-
71
-
-
33846228789
-
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
-
DOI 10.1158/1078-0432.CCR-06-1516
-
Soverini, S.; Colarossi, S.; Gnani, A.; Rosti, G.; Castagnetti, F.; Poerio, A.; Iacobucci, I.; Amabile, M.; Abruzzese, E.; Orlandi, E.; Radaelli, F.; Ciccone, F.; Tiribelli, M.; di Lorenzo, R.; Caracciolo, C.; Izzo, B.; Pane, F.; Saglio, G.; Baccarani, M.; Martinelli, G. GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 2006, 12, 7374-17349 (Pubitemid 46095411)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.24
, pp. 7374-7379
-
-
Soverini, S.1
Colarossi, S.2
Gnani, A.3
Rosti, G.4
Castagnetti, F.5
Poerio, A.6
Iacobucci, I.7
Amabile, M.8
Abruzzese, E.9
Orlandi, E.10
Radaelli, F.11
Ciccone, F.12
Tiribelli, M.13
Di Lorenzo, R.14
Caracciolo, C.15
Izzo, B.16
Pane, F.17
Saglio, G.18
Baccarani, M.19
Martinelli, G.20
more..
-
72
-
-
33847191776
-
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
-
Sherbenou, D. W.; Wong, M. J.; Humayun, A.; McGreevey, L. S.; Harrell, P.; Yang, R.; Mauro, M.; Heinrich, M. C.; Press, R. D.; Druker, B. J.; Deininger, M. W. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007, 21, 489-499
-
(2007)
Leukemia
, vol.21
, pp. 489-499
-
-
Sherbenou, D.W.1
Wong, M.J.2
Humayun, A.3
McGreevey, L.S.4
Harrell, P.5
Yang, R.6
Mauro, M.7
Heinrich, M.C.8
Press, R.D.9
Druker, B.J.10
Deininger, M.W.11
-
73
-
-
24644523246
-
Resistance to tyrosine kinase inhibitors: Calling on extra forces
-
DOI 10.1016/j.drup.2005.04.005, PII S1368764605000312
-
Cools, J.; Maertens, C.; Marynen, P. Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist. Updat. 2005, 8, 119-129. (Pubitemid 41267063)
-
(2005)
Drug Resistance Updates
, vol.8
, Issue.3
, pp. 119-129
-
-
Cools, J.1
Maertens, C.2
Marynen, P.3
-
74
-
-
40849105148
-
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
-
Ernst, T.; Erben, P.; Muller, M. C.; Paschka, P.; Schenk, T.; Hoffmann, J.; Kreil, S.; La Rosee, P.; Hehlmann, R.; Hochhaus, A. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008, 93, 186-192.
-
(2008)
Haematologica
, vol.93
, pp. 186-192
-
-
Ernst, T.1
Erben, P.2
Muller, M.C.3
Paschka, P.4
Schenk, T.5
Hoffmann, J.6
Kreil, S.7
La Rosee, P.8
Hehlmann, R.9
Hochhaus, A.10
-
75
-
-
29244436704
-
BCR-ABL kinase domain mutations in chronic myeloid leukemia: Not quite enough to cause resistance to imatinib therapy?
-
Lange, T.; Park, B.; Willis, S. G.; Deininger, M. W. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 2005, 4, 1761-1766.
-
(2005)
Cell Cycle
, vol.4
, pp. 1761-1766
-
-
Lange, T.1
Park, B.2
Willis, S.G.3
Deininger, M.W.4
-
76
-
-
33646483941
-
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
-
Khorashad, J. S.; Anand, M.; Marin, D.; Saunders, S.; Al-Jabary, T.; Iqbal, A.; Margerison, S.; Melo, J. V.; Goldman, J. M.; Apperley, J. F.; Kaeda, J. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006, 20, 658-663.
-
(2006)
Leukemia
, vol.20
, pp. 658-663
-
-
Khorashad, J.S.1
Anand, M.2
Marin, D.3
Saunders, S.4
Al-Jabary, T.5
Iqbal, A.6
Margerison, S.7
Melo, J.V.8
Goldman, J.M.9
Apperley, J.F.10
Kaeda, J.11
-
77
-
-
33750077276
-
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
-
DOI 10.1038/sj.leu.2404318, PII 2404318
-
Jabbour, E.; Kantarjian, H.; Jones, D.; Talpaz, M.; Bekele, N.; O'Brien, S.; Zhou, X.; Luthra, R.; Garcia-Manero, G.; Giles, F.; Rios, M. B.; Verstovsek, S.; Cortes, J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20, 1767-1773 (Pubitemid 44574988)
-
(2006)
Leukemia
, vol.20
, Issue.10
, pp. 1767-1773
-
-
Jabbour, E.1
Kantarjian, H.2
Jones, D.3
Talpaz, M.4
Bekele, N.5
O'Brien, S.6
Zhou, X.7
Luthra, R.8
Garcia-Manero, G.9
Giles, F.10
Rios, M.B.11
Verstovsek, S.12
Cortes, J.13
-
78
-
-
39749189452
-
Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up
-
DOI 10.1002/ajh.21055
-
Hess, G.; Meyer, R. G.; Schuch, B.; Bechthold, K.; El-Kholy, I.; Huber C. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up. Am. J. Hematol. 2008, 83, 178-184. (Pubitemid 351303939)
-
(2008)
American Journal of Hematology
, vol.83
, Issue.3
, pp. 178-184
-
-
Hess, G.1
Meyer, R.G.2
Schuch, B.3
Bechthold, K.4
El-Kholy, I.5
Huber, C.6
-
79
-
-
47249123747
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
-
Jabbour, E.; Kantarjian, H.; Jones, D.; Breeden, M.; Garcia-Manero, G.; O'Brien, S.; Ravandi, F.; Borthakur, G.; Cortes, J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008, 112, 53-55.
-
(2008)
Blood
, vol.112
, pp. 53-55
-
-
Jabbour, E.1
Kantarjian, H.2
Jones, D.3
Breeden, M.4
Garcia-Manero, G.5
O'Brien, S.6
Ravandi, F.7
Borthakur, G.8
Cortes, J.9
-
80
-
-
0038375012
-
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
-
DOI 10.1182/blood-2002-12-3659
-
Corbin, A. S.; La Rosée, P.; Stoffregen, E. P.; Druker, B. J.; Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003, 101, 4611-4614. (Pubitemid 36857835)
-
(2003)
Blood
, vol.101
, Issue.11
, pp. 4611-4614
-
-
Corbin, A.S.1
La Rosee, P.2
Stoffregen, E.P.3
Druker, B.J.4
Deininger, M.W.5
-
81
-
-
14944338660
-
Punish the parent not the progeny
-
Elrick, L. J.; Jorgensen, H. G.; Mountford, J. C.; Holyoake, T. L. Punish the parent not the progeny. Blood 2005, 105, 1862-1866.
-
(2005)
Blood
, vol.105
, pp. 1862-1866
-
-
Elrick, L.J.1
Jorgensen, H.G.2
Mountford, J.C.3
Holyoake, T.L.4
-
82
-
-
21744462100
-
Dynamics of chronic myeloid leukaemia
-
Michor, F.; Hughes, T. P.; Iwasa, Y.; Branford, S.; Shah, N. P.; Sawyers, C. L.; Nowak, M. A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435, 1267-1270.
-
(2005)
Nature
, vol.435
, pp. 1267-1270
-
-
Michor, F.1
Hughes, T.P.2
Iwasa, Y.3
Branford, S.4
Shah, N.P.5
Sawyers, C.L.6
Nowak, M.A.7
-
83
-
-
0035499267
-
Stem cells, cancer, and cancer stem cells
-
Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
-
(2001)
Nature
, vol.414
, pp. 105-111
-
-
Reya, T.1
Morrison, S.J.2
Clarke, M.F.3
Weissman, I.L.4
-
84
-
-
0036090222
-
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
-
Graham, S. M.; Jorgensen, H. G.; Allan, E.; Pearson, C.; Alcorn, M. J.; Richmond, L.; Holyoake, T. L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99, 319-325.
-
(2002)
Blood
, vol.99
, pp. 319-325
-
-
Graham, S.M.1
Jorgensen, H.G.2
Allan, E.3
Pearson, C.4
Alcorn, M.J.5
Richmond, L.6
Holyoake, T.L.7
-
85
-
-
0038454621
-
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
-
Bhatia, R.; Holtz, M.; Niu, N.; Gray, R.; Snyder, D. S.; Sawyers, C. L.; Arber, D. A.; Slovak, M. L.; Forman, S. J. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101, 4701-4707.
-
(2003)
Blood
, vol.101
, pp. 4701-4707
-
-
Bhatia, R.1
Holtz, M.2
Niu, N.3
Gray, R.4
Snyder, D.S.5
Sawyers, C.L.6
Arber, D.A.7
Slovak, M.L.8
Forman, S.J.9
-
86
-
-
4544312606
-
Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia
-
Sorel, N.; Bonnet, M. L.; Guillier, M.; Guilhot, F.; Brizard, A.; Turhan, A. G. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem. Biophys. Res Commun. 2004, 323, 728-730.
-
(2004)
Biochem. Biophys. Res Commun.
, vol.323
, pp. 728-730
-
-
Sorel, N.1
Bonnet, M.L.2
Guillier, M.3
Guilhot, F.4
Brizard, A.5
Turhan, A.G.6
-
87
-
-
0842322903
-
Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells
-
DOI 10.1080/1042819031000151905
-
Holtz, M. S.; Bhatia R. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk. Lymphoma 2004, 45, 237-245. (Pubitemid 38181424)
-
(2004)
Leukemia and Lymphoma
, vol.45
, Issue.2
, pp. 237-245
-
-
Holtz, M.S.1
Bhatia, R.2
-
88
-
-
38349168416
-
Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors
-
Li, S.; Li, D. Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors. J. Cell.Mol. Med.2007, 11, 1251-1262.
-
(2007)
J. Cell.Mol. Med.
, vol.11
, pp. 1251-1262
-
-
Li, S.1
Li, D.2
-
89
-
-
0025799513
-
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
-
Chaudhary, P. M.; Roninson, I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66, 85-94.
-
(1991)
Cell
, vol.66
, pp. 85-94
-
-
Chaudhary, P.M.1
Roninson, I.B.2
-
90
-
-
2942590202
-
ABC transporter activities of murine hematopoietic stem cells vary according to their developmental and activation status
-
DOI 10.1182/blood-2003-11-3989
-
Uchida, N.; Dykstra, B.; Lyons, K.; Leung, F.; Kristiansen, M.; Eaves, C. ABC transporter activities of murine hematopoietic stem cells vary according to their developmental and activation status. Blood 2004, 103, 4487-4495 (Pubitemid 38745974)
-
(2004)
Blood
, vol.103
, Issue.12
, pp. 4487-4495
-
-
Uchida, N.1
Dykstra, B.2
Lyons, K.3
Leung, F.4
Kristiansen, M.5
Eaves, C.J.6
-
91
-
-
27144512265
-
+ hematopoietic stem and progenitor cells
-
DOI 10.1634/stemcells.2005-0066
-
Soucek, P.; Anzenbacher, P.; Skoumalova, I.; Dvorak, M. Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells. 2005, 23, 1417-1422. (Pubitemid 41504929)
-
(2005)
Stem Cells
, vol.23
, Issue.9
, pp. 1417-1422
-
-
Soucek, P.1
Anzenbacher, P.2
Skoumalova, I.3
Dvorak, M.4
-
92
-
-
42049098091
-
In vitro Biotransformation of Imatinib by the Tumor Expressed CYP1A1 and CYP1B1
-
Rochat, B.; Zoete, V.; Grosdidier, A.; von Grünigen, S.; Marull, M.; Michielin, O. In vitro Biotransformation of Imatinib by the Tumor Expressed CYP1A1 and CYP1B1. Biopharm. Drug Dispos. 2008, 29,103-118.
-
(2008)
Biopharm. Drug Dispos.
, vol.29
, pp. 103-118
-
-
Rochat, B.1
Zoete, V.2
Grosdidier, A.3
Von Grünigen, S.4
Marull, M.5
Michielin, O.6
-
93
-
-
44649098271
-
Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity
-
Auman, J. T. ; McLeod, H. L. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity. Drug Metab. Rev. 2008, 40, 303-315.
-
(2008)
Drug Metab. Rev.
, vol.40
, pp. 303-315
-
-
Auman, J.T.1
McLeod, H.L.2
-
94
-
-
46749141730
-
Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry
-
DOI 10.1002/jms.1369
-
Rochat, B.; Fayet, A.; Widmer, N.; Lahrichi, S. L.; Pesse, B.; Décosterd, L. A.; Biollaz, J. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J. Mass Spectrom. 2008, 43, 43736-43752. (Pubitemid 351954808)
-
(2008)
Journal of Mass Spectrometry
, vol.43
, Issue.6
, pp. 736-752
-
-
Rochat, B.1
Fayet, A.2
Widmer, N.3
Lahrichi, S.L.4
Pesse, B.5
Decosterd, L.A.6
Biollaz, J.7
-
95
-
-
11144354274
-
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
-
DOI 10.1182/blood-2003-11-3800
-
Kantarjian, H.; Talpaz, M.; O'Brien, S.; Garcia-Manero, G.; Verstovsek, S.; Giles, F.; Rios, M. B.; Shan, J.; Letvak, L.; Thomas, D.; Faderl, S.; Ferrajoli, A.; Cortes, J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103, 2873-2878. (Pubitemid 38451654)
-
(2004)
Blood
, vol.103
, Issue.8
, pp. 2873-2878
-
-
Kantarjian, H.1
Talpaz, M.2
O'Brien, S.3
Garcia-Manero, G.4
Verstovsek, S.5
Giles, F.6
Rios, M.B.7
Shan, J.8
Letvak, L.9
Thomas, D.10
Faderl, S.11
Ferrajoli, A.12
Cortes, J.13
-
96
-
-
0037438467
-
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
-
DOI 10.1182/blood-2002-05-1451
-
Kantarjian, H. M.; Talpaz, M.; O'Brien, S.; Giles, F.; Garcia-Manero, G.; Faderl, S.; Thomas, D.; Shan, J.; Rios, M. B.; Cortes, J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003, 101, 473-475. (Pubitemid 36077567)
-
(2003)
Blood
, vol.101
, Issue.2
, pp. 473-475
-
-
Kantarjian, H.M.1
Talpaz, M.2
O'Brien, S.3
Giles, F.4
Garcia-Manero, G.5
Faded, S.6
Thomas, D.7
Shan, J.8
Rios, M.B.9
Cortes, J.10
-
97
-
-
24944529613
-
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study
-
Van Glabbeke, M.; Verweij, J.; Casali, P. G.; Le Cesne, A.; Hohenberger, P.; Ray-Coquard, I.; Schlemmer, M.; van Oosterom, A. T.; Goldstein, D.; Sciot, R.; Hogendoorn, P. C.; Brown, M.; Bertulli, R.; Judson, I. R. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J. Clin. Oncol. 2005, 23, 5795-5804.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5795-5804
-
-
Van Glabbeke, M.1
Verweij, J.2
Casali, P.G.3
Le Cesne, A.4
Hohenberger, P.5
Ray-Coquard, I.6
Schlemmer, M.7
Van Oosterom, A.T.8
Goldstein, D.9
Sciot, R.10
Hogendoorn, P.C.11
Brown, M.12
Bertulli, R.13
Judson, I.R.14
-
98
-
-
23644452642
-
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
-
EORTC Soft Tissue and Bone Sarcoma Group; the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group.
-
Zalcberg, J. R.; Verweij, J.; Casali, P. G.; Le Cesne, A.; Reichardt, P.; Blay, J. Y.; Schlemmer, M.; Van Glabbeke, M.; Brown, M.; Judson, I. R.; EORTC Soft Tissue and Bone Sarcoma Group; the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur. J. Cancer 2005, 41, 1751-1757.
-
(2005)
Eur. J. Cancer
, vol.41
, pp. 1751-1757
-
-
Zalcberg, J.R.1
Verweij, J.2
Casali, P.G.3
Le Cesne, A.4
Reichardt, P.5
Blay, J.Y.6
Schlemmer, M.7
Van Glabbeke, M.8
Brown, M.9
Judson, I.R.10
-
99
-
-
20844447330
-
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
-
DOI 10.1182/blood-2004-03-1134
-
Branford, S.; Rudzki, Z.; Parkinson, I.; Grigg, A.; Taylor, K.; Seymour, J. F.; Durrant, S.; Browett, P.; Schwarer, A. P.; Arthur, C.; Catalano, J.; Leahy, M. F.; Filshie, R.; Bradstock, K.; Herrmann, R.; Joske, D.; Lynch, K.; Hughes T. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004, 104, 2926-2932. (Pubitemid 39434981)
-
(2004)
Blood
, vol.104
, Issue.9
, pp. 2926-2932
-
-
Branford, S.1
Rudzki, Z.2
Parkinson, I.3
Grigg, A.4
Taylor, K.5
Seymour, J.F.6
Durrant, S.7
Browett, P.8
Schwarer, A.P.9
Arthur, C.10
Catalano, J.11
Leahy, M.F.12
Filshie, R.13
Bradstock, K.14
Herrmann, R.15
Joske, D.16
Lynch, K.17
Hughes, T.18
-
100
-
-
1042289341
-
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
-
Moravcova, J.; Zmekova, V.; Klamova, H.; Voglova, J.; Faber, E.; Michalova, K.; Rabasova, J.; Jarosova, M. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leuk. Res. 2004, 28, 415-419.
-
(2004)
Leuk. Res.
, vol.28
, pp. 415-419
-
-
Moravcova, J.1
Zmekova, V.2
Klamova, H.3
Voglova, J.4
Faber, E.5
Michalova, K.6
Rabasova, J.7
Jarosova, M.8
-
101
-
-
25444488489
-
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
-
Barnes, D. J.; Palaiologou, D.; Panousopoulou, E.; Schultheis, B.; Yong, A. S.; Wong, A.; Pattacini, L.; Goldman, J. M.; Melo, J. V. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005, 65, 8912-8919.
-
(2005)
Cancer Res.
, vol.65
, pp. 8912-8919
-
-
Barnes, D.J.1
Palaiologou, D.2
Panousopoulou, E.3
Schultheis, B.4
Yong, A.S.5
Wong, A.6
Pattacini, L.7
Goldman, J.M.8
Melo, J.V.9
-
102
-
-
31344441164
-
Looking beyond imatinib: Next line of targeted drugs for CML shows promise
-
DOI 10.1001/jama.295.4.369
-
Hampton, T. Looking beyond imatinib: next line of targeted drugs for CML shows promise. JAMA 2006, 295, 369-370. (Pubitemid 43144964)
-
(2006)
Journal of the American Medical Association
, vol.295
, Issue.4
, pp. 369-370
-
-
Hampton, T.1
-
103
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65, 4500-4505.
-
(2005)
Cancer Res.
, vol.65
, pp. 4500-4505
-
-
O'Hare, T.1
Walters, D.K.2
Stoffregen, E.P.3
Jia, T.4
Manley, P.W.5
Mestan, J.6
Cowan-Jacob, S.W.7
Lee, F.Y.8
Heinrich, M.C.9
Deininger, M.W.10
Druker, B.J.11
-
104
-
-
34249074686
-
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial
-
DOI 10.1182/blood-2006-11-056028
-
Kantarjian, H.; Pasquini, R.; Hamerschlak, N.; Rousselot, P.; Holowiecki, J.; Jootar, S.; Robak, T.; Khoroshko, N.; Masszi, T.; Skotnicki, A.; Hellmann, A.; Zaritsky, A.; Golenkov, A.; Radich, J.; Hughes, T.; Countouriotis, A.; Shah, N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007, 109, 5143-5150. (Pubitemid 46890528)
-
(2007)
Blood
, vol.109
, Issue.12
, pp. 5143-5150
-
-
Kantarjian, H.1
Pasquini, R.2
Hamerschlak, N.3
Rousselot, P.4
Holowiecki, J.5
Jootar, S.6
Robak, T.7
Khoroshko, N.8
Masszi, T.9
Skotnicki, A.10
Hellmann, A.11
Zaritsky, A.12
Golenkov, A.13
Radich, J.14
Hughes, T.15
Countouriotis, A.16
Shah, N.17
-
105
-
-
41349083969
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
-
le Coutre, P.; Ottmann, O. G.; Giles, F.; Kim, D. W.; Cortes, J.; Gattermann, N.; Apperley, J. F.; Larson, R. A.; Abruzzese, E.; O'Brien, S. G.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F. X.; Saglio, G.; Gobbi, M.; Kwong, Y. L.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J. P.; Zheng, M.; Shou, Y.; Kantarjian, H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111, 1834-1839.
-
(2008)
Blood
, vol.111
, pp. 1834-1839
-
-
Le Coutre, P.1
Ottmann, O.G.2
Giles, F.3
Kim, D.W.4
Cortes, J.5
Gattermann, N.6
Apperley, J.F.7
Larson, R.A.8
Abruzzese, E.9
O'Brien, S.G.10
Kuliczkowski, K.11
Hochhaus, A.12
Mahon, F.X.13
Saglio, G.14
Gobbi, M.15
Kwong, Y.L.16
Baccarani, M.17
Hughes, T.18
Martinelli, G.19
Radich, J.P.20
Zheng, M.21
Shou, Y.22
Kantarjian, H.23
more..
-
106
-
-
34247570352
-
Dasatinib is effective in imatinib-resistant CML
-
Cannell, E. Dasatinib is effective in imatinib-resistant CML. Lancet Oncol. 2007, 8, 286.
-
(2007)
Lancet Oncol.
, vol.8
, pp. 286
-
-
Cannell, E.1
-
107
-
-
33947356135
-
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
-
DOI 10.1182/blood-2006-09-046888
-
Cortes, J.; Rousselot, P.; Kim, D. W.; Ritchie, E.; Hamerschlak, N.; Coutre, S.; Hochhaus, A.; Guilhot, F.; Saglio, G.; Apperley, J.; Ottmann, O.; Shah, N.; Erben, P.; Branford, S.; Agarwal, P.; Gollerkeri, A.; Baccarani, M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109, 3207-3213. (Pubitemid 46572505)
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3207-3213
-
-
Cortes, J.1
Rousselot, P.2
Kim, D.-W.3
Ritchie, E.4
Hamerschlak, N.5
Coutre, S.6
Hochhaus, A.7
Guilhot, F.8
Saglio, G.9
Apperley, J.10
Ottmann, O.11
Shah, N.12
Erben, P.13
Branford, S.14
Agarwal, P.15
Gollerkeri, A.16
Baccarani, M.17
-
108
-
-
34948829146
-
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study
-
DOI 10.1182/blood-2007-02-073528
-
Ottmann, O.; Dombret, H.; Martinelli, G.; Simonsson, B.; Guilhot, F.; Larson, R. A.; Rege-Cambrin, G.; Radich, J.; Hochhaus, A.; Apanovitch, A. M.; Gollerkeri, A.; Coutre, S. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110, 2309-2315. (Pubitemid 47523149)
-
(2007)
Blood
, vol.110
, Issue.7
, pp. 2309-2315
-
-
Ottmann, O.1
Dombret, H.2
Martinelli, G.3
Simonsson, B.4
Guilhot, F.5
Larson, R.A.6
Rege-Cambrin, G.7
Radich, J.8
Hochhaus, A.9
Apanovitch, A.M.10
Gollerkeri, A.11
Coutre, S.12
-
109
-
-
34248324467
-
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
-
DOI 10.1182/blood-2006-09-046839
-
Guilhot, F.; Apperley, J.; Kim, D. W.; Bullorsky, E. O.; Baccarani, M.; Roboz, G. J.; Amadori, S.; de Souza, C. A.; Lipton, J. H.; Hochhaus, A.; Heim, D.; Larson, R. A.; Branford, S.; Muller, M. C.; Agarwal, P.; Gollerkeri, A.; Talpaz, M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007, 109, 4143-4150. (Pubitemid 46743375)
-
(2007)
Blood
, vol.109
, Issue.10
, pp. 4143-4150
-
-
Guilhot, F.1
Apperley, J.2
Kim, D.-W.3
Bullorsky, E.O.4
Baccarani, M.5
Roboz, G.J.6
Amadori, S.7
De Souza, C.A.8
Lipton, J.H.9
Hochhaus, A.10
Heim, D.11
Larson, R.A.12
Branford, S.13
Muller, M.C.14
Agarwal, P.15
Gollerkeri, A.16
Talpaz, M.17
-
110
-
-
42049123098
-
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
-
Hantschel, O.; Rix, U.; Superti-Furga, G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 2008, 49, 615-619.
-
(2008)
Leuk. Lymphoma
, vol.49
, pp. 615-619
-
-
Hantschel, O.1
Rix, U.2
Superti-Furga, G.3
-
111
-
-
33745069351
-
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
-
DOI 10.1182/blood-2005-12-010132
-
von Bubnoff, N.; Manley, P. W.; Mestan, J.; Sanger, J.; Peschel, C.; Duyster, J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006, 108, 1328-1333. (Pubitemid 44232032)
-
(2006)
Blood
, vol.108
, Issue.4
, pp. 1328-1333
-
-
Von Bubnoff, N.1
Manley, P.W.2
Mestan, J.3
Sanger, J.4
Peschel, C.5
Duyster, J.6
-
112
-
-
33646516407
-
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines
-
Prenen, H.; Guetens, G.; de Boeck, G.; Debiec-Rychter, M.; Manley, P.; Schoffski, P.; van Oosterom, A. T.; de Bruijn, E. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006, 77, 11-16.
-
(2006)
Pharmacology
, vol.77
, pp. 11-16
-
-
Prenen, H.1
Guetens, G.2
De Boeck, G.3
Debiec-Rychter, M.4
Manley, P.5
Schoffski, P.6
Van Oosterom, A.T.7
De Bruijn, E.8
-
113
-
-
33847164409
-
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
-
DOI 10.1016/S1470-2045(07)70078-5, PII S1470204507700785
-
Soverini, S.; Martinelli, G.; Colarossi, S.; Gnani, A.; Rondoni, M.; Castagnetti, F.; Paolini, S.; Rosti, G.; Baccarani, M. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol. 2007, 8, 273-274. (Pubitemid 46291717)
-
(2007)
Lancet Oncology
, vol.8
, Issue.3
, pp. 273-274
-
-
Soverini, S.1
Martinelli, G.2
Colarossi, S.3
Gnani, A.4
Rondoni, M.5
Castagnetti, F.6
Paolini, S.7
Rosti, G.8
Baccarani, M.9
-
114
-
-
37749053902
-
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
-
Kaur, P.; Feldhahn, N.; Zhang, B.; Trageser, D.; Müschen, M.; Pertz, V.; Groffen, J.; Heisterkamp, N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol. Cancer 2007, 6, 67-77.
-
(2007)
Mol. Cancer
, vol.6
, pp. 67-77
-
-
Kaur, P.1
Feldhahn, N.2
Zhang, B.3
Trageser, D.4
Müschen, M.5
Pertz, V.6
Groffen, J.7
Heisterkamp, N.8
-
115
-
-
33846200681
-
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
-
Quintas-Cardama, A.; Kantarjian, H.; Jones, D.; Nicaise, C.; O'Brien, S.; Giles, F.; Talpaz, M.; Cortes, J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109, 497-1479
-
(2007)
Blood
, vol.109
, pp. 497-1479
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Jones, D.3
Nicaise, C.4
O'Brien, S.5
Giles, F.6
Talpaz, M.7
Cortes, J.8
-
116
-
-
35548930789
-
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy
-
DOI 10.1159/000108639
-
Breccia, M.; Cannella, L.; Nanni, M.; Stefanizzi, C.; Alimena, G. Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta Haematol. 2007, 118, 162-164. (Pubitemid 350014906)
-
(2007)
Acta Haematologica
, vol.118
, Issue.3
, pp. 162-164
-
-
Breccia, M.1
Cannella, L.2
Nanni, M.3
Stefanizzi, C.4
Alimena, G.5
-
117
-
-
33847379510
-
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias
-
Weisberg, E.; Catley, L.; Wright, R. D.; Moreno, D.; Banerji, L.; Ray, A.; Manley, P. W.; Mestan, J.; Fabbro, D.; Jiang, J.; Hall-Meyers, E.; Callahan, L.; DellaGatta, J. L.; Kung, A. L.; Griffin, J. D. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007, 109, 2112-2120.
-
(2007)
Blood
, vol.109
, pp. 2112-2120
-
-
Weisberg, E.1
Catley, L.2
Wright, R.D.3
Moreno, D.4
Banerji, L.5
Ray, A.6
Manley, P.W.7
Mestan, J.8
Fabbro, D.9
Jiang, J.10
Hall-Meyers, E.11
Callahan, L.12
DellaGatta, J.L.13
Kung, A.L.14
Griffin, J.D.15
-
118
-
-
43749086323
-
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
-
O'Hare, T.; Eide, C. A.; Tyner, J. W.; Corbin, A. S.; Wong, M. J.; Buchanan, S.; Holme, K.; Jessen, K. A.; Tang, C.; Lewis, H. A.; Romero, R. D.; Burley, S. K.; Deininger, M. W. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl. Acad. Sci. USA 2008, 105, 5507-5512.
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 5507-5512
-
-
O'Hare, T.1
Eide, C.A.2
Tyner, J.W.3
Corbin, A.S.4
Wong, M.J.5
Buchanan, S.6
Holme, K.7
Jessen, K.A.8
Tang, C.9
Lewis, H.A.10
Romero, R.D.11
Burley, S.K.12
Deininger, M.W.13
-
119
-
-
33846849302
-
New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to
-
DOI 10.1053/j.seminhematol.2006.12.003, PII S0037196306002563, Integrating the New Generation of Targeted Therapies for Chronic Myelogenous Leukemia
-
Jabbour, E.; Cortes, J.; O'Brien, S.; Giles, F.; Kantarjian, H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin. Hematol. 2007, 44, 25-31. (Pubitemid 46209244)
-
(2007)
Seminars in Hematology
, vol.44
, Issue.SUPPL. 1
, pp. 25-31
-
-
Jabbour, E.1
Cortes, J.2
O'Brien, S.3
Giles, F.4
Kantarjian, H.5
-
120
-
-
34548799800
-
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
-
Cortes, J.; Jabbour, E.; Daley, G. Q.; O'brien, S.; Verstovsek, S.; Ferrajoli, A.; Koller, C.; Zhu, Y.; Statkevich, P.; Kantarjian, H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007, 110, 1295-1302.
-
(2007)
Cancer
, vol.110
, pp. 1295-1302
-
-
Cortes, J.1
Jabbour, E.2
Daley, G.Q.3
O'Brien, S.4
Verstovsek, S.5
Ferrajoli, A.6
Koller, C.7
Zhu, Y.8
Statkevich, P.9
Kantarjian, H.10
-
121
-
-
33947216149
-
Important therapeutic targets in chronic myelogenous leukemia
-
DOI 10.1158/1078-0432.CCR-06-2147
-
Kantarjian, H. M.; Giles, F.; Quintas-Cardama, A.; Cortes, J. Important therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res. 2007, 13, 1089-1097. (Pubitemid 46424047)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.4
, pp. 1089-1097
-
-
Kantarjian, H.M.1
Giles, F.2
Quintas-Cardama, A.3
Cortes, J.4
-
123
-
-
40749154745
-
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia
-
Giles, F. J.; DeAngelo, D. J.; Baccarani, M.; Deininger, M.; Guilhot, F.; Hughes, T.; Mauro, M.; Radich, J.; Ottmann, O.; Cortes, J. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin. Oncol. 2008, 35, 1-17.
-
(2008)
Semin. Oncol.
, vol.35
, pp. 1-17
-
-
Giles, F.J.1
DeAngelo, D.J.2
Baccarani, M.3
Deininger, M.4
Guilhot, F.5
Hughes, T.6
Mauro, M.7
Radich, J.8
Ottmann, O.9
Cortes, J.10
-
125
-
-
0030010301
-
Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient
-
Conus, P.; Bondolfi, G.; Eap, C. B.; Macciardi, F.; Baumann, P. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry. 1996, 29, 108-110.
-
(1996)
Pharmacopsychiatry
, vol.29
, pp. 108-110
-
-
Conus, P.1
Bondolfi, G.2
Eap, C.B.3
Macciardi, F.4
Baumann, P.5
-
126
-
-
0031945353
-
Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping
-
Baumann, P.; Broly, F.; Kosel, M.; Eap, C. B. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. Pharmacopsychiatry 1998, 31, 72.
-
(1998)
Pharmacopsychiatry
, vol.31
, pp. 72
-
-
Baumann, P.1
Broly, F.2
Kosel, M.3
Eap, C.B.4
-
127
-
-
34147107091
-
Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs
-
White, D. L.; Saunders, V. A.; Quinn, S. R.; Manley, P. W.; Hughes, T. P. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007, 109, 3609-3610.
-
(2007)
Blood
, vol.109
, pp. 3609-3610
-
-
White, D.L.1
Saunders, V.A.2
Quinn, S.R.3
Manley, P.W.4
Hughes, T.P.5
-
128
-
-
17644448304
-
P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in viva in patients with P-glycoprotein- Positive acute myeloid leukemia
-
Tidefelt, U.; Liliemark, J.; Gruber, A.; Liliemark, E.; Sundman-Engberg, B.; Juliusson, G.; Stenke, L.; Elmhorn-Rosenborg, A.; Möllgård, L.; Lehman, S.; Xu, D.; Covelli, A.; Gustavsson, B.; Paul, C. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J. Clin. Oncol. 2000, 18, 1837-1844. (Pubitemid 30261921)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.9
, pp. 1837-1844
-
-
Tidefelt, U.1
Liliemark, J.2
Gruber, A.3
Liliemark, E.4
Sundman-Engberg, B.5
Juliusson, G.6
Stenke, L.7
Elmhorn-Rosenborg, A.8
Mollgard, L.9
Lehman, S.10
Xu, D.11
Covelli, A.12
Gustavsson, B.13
Paul, C.14
-
129
-
-
0031973816
-
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours
-
McLeod, H. L.; Sludden, J.; Murray, G. I.; Keenan, R. A.; Davidson, A.; Park, K.; Koruth, M.; Cassidy, J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br. J. Cancer 1998, 77, 461-465. (Pubitemid 28044052)
-
(1998)
British Journal of Cancer
, vol.77
, Issue.3
, pp. 461-465
-
-
McLeod, H.L.1
Sludden, J.2
Murray, G.I.3
Keenan, R.A.4
Davidson, A.I.5
Park, K.6
Koruth, M.7
Cassidy, J.8
-
130
-
-
0043245793
-
Functional consequence of MDR1 expression on imatinib intracellular concentrations
-
Widmer, N.; Colombo, S.; Buclin, T.; Decosterd, L. A. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003, 102, 1142.
-
(2003)
Blood
, vol.102
, pp. 1142
-
-
Widmer, N.1
Colombo, S.2
Buclin, T.3
Decosterd, L.A.4
-
131
-
-
33750355434
-
Extracellular concentration of anticancer drugs that regulates their intracellular distribution and binding to DNA in cells with multidrug resistant phenotype
-
Bogush, T. A.; Ravcheeva, A. B.; Bogush, E. A.; Konukhova, A. V.; Kuz'mina, K. E.; Baryshnikov, A. Y.; Davydov, M. I. Extracellular concentration of anticancer drugs that regulates their intracellular distribution and binding to DNA in cells with multidrug resistant phenotype. Dokl. Biochem. Biophys. 2006, 410, 273-277.
-
(2006)
Dokl. Biochem. Biophys.
, vol.410
, pp. 273-277
-
-
Bogush, T.A.1
Ravcheeva, A.B.2
Bogush, E.A.3
Konukhova, A.V.4
Kuz'Mina, K.E.5
Baryshnikov, A.Y.6
Davydov, M.I.7
-
132
-
-
0041766239
-
An automated HPLC method to determine intracellular vincristine concentrations in mononuclear cells of children with acute lymphoblastic leukemia
-
DOI 10.1097/00007691-200308000-00004
-
Groninger, E.; Koopmans, P.; Kamps, W.; de Graaf, S.; Uges, D. An automated HPLC method to determine intracellular vincristine concentrations in mononuclear cells of children with acute lymphoblastic leukemia. Ther. Drug Monit. 2003, 25, 441-446. (Pubitemid 36927974)
-
(2003)
Therapeutic Drug Monitoring
, vol.25
, Issue.4
, pp. 441-446
-
-
Groninger, E.1
Koopmans, P.2
Kamps, W.3
De Graaf, S.4
Uges, D.5
-
133
-
-
12144286457
-
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: Relationship with P-glycoprotein expression
-
Ford, J.; Cornforth, D.; Hoggard, P. G.; Cuthbertson, Z.; Meaden, E. R.; Williams, I.; Johnson, M.; Daniels, E.; Hsyu, P.; Back, D. J.; Khoo, S. H. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with Pglycoprotein expression. Antivir. Ther. 2004, 9, 77-84. (Pubitemid 38313950)
-
(2004)
Antiviral Therapy
, vol.9
, Issue.1
, pp. 77-84
-
-
Ford, J.1
Cornforth, D.2
Hoggard, P.G.3
Cuthbertson, Z.4
Meaden, E.R.5
Williams, I.6
Johnson, M.7
Daniels, E.8
Hsyu, P.9
Back, D.J.10
Khoo, S.H.11
-
134
-
-
33748163469
-
Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
-
Swiss HIV Cohort Study
-
Colombo, S.; Telenti, A.; Buclin, T.; Furrer, H.; Lee, B. L.; Biollaz, J.; Decosterd, L. A.; Swiss HIV Cohort Study. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Ther. Drug Monit. 2006, 28, 332-338.
-
(2006)
Ther. Drug Monit.
, vol.28
, pp. 332-338
-
-
Colombo, S.1
Telenti, A.2
Buclin, T.3
Furrer, H.4
Lee, B.L.5
Biollaz, J.6
Decosterd, L.A.7
-
135
-
-
36749068990
-
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment
-
Ma, J.; Waxman, D. J. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol. Cancer Ther. 2007, 6, 2879-2890.
-
(2007)
Mol. Cancer Ther.
, vol.6
, pp. 2879-2890
-
-
Ma, J.1
Waxman, D.J.2
-
136
-
-
36148937068
-
Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model
-
Chen, C. S.; Jounaidi, Y.; Su, T.; Waxman, D. J. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer Gene Ther. 2007, 14, 935-944.
-
(2007)
Cancer Gene Ther.
, vol.14
, pp. 935-944
-
-
Chen, C.S.1
Jounaidi, Y.2
Su, T.3
Waxman, D.J.4
-
137
-
-
33645466808
-
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11
-
Jounaidi, Y.; Chen, C. S.; Veal, G. J.; Waxman, D. J. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther. 2006, 5, 541-555.
-
(2006)
Mol. Cancer Ther.
, vol.5
, pp. 541-555
-
-
Jounaidi, Y.1
Chen, C.S.2
Veal, G.J.3
Waxman, D.J.4
-
138
-
-
0033828231
-
The evolution of drug metabolism
-
Nebert, D. W.; Dieter, M. Z. The evolution of drug metabolism. Pharmacology 2000, 61, 124-135.
-
(2000)
Pharmacology
, vol.61
, pp. 124-135
-
-
Nebert, D.W.1
Dieter, M.Z.2
-
139
-
-
0041930641
-
Vertebrate UDP-glucuronosyltransferases: Functional and evolutionary aspects
-
DOI 10.1016/S0006-2952(03)00296-X
-
Bock, K. W. Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem. Pharmacol. 2003, 66, 691-696. (Pubitemid 37011407)
-
(2003)
Biochemical Pharmacology
, vol.66
, Issue.5
, pp. 691-696
-
-
Bock, K.W.1
-
140
-
-
25844487733
-
Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates
-
DOI 10.1146/annurev.genom.6.080604.162122
-
Dean, M.; Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 2005, 6, 123-142. (Pubitemid 41397078)
-
(2005)
Annual Review of Genomics and Human Genetics
, vol.6
, pp. 123-142
-
-
Dean, M.1
Annilo, T.2
-
141
-
-
0025333289
-
Evolution of the P450 gene superfamily: Animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation
-
Gonzalez, F. J.; Nebert, D. W. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet. 1990, 6, 182-186.
-
(1990)
Trends Genet.
, vol.6
, pp. 182-186
-
-
Gonzalez, F.J.1
Nebert, D.W.2
-
142
-
-
0032102916
-
Evolution of the cytochrome P450 superfamily: Sequence alignments and pharmacogenetics
-
Lewis, D. F.; Watson, E.; Lake, B. G. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat. Res. 1998, 410, 245-270.
-
(1998)
Mutat. Res.
, vol.410
, pp. 245-270
-
-
Lewis, D.F.1
Watson, E.2
Lake, B.G.3
-
143
-
-
1242340323
-
The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction
-
Hediger, M. A.; Romero, M. F.; Peng, J. B.; Rolfs, A.; Takanaga, H.; Bruford, E. A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch. 2004, 447, 465-468.
-
(2004)
Pflugers Arch.
, vol.447
, pp. 465-468
-
-
Hediger, M.A.1
Romero, M.F.2
Peng, J.B.3
Rolfs, A.4
Takanaga, H.5
Bruford, E.A.6
-
144
-
-
65249139907
-
Analysis and update of the human solute carrier (SLC) gene superfamily
-
He, L.; Vasiliou, K.; Nebert, D. W. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum. Genomics 2009, 3, 195-206.
-
(2009)
Hum. Genomics
, vol.3
, pp. 195-206
-
-
He, L.1
Vasiliou, K.2
Nebert, D.W.3
-
146
-
-
33745835398
-
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins
-
Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86, 849-899.
-
(2006)
Physiol. Rev.
, vol.86
, pp. 849-899
-
-
Deeley, R.G.1
Westlake, C.2
Cole, S.P.3
-
147
-
-
33749488939
-
Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system
-
DOI 10.1152/physrev.00037.2005
-
Sarkadi, B.; Homolya, L.; Szakács, G.; Váradi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 2006, 86, 1179-1236. (Pubitemid 44521651)
-
(2006)
Physiological Reviews
, vol.86
, Issue.4
, pp. 1179-1236
-
-
Sarkadi, B.1
Homolya, L.2
Szakacs, G.3
Varadi, A.4
-
148
-
-
0035660288
-
Human cytochrome P-450 (CYP) genes: A web page for the nomenclature of alleles
-
Ingelman-Sundberg, M.; Oscarson, M.; Daly, A. K.; Garte, S.; Nebert, D. W. Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol. Biomarkers Prev. 2001, 10, 1307-1308.
-
(2001)
Cancer Epidemiol. Biomarkers Prev.
, vol.10
, pp. 1307-1308
-
-
Ingelman-Sundberg, M.1
Oscarson, M.2
Daly, A.K.3
Garte, S.4
Nebert, D.W.5
-
149
-
-
6344250770
-
57 varieties: The human cytochromes P450
-
Lewis, D. F. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004, 5, 305-318.
-
(2004)
Pharmacogenomics
, vol.5
, pp. 305-318
-
-
Lewis, D.F.1
-
150
-
-
0028237729
-
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
-
Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
-
(1994)
J. Pharmacol. Exp. Ther.
, vol.270
, pp. 414-423
-
-
Shimada, T.1
Yamazaki, H.2
Mimura, M.3
Inui, Y.4
Guengerich, F.P.5
-
151
-
-
34548381638
-
Characterization of orphan human cytochromes P450
-
DOI 10.1080/03602530701467708, PII 781832530
-
Stark, K.; Guengerich, F. P. Characterization of orphan human cytochromes P450. Drug. Metab. Rev. 2007, 39, 627-637. (Pubitemid 47355742)
-
(2007)
Drug Metabolism Reviews
, vol.39
, Issue.2-3
, pp. 627-637
-
-
Stark, K.1
Guengerich, F.P.2
-
152
-
-
17844408291
-
Novel extrahepatic cytochrome P450s
-
Karlgren, M.; Miura, S.; Ingelman-Sundberg, M. Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. 2005, 207, 57-61.
-
(2005)
Toxicol. Appl. Pharmacol.
, vol.207
, pp. 57-61
-
-
Karlgren, M.1
Miura, S.2
Ingelman-Sundberg, M.3
-
153
-
-
33847092271
-
The biochemistry of drug metabolism - An introduction part 2. Redox reactions and their enzymes
-
DOI 10.1002/cbdv.200790032
-
Testa, B.; Kramer, S. D. The biochemistry of drug metabolism - an introduction: part 2. Redox reactions and their enzymes. Chem. Biodivers. 2007, 4, 257-405. (Pubitemid 46937873)
-
(2007)
Chemistry and Biodiversity
, vol.4
, Issue.3
, pp. 257-405
-
-
Testa, B.1
Kramer, S.D.2
-
155
-
-
33747871144
-
ABC drug transporter at the blood-brain barrier: Effects on drug metabolism and drug response
-
DOI 10.1007/s00406-006-0664-4
-
Ebinger, M.; Uhr, M. ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur Arch. Psychiatr. Clin. Neurosci. 2006, 256, 294-298. (Pubitemid 44285053)
-
(2006)
European Archives of Psychiatry and Clinical Neuroscience
, vol.256
, Issue.5
, pp. 294-298
-
-
Ebinger, M.1
Uhr, M.2
-
156
-
-
0011099824
-
Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain
-
El-Bacha, R. S.; Minn, A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell. Mol. Biol. 1999, 45, 15-23.
-
(1999)
Cell. Mol. Biol.
, vol.45
, pp. 15-23
-
-
El-Bacha, R.S.1
Minn, A.2
-
157
-
-
56749151204
-
ABC transporters, cytochromes P450 and their main transcription factors: Expression at the human blood-brain barrier
-
Dauchy, S.; Dutheil, F.; Weaver, R. J.; Chassoux, F; Daumas-Duport, C.; Couraud, P. O.; Scherrmann, J. M.; De Waziers, I.; Declèves, X. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 2008, 107, 1518-1528.
-
(2008)
J. Neurochem.
, vol.107
, pp. 1518-1528
-
-
Dauchy, S.1
Dutheil, F.2
Weaver, R.J.3
Chassoux, F.4
Daumas-Duport, C.5
Couraud, P.O.6
Scherrmann, J.M.7
De Waziers, I.8
Declèves, X.9
-
158
-
-
25144500468
-
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily
-
Mackenzie, P. I.; Bock, K. W.; Burchell, B.; Guillemette, C.; Ikushiro, S.; Iyanagi, T.; Miners, J. O.; Owens, I. S.; Nebert, D. W. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 2005, 15, 677-685.
-
(2005)
Pharmacogenet. Genomics
, vol.15
, pp. 677-685
-
-
Mackenzie, P.I.1
Bock, K.W.2
Burchell, B.3
Guillemette, C.4
Ikushiro, S.5
Iyanagi, T.6
Miners, J.O.7
Owens, I.S.8
Nebert, D.W.9
-
159
-
-
21644475953
-
Analysis of the glutathione S-transferase (GST) gene family
-
Nebert, D. W.; Vasiliou, V. Analysis of the glutathione S-transferase (GST) gene family. Hum. Genomics 2004, 1, 460-464.
-
(2004)
Hum. Genomics
, vol.1
, pp. 460-464
-
-
Nebert, D.W.1
Vasiliou, V.2
-
160
-
-
33847021147
-
Aldo-keto reductases and bioactivation/detoxication
-
Jin, Y.; Penning, T. M. Aldo-keto reductases and bioactivation/ detoxication. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 263-292.
-
(2007)
Annu. Rev. Pharmacol. Toxicol.
, vol.47
, pp. 263-292
-
-
Jin, Y.1
Penning, T.M.2
-
161
-
-
0033988708
-
Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction
-
DOI 10.1016/S0006-2952(99)00322-6, PII S0006295299003226
-
Ax, W.; Soldan, M.; Koch, L.; Maser, E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 2000, 59, 293-300. (Pubitemid 30001756)
-
(2000)
Biochemical Pharmacology
, vol.59
, Issue.3
, pp. 293-300
-
-
Ax, W.1
Soldan, M.2
Koch, L.3
Maser, E.4
-
162
-
-
34547679864
-
Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes
-
DOI 10.1016/j.canlet.2007.03.018, PII S0304383507001565
-
Plebuch, M.; Soldan, M.; Hungerer, C.; Koch, L.; Maser, E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 2007, 255, 49-56. (Pubitemid 47212606)
-
(2007)
Cancer Letters
, vol.255
, Issue.1
, pp. 49-56
-
-
Plebuch, M.1
Soldan, M.2
Hungerer, C.3
Koch, L.4
Maser, E.5
-
163
-
-
33845499493
-
Overexpression of aldose reductase in human cancer tissues
-
Saraswat, M.; Mrudula, T.; Kumar, P. U.; Suneetha, A.; Rao Rao, T. S.; Srinivasulu, M.; Reddy, B. Overexpression of aldose reductase in human cancer tissues. Med. Sci. Monit. 2006, 12, 525-529.
-
(2006)
Med. Sci. Monit.
, vol.12
, pp. 525-529
-
-
Saraswat, M.1
Mrudula, T.2
Kumar, P.U.3
Suneetha, A.4
Rao Rao, T.S.5
Srinivasulu, M.6
Reddy, B.7
-
164
-
-
0035097039
-
Overexpression of aldose reductase in liver cancers may contribute to drug resistance
-
Lee, K. W.; Ko, B. C.; Jiang, Z.; Cao, D.; Chung, S. S. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 2001, 12, 129-132.
-
(2001)
Anticancer Drugs
, vol.12
, pp. 129-132
-
-
Lee, K.W.1
Ko, B.C.2
Jiang, Z.3
Cao, D.4
Chung, S.S.5
-
165
-
-
33847083503
-
Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily
-
DOI 10.1080/03602530600969440, PII 770753014
-
Hoffmann, F.; Maser, E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev. 2007, 39, 87-144. (Pubitemid 46263532)
-
(2007)
Drug Metabolism Reviews
, vol.39
, Issue.1
, pp. 87-144
-
-
Hoffmann, F.1
Maser, E.2
-
167
-
-
0028678077
-
Alcohol dehydrogenase: Enzymology and metabolism
-
Yin, S. J. Alcohol dehydrogenase: enzymology and metabolism. Alcohol. Alcohol. Suppl. 1994, 2, 113-119.
-
(1994)
Alcohol. Alcohol. Suppl.
, vol.2
, pp. 113-119
-
-
Yin, S.J.1
-
168
-
-
32444448861
-
Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family
-
Vasiliou, V.; Nebert, D. W. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum. Genomics 2005, 2, 138-143.
-
(2005)
Hum. Genomics
, vol.2
, pp. 138-143
-
-
Vasiliou, V.1
Nebert, D.W.2
-
169
-
-
0030772328
-
The role of non-P450 enzymes in drug oxidation
-
DOI 10.1023/A:1008668913093
-
Beedham, C. The role of non-P450 enzymes in drug oxidation. Pharm. World Sci. 1997, 19, 255-263. (Pubitemid 27511692)
-
(1997)
Pharmacy World and Science
, vol.19
, Issue.6
, pp. 255-263
-
-
Beedham, C.1
-
170
-
-
6344270255
-
Contribution of aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehydes
-
DOI 10.1021/tx030059u
-
Panoutsopoulos, G. I.; Kouretas, D.; Beedham, C. Contribution of aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehydes. Chem. Res.Toxicol. 2004, 17, 1368-1376. (Pubitemid 39403051)
-
(2004)
Chemical Research in Toxicology
, vol.17
, Issue.10
, pp. 1368-1376
-
-
Panoutsopoulos, G.I.1
Kouretas, D.2
Beedham, C.3
-
171
-
-
33645221836
-
Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family
-
Vasiliou, V.; Ross, D.; Nebert, D. W. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum. Genomics 2006, 2, 329-335.
-
(2006)
Hum. Genomics
, vol.2
, pp. 329-335
-
-
Vasiliou, V.1
Ross, D.2
Nebert, D.W.3
-
172
-
-
45249103473
-
Flavin mono-oxygenase (FMO) - The 'other' oxidase
-
Mitchell, S. C. Flavin mono-oxygenase (FMO) - the 'other' oxidase. Curr. Drug Metab. 2008, 9, 280-284.
-
(2008)
Curr. Drug Metab.
, vol.9
, pp. 280-284
-
-
Mitchell, S.C.1
-
173
-
-
0742321737
-
Pharmacogenetics of soluble sulfotransferases (SULTs)
-
Glatt, H.; Meinl, W. Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369, 55-68.
-
(2004)
Naunyn Schmiedebergs Arch. Pharmacol.
, vol.369
, pp. 55-68
-
-
Glatt, H.1
Meinl, W.2
-
174
-
-
33144464115
-
Human sulfotransferases and their role in chemical metabolism
-
DOI 10.1093/toxsci/kfj061
-
Gamage, N.; Barnett, A.; Hempel, N.; Duggleby, R. G.; Windmill, K. F.; Martin, J. L.; McManus, M. E. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 2006, 90, 5-22. (Pubitemid 43264722)
-
(2006)
Toxicological Sciences
, vol.90
, Issue.1
, pp. 5-22
-
-
Gamage, N.1
Barnett, A.2
Hempel, N.3
Duggleby, R.G.4
Windmill, K.F.5
Martin, J.L.6
McManus, M.E.7
-
175
-
-
34547180380
-
Arylamine N-acetyltransferases
-
Sim, E.; Westwood, I.; Fullam, E. Arylamine N-acetyltransferases. Expert. Opin. Drug Metab. Toxicol. 2007, 3, 169-184.
-
(2007)
Expert. Opin. Drug Metab. Toxicol.
, vol.3
, pp. 169-184
-
-
Sim, E.1
Westwood, I.2
Fullam, E.3
-
176
-
-
30144442042
-
Epoxide hydrolases: Structure, function, mechanism, and assay
-
DOI 10.1016/S0076-6879(05)00032-7, PII S0076687905000327, 32, Phase II Conjugation Enzymes and Transport Systems
-
Arand, M.; Cronin, A.; Adamska, M.; Oesch, F. Epoxide hydrolases: structure, function, mechanism, and assay. Methods Enzymol. 2005, 400, 569-588. (Pubitemid 43052441)
-
(2005)
Methods in Enzymology
, vol.400
, pp. 569-588
-
-
Arand, M.1
Cronin, A.2
Adamska, M.3
Oesch, F.4
-
177
-
-
34547899883
-
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues
-
DOI 10.1097/FPC.0b013e32810f2e58, PII 0121301120070900000006
-
Bièche, I.; Narjoz, C.; Asselah, T.; Vacher, S.; Marcellin, P.; Lidereau, R.; Beaune, P.; de Waziers, I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 2007, 17, 731-742. (Pubitemid 47263068)
-
(2007)
Pharmacogenetics and Genomics
, vol.17
, Issue.9
, pp. 731-742
-
-
Bieche, I.1
Narjoz, C.2
Asselah, T.3
Vacher, S.4
Marcellin, P.5
Lidereau, R.6
Beaune, P.7
De Waziers, I.8
-
178
-
-
0037478407
-
Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts
-
Ding, X.; Kaminsky, L. S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 149-173.
-
(2003)
Annu. Rev. Pharmacol. Toxicol.
, vol.43
, pp. 149-173
-
-
Ding, X.1
Kaminsky, L.S.2
-
179
-
-
33845348869
-
Xenobiotic-metabolizing enzymes in human lung
-
Zhang, J. Y.; Wang, Y.; Prakash, C. Xenobiotic-metabolizing enzymes in human lung. Curr. Drug Metab. 2006, 7, 939-948.
-
(2006)
Curr. Drug Metab.
, vol.7
, pp. 939-948
-
-
Zhang, J.Y.1
Wang, Y.2
Prakash, C.3
-
180
-
-
44249098959
-
Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases
-
Hardwick, J. P. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem. Pharmacol. 2008, 75, 2263-2275.
-
(2008)
Biochem. Pharmacol.
, vol.75
, pp. 2263-2275
-
-
Hardwick, J.P.1
-
181
-
-
34548390084
-
Human cytochrome p450 family 4 enzymes: Function, genetic variation and regulation
-
Hsu, M. H.; Savas, U.; Griffin, K. J.; Johnson, E. F. Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab. Rev. 2007, 39, 515-538.
-
(2007)
Drug Metab. Rev.
, vol.39
, pp. 515-538
-
-
Hsu, M.H.1
Savas, U.2
Griffin, K.J.3
Johnson, E.F.4
-
182
-
-
27744454598
-
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)
-
DOI 10.1016/j.bcp.2005.09.011, PII S0006295205005885
-
Müller, J.; Lips, K. S.; Metzner, L.; Neubert, R. H.; Koepsell, H.; Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem. Pharmacol. 2005, 70, 1851-1860. (Pubitemid 41612016)
-
(2005)
Biochemical Pharmacology
, vol.70
, Issue.12
, pp. 1851-1860
-
-
Muller, J.1
Lips, K.S.2
Metzner, L.3
Neubert, R.H.H.4
Koepsell, H.5
Brandsch, M.6
-
183
-
-
25644452793
-
2 receptor antagonists by rat and human renal organic anion and cation transporters
-
DOI 10.1124/jpet.105.088104
-
Tahara, H.; Kusuhara, H.; Endou, H.; Koepsell, H.; Imaoka, T.; Fuse, E.; Sugiyama, Y. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 2005, 315, 337-345. (Pubitemid 41380529)
-
(2005)
Journal of Pharmacology and Experimental Therapeutics
, vol.315
, Issue.1
, pp. 337-345
-
-
Tahara, H.1
Kusuhara, H.2
Endou, H.3
Koepsell, H.4
Imaoka, T.5
Fuse, E.6
Sugiyama, Y.7
-
184
-
-
33745953360
-
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants
-
Badagnani, I.; Castro, R. A.; Taylor, T. R.; Brett, C. M.; Huang, C. C.; Stryke, D.; Kawamoto, M.; Johns, S. J.; Ferrin, T. E.; Carlson, E. J.; Burchard, E. G.; Giacomini, K. M. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 2006, 318, 521-529.
-
(2006)
J. Pharmacol. Exp. Ther.
, vol.318
, pp. 521-529
-
-
Badagnani, I.1
Castro, R.A.2
Taylor, T.R.3
Brett, C.M.4
Huang, C.C.5
Stryke, D.6
Kawamoto, M.7
Johns, S.J.8
Ferrin, T.E.9
Carlson, E.J.10
Burchard, E.G.11
Giacomini, K.M.12
-
185
-
-
33644841714
-
Functional characterization of a human organic anion transporter hOAT4 in placental BeWo cells
-
DOI 10.1016/j.ejps.2005.09.008, PII S0928098705002812, Drug Transporters: Integration in Understanding ADME
-
Zhou, F.; Illsley, N. P.; You, G. Functional characterization of a human organic anion transporter hOAT4 in placental BeWo cells. Eur. J. Pharm. Sci. 2006, 27, 518-523. (Pubitemid 43363342)
-
(2006)
European Journal of Pharmaceutical Sciences
, vol.27
, Issue.5
, pp. 518-523
-
-
Zhou, F.1
Illsley, N.P.2
You, G.3
-
186
-
-
16844384592
-
Metformin transport by renal basolateral organic cation transporter hOCT2
-
DOI 10.1007/s11095-004-1193-3
-
Kimura, N.; Okuda, M.; Inui, K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm. Res. 2005, 22, 255-259. (Pubitemid 40487209)
-
(2005)
Pharmaceutical Research
, vol.22
, Issue.2
, pp. 255-259
-
-
Kimura, N.1
Okuda, M.2
Inui, K.-I.3
-
187
-
-
0032455502
-
Transport of temocaprilat into rat hepatocytes: Role of organic anion transporting polypeptide
-
Ishizuka, H.; Konno, K.; Naganuma, H.; Nishimura, K.; Kouzuki, H.; Suzuki, H.; Stieger, B.; Meier, P. J.; Sugiyama, Y. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 1998, 287, 37-42. (Pubitemid 29140183)
-
(1998)
Journal of Pharmacology and Experimental Therapeutics
, vol.287
, Issue.1
, pp. 37-42
-
-
Ishizuka, H.1
Konno, K.2
Naganuma, H.3
Nishimura, K.4
Kouzuki, H.5
Suzuki, H.6
Stieger, B.7
Meier, P.J.8
Sugiyama, Y.9
-
188
-
-
0030824648
-
Carrier-mediated hepatic uptake of quinolone antibiotics in the rat
-
Sasabe, H.; Terasaki, T.; Tsuji, A.; Sugiyama, Y. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J. Pharmacol. Exp. Ther. 1997, 282, 162-171. (Pubitemid 27425538)
-
(1997)
Journal of Pharmacology and Experimental Therapeutics
, vol.282
, Issue.1
, pp. 162-171
-
-
Sasabe, H.1
Terasaki, T.2
Tsuji, A.3
Sugiyama, Y.4
-
189
-
-
10644270827
-
Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population
-
DOI 10.1002/jps.20190
-
Kawasaki, Y.; Kato, Y.; Sai, Y.; Tsuji, A. Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population. J. Pharm. Sci. 2004, 93, 2920-2926. (Pubitemid 39657796)
-
(2004)
Journal of Pharmaceutical Sciences
, vol.93
, Issue.12
, pp. 2920-2926
-
-
Kawasaki, Y.1
Kato, Y.2
Sai, Y.3
Tsuji, A.4
-
190
-
-
20744450287
-
Characterization of the organic cation transporter SLC22A16: A doxorubicin importer
-
DOI 10.1016/j.bbrc.2005.05.174, PII S0006291X05011873
-
Okabe, M.; Unno, M.; Harigae, H.; Kaku, M.; Okitsu, Y.; Sasaki, T.; Mizoi, T.; Shiiba, K.; Takanaga, H.; Terasaki, T.; Matsuno, S.; Sasaki, I.; Ito, S.; Abe, T. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 2005, 333, 754-762. (Pubitemid 40854224)
-
(2005)
Biochemical and Biophysical Research Communications
, vol.333
, Issue.3
, pp. 754-762
-
-
Okabe, M.1
Unno, M.2
Harigae, H.3
Kaku, M.4
Okitsu, Y.5
Sasaki, T.6
Mizoi, T.7
Shiiba, K.8
Takanaga, H.9
Terasaki, T.10
Matsuno, S.11
Sasaki, I.12
Ito, S.13
Abe, T.14
-
191
-
-
0034753042
-
Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2
-
Cui, Y.; König, J.; Keppler, D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol. 2001, 60, 934-943. (Pubitemid 33027428)
-
(2001)
Molecular Pharmacology
, vol.60
, Issue.5
, pp. 934-943
-
-
Cui, Y.1
Konig, J.2
Keppler, D.3
-
192
-
-
34447339394
-
Expression of 25 human ABC transporters in the yeast Pichia pastoris and characterization of the purified ABCC3 ATPase activity
-
DOI 10.1021/bi700020m
-
Chloupková, M.; Pickert, A.; Lee, J.Y.; Souza, S.; Trinh, Y.T.; Connelly, S.M.; Dumont. M.E.; Dean, M.; Urbatsch, I.L. Expression of 25 human ABC transporters in the yeast Pichia pastoris and characterization of the purified ABCC3 ATPase activity. Biochemistry 2007, 46, 7992-8003. (Pubitemid 47051635)
-
(2007)
Biochemistry
, vol.46
, Issue.27
, pp. 7992-8003
-
-
Chloupkova, M.1
Pickert, A.2
Lee, J.-Y.3
Souza, S.4
Trinh, Y.T.5
Connelly, S.M.6
Dumont, M.E.7
Dean, M.8
Urbatsch, I.L.9
-
193
-
-
0035958862
-
Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1): Requirement for glutathione or a non-sulfur-containing analog
-
DOI 10.1074/jbc.M102453200
-
Leslie, E. M.; Ito, K.; Upadhyaya, P.; Hecht, S. S.; Deeley, R. G.; Cole, S. P. Transport of the beta -O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J. Biol. Chem. 2001, 276, 27846-27854. (Pubitemid 37391478)
-
(2001)
Journal of Biological Chemistry
, vol.276
, Issue.30
, pp. 27846-27854
-
-
Leslie, E.M.1
Ito, K.-I.2
Upadhyaya, P.3
Hecht, S.S.4
Deeley, R.G.5
Cole, S.P.C.6
-
194
-
-
0034282991
-
Transport of amphipathic anions by human multidrug resistance protein 3
-
Zeng, H.; Liu, G.; Rea, P. A.; Kruh, G. D. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000, 60, 4779-4784. (Pubitemid 30701488)
-
(2000)
Cancer Research
, vol.60
, Issue.17
, pp. 4779-4784
-
-
Zeng, H.1
Liu, G.2
Rea, P.A.3
Kruh, G.D.4
-
195
-
-
33646798056
-
Comparison of drug efflux transport kinetics in various blood-brain barrier models
-
Bachmeier, C. J.; Trickler, W. J.; Miller, D. W. Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab. Dispos. 2006, 34, 998-1003.
-
(2006)
Drug Metab. Dispos.
, vol.34
, pp. 998-1003
-
-
Bachmeier, C.J.1
Trickler, W.J.2
Miller, D.W.3
-
196
-
-
0030939976
-
Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells
-
DOI 10.1007/s002800050627
-
Kelner, M. J.; McMorris, T. C.; Montoya, M. A.; Estes, L.; Rutherford, M.; Samson, K. M.; Taetle, R. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. Cancer Chemother. Pharmacol. 1997, 40, 65-71. (Pubitemid 27160963)
-
(1997)
Cancer Chemotherapy and Pharmacology
, vol.40
, Issue.1
, pp. 65-71
-
-
Kelner, M.J.1
McMorris, T.C.2
Montoya, M.A.3
Estes, L.4
Rutherford, M.5
Samson, K.M.6
Taetle, R.7
-
197
-
-
0030070072
-
Transport mechanism of anthracycline derivatives in human leukemia cell lines: Uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells
-
DOI 10.1007/s002800050389
-
Nagasawa, K.; Natazuka, T.; Chihara, K.; Kitazawa, F.; Tsumura, A.; Takara, K.; Nomiyama, M.; Ohnishi, N.; Yokoyama ,T. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother. Pharmacol. 1996, 37, 297-304. (Pubitemid 26031009)
-
(1996)
Cancer Chemotherapy and Pharmacology
, vol.37
, Issue.4
, pp. 297-304
-
-
Nagasawa, K.1
Natazuka, T.2
Chihara, K.3
Kitazawa, F.4
Tsumura, A.5
Takara, K.6
Nomiyama, M.7
Ohnishi, N.8
Yokoyama, T.9
-
198
-
-
0242585000
-
Midazolam exhibits characteristics of a highly permeable Pglycoprotein substrate
-
Tolle-Sander, S.; Rautio, J.; Wring, S.; Polli, J. W.; Polli, J. E. Midazolam exhibits characteristics of a highly permeable Pglycoprotein substrate. Pharm. Res. 2003, 20, 757-764
-
(2003)
Pharm. Res.
, vol.20
, pp. 757-764
-
-
Tolle-Sander, S.1
Rautio, J.2
Wring, S.3
Polli, J.W.4
Polli, J.E.5
-
199
-
-
0029781372
-
Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles
-
DOI 10.1021/js9600540
-
Kwon, Y.; Kamath, A. V.; Morris, M. E. Inhibitors of P-glycoprotein- mediated daunomycin transport in rat liver canalicular membrane vesicles. J. Pharm. Sci. 1996, 85, 935-939. (Pubitemid 26300219)
-
(1996)
Journal of Pharmaceutical Sciences
, vol.85
, Issue.9
, pp. 935-939
-
-
Kwon, Y.1
Kamath, A.V.2
Morris, M.E.3
-
200
-
-
0035686183
-
Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes
-
Guns, E. S.; Bullock, P. L.; Reimer, M. L.; Dixon, R.; Bally, M.; Mayer, L. D. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 2001, 26, 273-282.
-
(2001)
Eur. J. Drug Metab. Pharmacokinet.
, vol.26
, pp. 273-282
-
-
Guns, E.S.1
Bullock, P.L.2
Reimer, M.L.3
Dixon, R.4
Bally, M.5
Mayer, L.D.6
-
201
-
-
18444395839
-
Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes
-
DOI 10.1248/bpb.28.124
-
Shiraga, T.; Tozuka, Z.; Ishimura, R.; Kawamura, A.; Kagayama, A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol. Pharm. Bull. 2005, 28, 124-129. (Pubitemid 40879796)
-
(2005)
Biological and Pharmaceutical Bulletin
, vol.28
, Issue.1
, pp. 124-129
-
-
Shiraga, T.1
Tozuka, Z.2
Ishimura, R.3
Kawamura, A.4
Kagayama, A.5
-
202
-
-
0037636423
-
Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones
-
Hu, M.; Krausz, K.; Chen, J.; Ge, X.; Li, J.; Gelboin, H. L.; Gonzalez, F. J. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos. 2003, 31, 924-931.
-
(2003)
Drug Metab. Dispos.
, vol.31
, pp. 924-931
-
-
Hu, M.1
Krausz, K.2
Chen, J.3
Ge, X.4
Li, J.5
Gelboin, H.L.6
Gonzalez, F.J.7
-
203
-
-
34748901348
-
Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases
-
DOI 10.1124/dmd.107.017145
-
Sun, D.; Sharma, A. K.; Dellinger, R. W.; Blevins-Primeau, A. S.; Balliet, R. M.; Chen, G.; Boyiri, T.; Amin, S.; Lazarus, P. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab. Dispos. 2007, 35, 2006-2014. (Pubitemid 350010805)
-
(2007)
Drug Metabolism and Disposition
, vol.35
, Issue.11
, pp. 2006-2014
-
-
Sun, D.1
Sharma, A.K.2
Dellinger, R.W.3
Blevins-Primeau, A.S.4
Balliet, R.M.5
Chen, G.6
Boyiri, T.7
Amin, S.8
Lazarus, P.9
-
204
-
-
24944464940
-
Contribution of human hepatic cytochrome P450 isoforms to the metabolism of psychotropic drugs
-
DOI 10.1248/bpb.28.1711
-
Niwa, T.; Shiraga, T.; Ishii, I.; Kagayama, A.; Takagi, A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol. Pharm. Bull. 2005, 28, 1711-1716. (Pubitemid 41324138)
-
(2005)
Biological and Pharmaceutical Bulletin
, vol.28
, Issue.9
, pp. 1711-1716
-
-
Niwa, T.1
Shiraga, T.2
Ishii, I.3
Kagayama, A.4
Takagi, A.5
-
205
-
-
0028201724
-
Cytochrome P450 3A-mediated human liver microsomal taxol 6alpha- Hydroxylation
-
Kumar, G. N.; Walle, U. K.; Walle, T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J. Pharmacol. Exp. Ther. 1994, 268, 1160-1165. (Pubitemid 24100328)
-
(1994)
Journal of Pharmacology and Experimental Therapeutics
, vol.268
, Issue.3
, pp. 1160-1165
-
-
Kumar, G.N.1
Walle, U.K.2
Walle, T.3
-
206
-
-
0032797632
-
Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways
-
DOI 10.1016/S0006-2952(99)00167-7, PII S0006295299001677
-
Bort, R.; Macé, K.; Boobis, A.; Gómez-Lechón, M. J.; Pfeifer, A.; Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem. Pharmacol. 1999, 58, 787-796. (Pubitemid 29329528)
-
(1999)
Biochemical Pharmacology
, vol.58
, Issue.5
, pp. 787-796
-
-
Bort, R.1
MacE, K.2
Boobis, A.3
Gomez-Lechon, M.-J.4
Pfeifer, A.5
Castell, J.6
-
207
-
-
37249048453
-
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): A potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
-
Kamath, A. V.; Wang, J.; Lee, F. Y.; Marathe, P. H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 2008, 61, 365-376.
-
(2008)
Cancer Chemother. Pharmacol.
, vol.61
, pp. 365-376
-
-
Kamath, A.V.1
Wang, J.2
Lee, F.Y.3
Marathe, P.H.4
-
208
-
-
34250694236
-
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
-
DOI 10.1158/1078-0432.CCR-07-0088
-
Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S. D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 2007, 13, 3731-3737. (Pubitemid 46955138)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.12
, pp. 3731-3737
-
-
Li, J.1
Zhao, M.2
He, P.3
Hidalgo, M.4
Baker, S.D.5
-
209
-
-
0037185964
-
FT-IR spectroscopic investigations of single cells on the subcellular level
-
DOI 10.1016/S0924-2031(01)00153-9, PII S0924203101001539
-
Lasch, P.; Boese, M.; Pacifico, A.; Diem, M. FT-IR spectroscopic investigations of single cells on the subcellular level. Vibrational Spectrosc., 2002, 28, 147-157. (Pubitemid 34291406)
-
(2002)
Vibrational Spectroscopy
, vol.28
, Issue.1
, pp. 147-157
-
-
Lasch, P.1
Boese, M.2
Pacifico, A.3
Diem, M.4
-
210
-
-
0023689651
-
Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics
-
Burt, R. K.; Thorgeirsson, S. S. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J. Natl. Cancer Inst. 1988, 80, 1383-1386.
-
(1988)
J. Natl. Cancer Inst.
, vol.80
, pp. 1383-1386
-
-
Burt, R.K.1
Thorgeirsson, S.S.2
-
211
-
-
0028004345
-
Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells
-
Schrenk, D.; Gant, T. W.; Michalke, A.; Orzechowski, A.; Silverman, J. A.; Battula, N.; Thorgeirsson, S. S. Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells. Carcinogenesis 1994, 15, 2541-2546.
-
(1994)
Carcinogenesis
, vol.15
, pp. 2541-2546
-
-
Schrenk, D.1
Gant, T.W.2
Michalke, A.3
Orzechowski, A.4
Silverman, J.A.5
Battula, N.6
Thorgeirsson, S.S.7
-
212
-
-
0035029345
-
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors
-
Huang, L.; Wring, S. A.; Woolley, J. L.; Brouwer, K. R.; Serabjit-Singh, C.; Polli, J. W. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 2001, 29, 754-760.
-
(2001)
Drug Metab. Dispos.
, vol.29
, pp. 754-760
-
-
Huang, L.1
Wring, S.A.2
Woolley, J.L.3
Brouwer, K.R.4
Serabjit-Singh, C.5
Polli, J.W.6
-
213
-
-
23344450788
-
Induction of phase I, II and III drug metabolism/transport by xenobiotics
-
Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005, 28, 249-268.
-
(2005)
Arch Pharm Res.
, vol.28
, pp. 249-268
-
-
Xu, C.1
Li, C.Y.2
Kong, A.N.3
-
214
-
-
23144456286
-
Regulation of hepatic transporters by xenobiotic receptors
-
DOI 10.2174/1389200054633826
-
Klaassen, C. D.; Slitt, A. L. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 2005, 6, 309-328. (Pubitemid 41086765)
-
(2005)
Current Drug Metabolism
, vol.6
, Issue.4
, pp. 309-328
-
-
Klaassen, C.D.1
Slitt, A.L.2
-
215
-
-
23944438892
-
Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways
-
Cheng, X.; Maher, J.; Dieter, M. Z.; Klaassen, C. D. Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab. Dispos. 2005, 33, 1276-1282.
-
(2005)
Drug Metab. Dispos.
, vol.33
, pp. 1276-1282
-
-
Cheng, X.1
Maher, J.2
Dieter, M.Z.3
Klaassen, C.D.4
-
216
-
-
33751092279
-
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine
-
Oscarson, M.; Zanger, U. M.; Rifki, O. F.; Klein, K.; Eichelbaum, M.; Meyer, U. A. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 2006, 80, 440-456.
-
(2006)
Clin. Pharmacol. Ther.
, vol.80
, pp. 440-456
-
-
Oscarson, M.1
Zanger, U.M.2
Rifki, O.F.3
Klein, K.4
Eichelbaum, M.5
Meyer, U.A.6
-
217
-
-
34247603065
-
Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2
-
Kohle, C.; Bock, K. W. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem. Pharmacol. 2007, 73, 1853-1862.
-
(2007)
Biochem. Pharmacol.
, vol.73
, pp. 1853-1862
-
-
Kohle, C.1
Bock, K.W.2
-
218
-
-
0035038919
-
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
-
Synold, T. W.; Dussault, I.; Forman, B. M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 2001, 7, 584-590.
-
(2001)
Nat. Med.
, vol.7
, pp. 584-590
-
-
Synold, T.W.1
Dussault, I.2
Forman, B.M.3
-
219
-
-
41349121332
-
Coordinated induction of drug transporters and phase I and II metabolism in human liver slices
-
Olinga, P.; Elferink, M. G.; Draaisma, A. L.; Merema, M. T.; Castell, J. V. Perez, G.; Groothuis, G. M. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharm. Sci. 2008, 33, 380-389.
-
(2008)
Eur. J. Pharm. Sci.
, vol.33
, pp. 380-389
-
-
Olinga, P.1
Elferink, M.G.2
Draaisma, A.L.3
Merema, M.T.4
Castell, J.V.5
Perez, G.6
Groothuis, G.M.7
-
220
-
-
22844451077
-
Role of efflux pumps and metabolising enzymes in drug delivery
-
Katragadda, S.; Budda, B.; Anand, B. S.; Mitra, A. K. Role of efflux pumps and metabolising enzymes in drug delivery. Expert. Opin. Drug Deliv. 2005, 2, 683-705.
-
(2005)
Expert. Opin. Drug Deliv.
, vol.2
, pp. 683-705
-
-
Katragadda, S.1
Budda, B.2
Anand, B.S.3
Mitra, A.K.4
-
221
-
-
33751345817
-
In vivo pharmacokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice
-
Hu, R.; Shen, G.; Yerramilli, U. R.; Lin, W.; Xu, C.; Nair, S.; Kong, A. N. In vivo pharmacokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice. Arch. Pharm. Res. 2006, 29, 911-920.
-
(2006)
Arch. Pharm. Res.
, vol.29
, pp. 911-920
-
-
Hu, R.1
Shen, G.2
Yerramilli, U.R.3
Lin, W.4
Xu, C.5
Nair, S.6
Kong, A.N.7
-
222
-
-
0032907322
-
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
-
Kim, R. B.; Wandel, C.; Leake, B.; Cvetkovic, M.; Fromm, M. F.; Dempsey, P. J.; Roden, M. M.; Belas, F.; Chaudhary, A. K.; Roden, D. M.; Wood, A. J.; Wilkinson, G. R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 16, 408-414.
-
(1999)
Pharm. Res.
, vol.16
, pp. 408-414
-
-
Kim, R.B.1
Wandel, C.2
Leake, B.3
Cvetkovic, M.4
Fromm, M.F.5
Dempsey, P.J.6
Roden, M.M.7
Belas, F.8
Chaudhary, A.K.9
Roden, D.M.10
Wood, A.J.11
Wilkinson, G.R.12
-
223
-
-
0029028792
-
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
-
Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995, 13, 129-134.
-
(1995)
Mol. Carcinog.
, vol.13
, pp. 129-134
-
-
Wacher, V.J.1
Wu, C.Y.2
Benet, L.Z.3
-
224
-
-
24944529235
-
Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions
-
DOI 10.2174/138920005774330657
-
Jeong, E. J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab. 2005, 6, 455-468. (Pubitemid 41300790)
-
(2005)
Current Drug Metabolism
, vol.6
, Issue.5
, pp. 455-468
-
-
Jeong, E.J.1
Liu, X.2
Jia, X.3
Chen, J.4
Hu, M.5
-
225
-
-
0024592166
-
Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia
-
Paul, C.; Liliemark, J.; Tidefelt, U.; Gahrton, G.; Peterson, C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther. Drug Monit. 1989, 11, 140-148. (Pubitemid 19064837)
-
(1989)
Therapeutic Drug Monitoring
, vol.11
, Issue.2
, pp. 140-148
-
-
Paul, C.1
Liliemark, J.2
Tidefelt, U.3
Gahrton, G.4
Peterson, C.5
-
226
-
-
28244485775
-
Pharmacogenomics of the human ABC transporter ABCG2: From functional evaluation to drug molecular design
-
DOI 10.1007/s00114-005-0019-4
-
Ishikawa, T.; Tamura, A.; Saito, H.; Wakabayashi, K.; Nakagawa, H. Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften 2005, 92, 451-463. (Pubitemid 41719161)
-
(2005)
Naturwissenschaften
, vol.92
, Issue.10
, pp. 451-463
-
-
Ishikawa, T.1
Tamura, A.2
Saito, H.3
Wakabayashi, K.4
Nakagawa, H.5
-
227
-
-
41549151966
-
ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells
-
Decleves, X.; Bihorel, S.; Debray, M.; Yousif, S.; Camenisch, G.; Scherrmann, J. M. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol. Res. 2008, 57, 214-222.
-
(2008)
Pharmacol. Res.
, vol.57
, pp. 214-222
-
-
Decleves, X.1
Bihorel, S.2
Debray, M.3
Yousif, S.4
Camenisch, G.5
Scherrmann, J.M.6
-
228
-
-
22144442645
-
Functional proteinprotein interaction of drug metabolizing enzymes
-
Ishii, Y.; Takeda, S.; Yamada, H.; Oguri, K. Functional proteinprotein interaction of drug metabolizing enzymes. Front. Biosci. 2005, 10, 887-895.
-
(2005)
Front. Biosci.
, vol.10
, pp. 887-895
-
-
Ishii, Y.1
Takeda, S.2
Yamada, H.3
Oguri, K.4
-
229
-
-
14944354806
-
Modulation of UDP-glucuronosyltransferase function by cytochrome P450: Evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4
-
DOI 10.1124/mol.104.007641
-
Takeda, S.; Ishii, Y.; Iwanaga, M.; Mackenzie, P. I.; Nagata, K.; Yamazoe, Y.; Oguri, K.; Yamada, H. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol. 2005, 67, 665-672. (Pubitemid 40365314)
-
(2005)
Molecular Pharmacology
, vol.67
, Issue.3
, pp. 665-672
-
-
Takeda, S.1
Ishii, Y.2
Iwanaga, M.3
Mackenzie, P.I.4
Nagata, K.5
Yamazoe, Y.6
Oguri, K.7
Yamada, H.8
-
230
-
-
0033745088
-
Hepatic secretion of conjugated drugs and endogenous substances
-
Keppler, D.; König, J. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 2000, 20, 265-272. (Pubitemid 30807964)
-
(2000)
Seminars in Liver Disease
, vol.20
, Issue.3
, pp. 265-272
-
-
Keppler, D.1
Konig, J.2
-
231
-
-
0037085032
-
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation
-
Cummings, J.; Boyd, G.; Ethell, B. T.; Macpherson, J. S.; Burchell, B.; Smyth, J. F.; Jodrell, D. I. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem. Pharmacol. 2002, 63, 607-613.
-
(2002)
Biochem. Pharmacol.
, vol.63
, pp. 607-613
-
-
Cummings, J.1
Boyd, G.2
Ethell, B.T.3
Macpherson, J.S.4
Burchell, B.5
Smyth, J.F.6
Jodrell, D.I.7
-
232
-
-
0345734082
-
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: Reversal of resistance by food additives
-
Cummings, J.; Ethell, B. T.; Jardine, L.; Boyd, G.; Macpherson, J. S.; Burchell, B.; Smyth, J. F.; Jodrell, D. I. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 2003, 63, 8443-8450.
-
(2003)
Cancer Res.
, vol.63
, pp. 8443-8450
-
-
Cummings, J.1
Ethell, B.T.2
Jardine, L.3
Boyd, G.4
Macpherson, J.S.5
Burchell, B.6
Smyth, J.F.7
Jodrell, D.I.8
-
233
-
-
0345549402
-
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: Contribution of drug transport proteins
-
Cummings, J.; Zelcer, N.; Allen, J. D.; Yao, D.; Boyd, G.; Maliepaard, M.; Friedberg, T. H.; Smyth, J. F.; Jodrell, D. I. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem. Pharmacol. 2004, 67, 31-39.
-
(2004)
Biochem. Pharmacol.
, vol.67
, pp. 31-39
-
-
Cummings, J.1
Zelcer, N.2
Allen, J.D.3
Yao, D.4
Boyd, G.5
Maliepaard, M.6
Friedberg, T.H.7
Smyth, J.F.8
Jodrell, D.I.9
-
234
-
-
0028578004
-
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
-
Muller, M.; Meijer, C.; Zaman, G. J.; Borst, P.; Scheper, R. J.; Mulder, N. H.; de Vries, E. G.; Jansen, P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA 1994, 91, 13033-13037.
-
(1994)
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 13033-13037
-
-
Muller, M.1
Meijer, C.2
Zaman, G.J.3
Borst, P.4
Scheper, R.J.5
Mulder, N.H.6
De Vries, E.G.7
Jansen, P.L.8
-
235
-
-
0031867669
-
Multidrug resistance protein and glutathione Stransferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity
-
Morrow, C. S.; Diah, S.; Smitherman, P. K.; Schneider, E.; Townsend, A. J. Multidrug resistance protein and glutathione Stransferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity. Carcinogenesis 1998, 19, 109-115.
-
(1998)
Carcinogenesis
, vol.19
, pp. 109-115
-
-
Morrow, C.S.1
Diah, S.2
Smitherman, P.K.3
Schneider, E.4
Townsend, A.J.5
-
236
-
-
0032493638
-
Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells
-
Morrow, C. S.; Smitherman, P. K.; Diah, S. K.; Schneider, E.; Townsend, A. J. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J. Biol. Chem. 1998, 273, 20114-20120.
-
(1998)
J. Biol. Chem.
, vol.273
, pp. 20114-20120
-
-
Morrow, C.S.1
Smitherman, P.K.2
Diah, S.K.3
Schneider, E.4
Townsend, A.J.5
-
237
-
-
0345267138
-
Glutathione metabolism and glutathione S-conjugate export ATPase (MRP1/GS-X pump) activity in cancer. I. Differential expression in human cancer cell lines
-
de Bittencourt Jr, P. I.; Senna, S. M.; Vidor, A. C.; Miyasaka, C. K.; Curi, R.; Williams, J. F. Glutathione metabolism and glutathione S-conjugate export ATPase (MRP1/GS-X pump) activity in cancer. I. Differential expression in human cancer cell lines. Biochem. Mol. Biol. Int. 1998, 45, 1227-1241.
-
(1998)
Biochem. Mol. Biol. Int.
, vol.45
, pp. 1227-1241
-
-
De Bittencourt Jr., P.I.1
Senna, S.M.2
Vidor, A.C.3
Miyasaka, C.K.4
Curi, R.5
Williams, J.F.6
-
238
-
-
0034002720
-
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein
-
Benderra, Z.; Trussardi, A.; Morjani, H.; Villa, A. M.; Doglia, S. M.; Manfait, M. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur. J. Cancer. 2000, 36, 428-434.
-
(2000)
Eur. J. Cancer.
, vol.36
, pp. 428-434
-
-
Benderra, Z.1
Trussardi, A.2
Morjani, H.3
Villa, A.M.4
Doglia, S.M.5
Manfait, M.6
-
239
-
-
0035896509
-
Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity
-
DOI 10.1074/jbc.M009400200
-
Paumi, C. M.; Ledford, B. G.; Smitherman, P. K.; Townsend, A. J.; Morrow, C. S. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem. 2001, 276, 7952-7956. (Pubitemid 37385593)
-
(2001)
Journal of Biological Chemistry
, vol.276
, Issue.11
, pp. 7952-7956
-
-
Paumi, C.M.1
Ledford, B.G.2
Smitherman, P.K.3
Townsend, A.J.4
Morrow, C.S.5
-
240
-
-
0346497684
-
Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione Stransferase A1-1-mediated resistance to chlorambucil cytotoxicity
-
Smitherman, P. K.; Townsend, A. J.; Kute, T. E.; Morrow, C. S. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione Stransferase A1-1-mediated resistance to chlorambucil cytotoxicity. J. Pharmacol. Exp. Ther. 2004, 308, 260-267.
-
(2004)
J. Pharmacol. Exp. Ther.
, vol.308
, pp. 260-267
-
-
Smitherman, P.K.1
Townsend, A.J.2
Kute, T.E.3
Morrow, C.S.4
-
241
-
-
0344845291
-
Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimaneglutathione
-
Bai, J.; Lai, L.; Yeo, H. C.; Goh, B. C.; Tan, T. M. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimaneglutathione. Int. J. Biochem. Cell. Biol. 2004, 36, 247-257.
-
(2004)
Int. J. Biochem. Cell. Biol.
, vol.36
, pp. 247-257
-
-
Bai, J.1
Lai, L.2
Yeo, H.C.3
Goh, B.C.4
Tan, T.M.5
-
242
-
-
14944364661
-
Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen
-
DOI 10.1124/mol.104.007393
-
Adachi, Y.; Suzuki, H.; Schinkel, A. H.; Sugiyama, Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol. Pharmacol. 2005, 67, 923-928. (Pubitemid 40365339)
-
(2005)
Molecular Pharmacology
, vol.67
, Issue.3
, pp. 923-928
-
-
Adachi, Y.1
Suzuki, H.2
Schinkel, A.H.3
Sugiyama, Y.4
-
243
-
-
15544376626
-
Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: Contributions of glutathione, glutathione S-transferase, and MRP1
-
Peklak-Scott, C.; Townsend, A. J.; Morrow, C. S. Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: contributions of glutathione, glutathione S-transferase, and MRP1. Biochemistry 2005, 44, 4426-4433.
-
(2005)
Biochemistry
, vol.44
, pp. 4426-4433
-
-
Peklak-Scott, C.1
Townsend, A.J.2
Morrow, C.S.3
-
244
-
-
0033230779
-
Export pumps for glutathione S-conjugates
-
Keppler, D. Export pumps for glutathione S-conjugates. Free Radic. Biol. Med. 1999, 27, 985-991.
-
(1999)
Free Radic. Biol. Med.
, vol.27
, pp. 985-991
-
-
Keppler, D.1
-
245
-
-
33751578245
-
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition
-
Bleasby, K.; Castle, J. C.; Roberts, C. J.; Cheng, C.; Bailey, W. J.; Sina, J. F.; Kulkarni, A. V.; Hafey, M. J.; Evers, R.; Johnson, J. M.; Ulrich, R. G.; Slatter, J. G. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006, 36, 963-988.
-
(2006)
Xenobiotica
, vol.36
, pp. 963-988
-
-
Bleasby, K.1
Castle, J.C.2
Roberts, C.J.3
Cheng, C.4
Bailey, W.J.5
Sina, J.F.6
Kulkarni, A.V.7
Hafey, M.J.8
Evers, R.9
Johnson, J.M.10
Ulrich, R.G.11
Slatter, J.G.12
-
246
-
-
23744464363
-
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver
-
Albermann, N.; Schmitz-Winnenthal, F. H.; Z'graggen, K.; Volk, C.; Hoffmann, M. M.; Haefeli, W. E.; Weiss, J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 2005, 70, 949-958.
-
(2005)
Biochem. Pharmacol.
, vol.70
, pp. 949-958
-
-
Albermann, N.1
Schmitz-Winnenthal, F.H.2
Z'Graggen, K.3
Volk, C.4
Hoffmann, M.M.5
Haefeli, W.E.6
Weiss, J.7
-
247
-
-
3042688858
-
Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver
-
DOI 10.1111/j.1349-7006.2004.tb03243.x
-
Furukawa, M.; Nishimura, M.; Ogino, D.; Chiba, R.; Ikai, I.; Ueda, N.; Naito, S.; Kuribayashi, S.; Moustafa, M. A.; Uchida, T.; Sawada, H.; Kamataki, T.; Funae, Y.; Fukumoto, M. Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci. 2004, 95, 520-529. (Pubitemid 38832702)
-
(2004)
Cancer Science
, vol.95
, Issue.6
, pp. 520-529
-
-
Furukawa, M.1
Nishimura, M.2
Ogino, D.3
Chiba, R.4
Ikai, I.5
Ueda, N.6
Naito, S.7
Kuribayashi, S.8
Moustafa, M.A.9
Uchida, T.10
Sawada, H.11
Kamataki, T.12
Funae, Y.13
Fukumoto, M.14
-
248
-
-
41549114526
-
Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues
-
Pavek, P.; Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 2008, 9, 129-143.
-
(2008)
Curr. Drug Metab.
, vol.9
, pp. 129-143
-
-
Pavek, P.1
Dvorak, Z.2
-
249
-
-
33744456008
-
Expression of drug pathway proteins is independent of tumour type
-
Zhang, W.; Shannon, W. D.; Duncan, J.; Scheffer, G. L.; Scheper, R. J.; McLeod, H. L. Expression of drug pathway proteins is independent of tumour type. J. Pathol. 2006, 209, 213-219.
-
(2006)
J. Pathol.
, vol.209
, pp. 213-219
-
-
Zhang, W.1
Shannon, W.D.2
Duncan, J.3
Scheffer, G.L.4
Scheper, R.J.5
McLeod, H.L.6
-
250
-
-
0035111995
-
P450 enzyme expression patterns in the NCI human tumor cell line panel
-
Yu L. J.; Matias, J.; Scudiero, D. A.; Hite, K. M.; Monks, A.; Sausville, E. A; Waxman, D. J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 2001, 29, 304-312.
-
(2001)
Drug Metab. Dispos.
, vol.29
, pp. 304-312
-
-
Yu, L.J.1
Matias, J.2
Scudiero, D.A.3
Hite, K.M.4
Monks, A.5
Sausville, E.A.6
Waxman, D.J.7
-
251
-
-
5144226566
-
Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells
-
DOI 10.1016/j.ccr.2004.06.026, PII S1535610804002065
-
Szakács, G.; Annereau, J. P.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K. J.; Reinhold, W.; Guo, Y.; Kruh, G. D.; Reimers, M.; Weinstein, J. N.; Gottesman, M. M. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004, 6, 129-137. (Pubitemid 39485685)
-
(2004)
Cancer Cell
, vol.6
, Issue.2
, pp. 129-137
-
-
Szakacs, G.1
Annereau, J.-P.2
Lababidi, S.3
Shankavaram, U.4
Arciello, A.5
Bussey, K.J.6
Reinhold, W.7
Guo, Y.8
Kruh, G.D.9
Reimers, M.10
Weinstein, J.N.11
Gottesman, M.M.12
-
252
-
-
3042655528
-
Membrane transporters and channels: Role of the transportome in cancer chemosensitivity and chemoresistance
-
DOI 10.1158/0008-5472.CAN-03-3884
-
Huang, Y.; Anderle, P.; Bussey, K. J.; Barbacioru, C.; Shankavaram, U.; Dai, Z.; Reinhold, W. C.; Papp, A.; Weinstein, J. N.; Sadee, W. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004, 64, 4294-4301. (Pubitemid 38802436)
-
(2004)
Cancer Research
, vol.64
, Issue.12
, pp. 4294-4301
-
-
Huang, Y.1
Anderle, P.2
Bussey, K.J.3
Barbacioru, C.4
Shankavaram, U.5
Dai, Z.6
Reinhold, W.C.7
Papp, A.8
Weinstein, J.N.9
Sadee, W.10
-
253
-
-
0037331756
-
Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines
-
Nakumura, T.; Sakaeda, T.; Ohmoto, N.; Moriya, Y.; Komoto, C.; Shirakawa, T.; Gotoh, A.; Matsuo, M.; Okmura, K. Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines. Pharm. Res. 2003, 20, 324-347.
-
(2003)
Pharm. Res.
, vol.20
, pp. 324-347
-
-
Nakumura, T.1
Sakaeda, T.2
Ohmoto, N.3
Moriya, Y.4
Komoto, C.5
Shirakawa, T.6
Gotoh, A.7
Matsuo, M.8
Okmura, K.9
-
254
-
-
9444282642
-
Active transport of imatinib into and out of cells: Implications for drug resistance
-
DOI 10.1182/blood-2003-12-4276
-
Thomas, J.; Wang, L.; Clark, R. E.; Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104, 3739-3745. (Pubitemid 39564452)
-
(2004)
Blood
, vol.104
, Issue.12
, pp. 3739-3745
-
-
Thomas, J.1
Wang, L.2
Clark, R.E.3
Pirmohamed, M.4
-
255
-
-
44849142072
-
Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl) benzothiazole in breast cancer cell lines
-
Bradshaw, T. D.; Stone, E. L.; Trapani, V.; Leong, C. O.; Matthews, C. S.; te Poele, R.; Stevens, M. F. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines. Breast Cancer Res. Treat. 2008, 110, 57-68.
-
(2008)
Breast Cancer Res. Treat.
, vol.110
, pp. 57-68
-
-
Bradshaw, T.D.1
Stone, E.L.2
Trapani, V.3
Leong, C.O.4
Matthews, C.S.5
Te Poele, R.6
Stevens, M.F.7
-
256
-
-
52949095077
-
Retrotransposons revisited: The restraint and rehabilitation of parasites
-
Goodier, J. L.; Kazazian, H. H. Jr. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell 2008, 135, 23-35.
-
(2008)
Cell
, vol.135
, pp. 23-35
-
-
Goodier, J.L.1
Kazazian Jr., H.H.2
-
257
-
-
52949110235
-
SnapShot: Vertebrate transposons
-
Mandal, P. K.; Kazazian, H. H. Jr. SnapShot: Vertebrate transposons. Cell 2008, 135, 192-192
-
(2008)
Cell
, vol.135
, pp. 192-192
-
-
Mandal, P.K.1
Kazazian Jr., H.H.2
-
258
-
-
33645319220
-
Retrotransposons
-
Schulz, W. A. Retrotransposons. J. Biomed. Biotechnol. 2006, 2006, 83672-83681.
-
(2006)
J. Biomed. Biotechnol.
, vol.2006
, pp. 83672-83681
-
-
Schulz, W.A.1
-
259
-
-
18144383865
-
Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: Alternative subcellular enzyme compartmentation may contribute to carcinogenesis
-
Leung, Y. K.; Lau, K. M.; Mobley, J.; Jiang, Z.; Ho, S. M. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 2005, 65, 3726-3734.
-
(2005)
Cancer Res.
, vol.65
, pp. 3726-3734
-
-
Leung, Y.K.1
Lau, K.M.2
Mobley, J.3
Jiang, Z.4
Ho, S.M.5
-
260
-
-
34247253801
-
Transposable elements are enriched within or in close proximity to xenobiotic-metabolizing cytochrome P450 genes
-
DOI 10.1186/1471-2148-7-46
-
Chen, S.; Li, X. Transposable elements are enriched within or in close proximity to xenobiotic-metabolizing cytochrome P450 genes. BMC Evol. Biol. 2007, 7, 46-58. (Pubitemid 46623219)
-
(2007)
BMC Evolutionary Biology
, vol.7
, pp. 46
-
-
Chen, S.1
Li, X.2
-
261
-
-
33846023369
-
Characterization of gene rearrangements leading to activation of MDR-1
-
DOI 10.1074/jbc.M602998200
-
Huff, L. M.; Lee, J. S.; Robey, R. W.; Fojo, T. Characterization of gene rearrangements leading to activation of MDR-1. J. Biol. Chem. 2006, 281, 36501-36509. (Pubitemid 46042117)
-
(2006)
Journal of Biological Chemistry
, vol.281
, Issue.48
, pp. 36501-36509
-
-
Huff, L.M.1
Lee, J.-S.2
Robey, R.W.3
Fojo, T.4
-
262
-
-
33846576044
-
Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance
-
DOI 10.1016/j.cancergencyto.2006.07.020, PII S0165460806005139
-
Yabuki, N.; Sakata, K.; Yamasaki, T.; Terashima, H.; Mio, T.; Miyazaki, Y.; Fujii, T.; Kitada, K. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet. Cytogenet. 2007, 173, 1-9. (Pubitemid 46187292)
-
(2007)
Cancer Genetics and Cytogenetics
, vol.173
, Issue.1
, pp. 1-9
-
-
Yabuki, N.1
Sakata, K.2
Yamasaki, T.3
Terashima, H.4
Mio, T.5
Miyazaki, Y.6
Fujii, T.7
Kitada, K.8
-
263
-
-
33846299874
-
Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilis
-
Pumbwe, L.; Wareham, D. W.; Aduse-Opoku, J.; Brazier, J. S.; Wexler, H. M. Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilis. Clin. Microbiol. Infect. 2007, 13, 183-189.
-
(2007)
Clin. Microbiol. Infect.
, vol.13
, pp. 183-189
-
-
Pumbwe, L.1
Wareham, D.W.2
Aduse-Opoku, J.3
Brazier, J.S.4
Wexler, H.M.5
-
264
-
-
16844361873
-
Genetic and structural analysis of the Bacteroides conjugative transposon CTn341
-
Bacic, M.; Parker, A. C.; Stagg, J.; Whitley, H. P.; Wells, W. G.; Jacob, L. A.; Smith, C. J. Genetic and structural analysis of the Bacteroides conjugative transposon CTn341. J. Bacteriol. 2005, 187, 2858-2869.
-
(2005)
J. Bacteriol.
, vol.187
, pp. 2858-2869
-
-
Bacic, M.1
Parker, A.C.2
Stagg, J.3
Whitley, H.P.4
Wells, W.G.5
Jacob, L.A.6
Smith, C.J.7
-
265
-
-
33947260230
-
Molecular Mechanisms of Antibacterial Multidrug Resistance
-
DOI 10.1016/j.cell.2007.03.004, PII S009286740700311X
-
Alekshun, M. N.; Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007, 128, 1037-1050. (Pubitemid 46427883)
-
(2007)
Cell
, vol.128
, Issue.6
, pp. 1037-1050
-
-
Alekshun, M.N.1
Levy, S.B.2
-
266
-
-
34548724460
-
Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria
-
Lubelski, J.; Konings, W. N.; Driessen, A. J. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol. Mol. Biol. Rev. 2007, 71, 463-476.
-
(2007)
Microbiol. Mol. Biol. Rev.
, vol.71
, pp. 463-476
-
-
Lubelski, J.1
Konings, W.N.2
Driessen, A.J.3
-
267
-
-
33646251815
-
Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria
-
Piddock, L. J. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 2006, 19, 382-402.
-
(2006)
Clin. Microbiol. Rev.
, vol.19
, pp. 382-402
-
-
Piddock, L.J.1
-
268
-
-
16244406203
-
Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: Natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins
-
Mussi, M. A.; Limansky, A. S.; Viale, A. M. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob. Agents Chemother. 2005, 49, 1432-1440.
-
(2005)
Antimicrob. Agents Chemother.
, vol.49
, pp. 1432-1440
-
-
Mussi, M.A.1
Limansky, A.S.2
Viale, A.M.3
-
269
-
-
0037183880
-
A single P450 allele associated with insecticide resistance in Drosophila
-
Daborn, P. J.; Yen, J. L.; Bogwitz, M. R.; Le Goff, G.; Feil, E.; Jeffers, S.; Tijet, N.; Perry, T.; Heckel, D.; Batterham, P.; Feyereisen, R.; Wilson, T. G.; Ffrench-Constant, R. H. A single P450 allele associated with insecticide resistance in Drosophila. Science 2002, 297, 2253-2256.
-
(2002)
Science
, vol.297
, pp. 2253-2256
-
-
Daborn, P.J.1
Yen, J.L.2
Bogwitz, M.R.3
Le Goff, G.4
Feil, E.5
Jeffers, S.6
Tijet, N.7
-
270
-
-
3242720690
-
World-wide survey of an Accord insertion and its association with DDT resistance in Drosophila melanogaster
-
DOI 10.1111/j.1365-294X.2004.02263.x
-
Catania, F.; Kauer, M. O.; Daborn, P. J.; Yen, J. L.; Ffrench-Constant, R.H.; Schlotterer, C. Worldwide survey of an Accord insertion and its association with DDT resistance in Drosophila melanogaster. Mol. Ecol. 2004, 13, 2491-2504. (Pubitemid 38946437)
-
(2004)
Molecular Ecology
, vol.13
, Issue.8
, pp. 2491-2504
-
-
Catania, F.1
Kauer, M.O.2
Daborn, P.J.3
Yen, J.L.4
Ffrench-Constant, R.H.5
Schlotterer, C.6
-
271
-
-
23044509495
-
Pesticide resistance via transposition-mediated adaptive gene truncation in Drosophila
-
Aminetzach, Y. T.; Macpherson, J. M.; Petrov, D. A. Pesticide resistance via transposition-mediated adaptive gene truncation in Drosophila. Science 2005, 309, 764-767.
-
(2005)
Science
, vol.309
, pp. 764-767
-
-
Aminetzach, Y.T.1
Macpherson, J.M.2
Petrov, D.A.3
-
272
-
-
24744438217
-
Evidence for a functional interaction between the Bari1 transposable element and the cytochrome P450 cyp12a4 gene in Drosophila melanogaster
-
DOI 10.1016/j.gene.2005.06.005, PII S0378111905003380
-
Marsano, R. M.; Caizzi, R.; Moschetti, R.; Junakovic, N. Evidence for a functional interaction between the Bari1 transposable element and the cytochrome P450 cyp12a4 gene in Drosophila melanogaster. Gene 2005, 357, 122-128. (Pubitemid 41297578)
-
(2005)
Gene
, vol.357
, Issue.2
, pp. 122-128
-
-
Marsano, R.M.1
Caizzi, R.2
Moschetti, R.3
Junakovic, N.4
-
273
-
-
34247854158
-
Cis-regulatory elements in the Accord retrotransposon result in tissue-specific expression of the Drosophila melanogaster insecticide resistance gene Cyp6g1
-
Chung, H.; Bogwitz, M. R.; McCart, C.; Andrianopoulos, A.; Ffrench-Constant, R.H.; Batterham, P.; Daborn, P.J. Cis-regulatory elements in the Accord retrotransposon result in tissue-specific expression of the Drosophila melanogaster insecticide resistance gene Cyp6g1. Genetics 2007, 175, 1071-1077.
-
(2007)
Genetics
, vol.175
, pp. 1071-1077
-
-
Chung, H.1
Bogwitz, M.R.2
McCart, C.3
Andrianopoulos, A.4
Ffrench-Constant, R.H.5
Batterham, P.6
Daborn, P.J.7
-
274
-
-
1542378140
-
Genomic structure of the NtPDR1 gene, harboring the two miniature inverted-repeat transposable elements, NtToya1 and NtStowaway101
-
DOI 10.1266/ggs.78.409
-
Schenke, D.; Sasabe, M.; Toyoda, K.; Inagaki, Y. S.; Shiraishi, T.; Ichinose, Y. Genomic structure of the NtPDR1 gene, harboring the two miniature inverted-repeat transposable elements, NtToya1 and NtStowaway101. Genes Genet. Syst. 2003, 78, 409-418. (Pubitemid 38298018)
-
(2003)
Genes and Genetic Systems
, vol.78
, Issue.6
, pp. 409-418
-
-
Schenke, D.1
Sasabe, M.2
Toyoda, K.3
Inagaki, Y.-S.4
Shiraishi, T.5
Ichinose, Y.6
-
275
-
-
34247568394
-
Efflux pumps as antimicrobial resistance mechanisms
-
DOI 10.1080/07853890701195262, PII 777631811
-
Poole, K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 2007, 39, 162-176. (Pubitemid 46676478)
-
(2007)
Annals of Medicine
, vol.39
, Issue.3
, pp. 162-176
-
-
Poole, K.1
-
276
-
-
34447553357
-
Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: Role of enhanced efflux pump activity and inactivation
-
DOI 10.1093/jac/dkl380
-
Schumacher, A.; Trittler, R.; Bohnert, J. A.; Kümmerer, K.; Pagès, J. M.; Kern, W. V. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J. Antimicrob. Chemother. 2007, 59, 1261-1264. (Pubitemid 47073344)
-
(2007)
Journal of Antimicrobial Chemotherapy
, vol.59
, Issue.6
, pp. 1261-1264
-
-
Schumacher, A.1
Trittler, R.2
Bohnert, J.A.3
Kummerer, K.4
Pages, J.-M.5
Kern, W.V.6
-
277
-
-
0034746955
-
Mechanism and clinical significance of metronidazole resistance in Helicobacter pylori
-
van der Wouden, E. J.; Thijs, J. C.; Kusters, J. G.; van Zwet, A. A.; Kleibeuker, J. H. Mechanism and clinical significance of metronidazole resistance in Helicobacter pylori. Scand. J. Gastroenterol. Suppl. 2001, 234, 10-14. (Pubitemid 33070906)
-
(2001)
Scandinavian Journal of Gastroenterology, Supplement
, vol.36
, Issue.234
, pp. 10-14
-
-
Van Der Wouden, E.-J.1
Thijs, J.C.2
Kusters, J.G.3
Van Zwet, J.A.4
Kleibeuker, J.H.5
-
279
-
-
39049134890
-
Metallo beta lactamases in Pseudomonas aeruginosa and acinetobacter species
-
DOI 10.1517/13543784.17.2.131
-
Gupta, V. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin. Investig. Drugs 2008, 17, 131-143. (Pubitemid 351578196)
-
(2008)
Expert Opinion on Investigational Drugs
, vol.17
, Issue.2
, pp. 131-143
-
-
Gupta, V.1
-
280
-
-
0035028431
-
Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone
-
Jellen-Ritter, A. S.; Kern, W. V. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone. Antimicrob. Agents Chemother. 2001, 45, 1467-1472.
-
(2001)
Antimicrob. Agents Chemother.
, vol.45
, pp. 1467-1472
-
-
Jellen-Ritter, A.S.1
Kern, W.V.2
-
281
-
-
33646825385
-
Mechanisms of antimicrobial resistance in bacteria
-
Tenover, F. C. Mechanisms of antimicrobial resistance in bacteria. Am. J. Med. 2006, 119, 3-10.
-
(2006)
Am. J. Med.
, vol.119
, pp. 3-10
-
-
Tenover, F.C.1
-
282
-
-
37249087837
-
Genetic support of extended-spectrum beta-lactamases
-
Poirel, L.; Naas, T.; Nordmann, P. Genetic support of extended-spectrum beta-lactamases. Clin. Microbiol. Infect. 2008, 14, 75-81.
-
(2008)
Clin. Microbiol. Infect.
, vol.14
, pp. 75-81
-
-
Poirel, L.1
Naas, T.2
Nordmann, P.3
-
283
-
-
34249996213
-
Unexpected effect of a Bacteroides conjugative transposon, CTnDOT, on chromosomal gene expression in its bacterial host
-
Moon, K.; Sonnenburg, J.; Salyers, A. A. Unexpected effect of a Bacteroides conjugative transposon, CTnDOT, on chromosomal gene expression in its bacterial host. Mol. Microbiol. 2007, 64, 1562-1571.
-
(2007)
Mol. Microbiol.
, vol.64
, pp. 1562-1571
-
-
Moon, K.1
Sonnenburg, J.2
Salyers, A.A.3
-
284
-
-
34250219965
-
Chemotherapy-induced resistance by ATP-binding cassette transporter genes
-
DOI 10.1016/j.bbcan.2007.05.002, PII S0304419X07000054
-
Gillet, J. P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775, 237-262. (Pubitemid 46899341)
-
(2007)
Biochimica et Biophysica Acta - Reviews on Cancer
, vol.1775
, Issue.2
, pp. 237-262
-
-
Gillet, J.-P.1
Efferth, T.2
Remacle, J.3
-
285
-
-
33745736603
-
Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment
-
Pérez-Tomás, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 2006, 13, 1859-1876.
-
(2006)
Curr. Med. Chem.
, vol.13
, pp. 1859-1876
-
-
Pérez-Tomás, R.1
-
286
-
-
33745746815
-
Pharmacological strategies for overcoming multidrug resistance
-
Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7, 861-879.
-
(2006)
Curr. Drug Targets
, vol.7
, pp. 861-879
-
-
Nobili, S.1
Landini, I.2
Giglioni, B.3
Mini, E.4
-
287
-
-
32544437036
-
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group
-
Friedenberg, W. R.; Rue, M.; Blood, E. A.; Dalton, W. S.; Shustik, C.; Larson, R. A.; Sonneveld, P.; Greipp, P. R. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006, 106, 830-838.
-
(2006)
Cancer
, vol.106
, pp. 830-838
-
-
Friedenberg, W.R.1
Rue, M.2
Blood, E.A.3
Dalton, W.S.4
Shustik, C.5
Larson, R.A.6
Sonneveld, P.7
Greipp, P.R.8
-
288
-
-
33846209483
-
Tumour-specific expression of CYP2W1: Its potential as a drug target in cancer therapy
-
DOI 10.1517/14728222.11.1.61
-
Karlgren, M.; Ingelman-Sundberg, M. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin. Ther. Targets 2007, 11, 61-67. (Pubitemid 46099752)
-
(2007)
Expert Opinion on Therapeutic Targets
, vol.11
, Issue.1
, pp. 61-67
-
-
Karlgen, M.1
Ingelman-Sundberg, M.2
-
289
-
-
31444443707
-
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
-
Karlgren, M.; Gomez, A.; Stark, K.; Svärd, J.; Rodriguez-Antona, C.; Oliw, E.; Bernal, M. L.; Ramón y Cajal, S.; Johansson, I.; Ingelman-Sundberg, M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 2006, 341, 451-458.
-
(2006)
Biochem. Biophys. Res. Commun.
, vol.341
, pp. 451-458
-
-
Karlgren, M.1
Gomez, A.2
Stark, K.3
Svärd, J.4
Rodriguez-Antona, C.5
Oliw, E.6
Bernal, M.L.7
Ramón Y Cajal, S.8
Johansson, I.9
Ingelman-Sundberg, M.10
-
290
-
-
33646463990
-
Cytochrome P450 1B1: A novel anticancer therapeutic target
-
McFadyen, M. C.; Murray, G. I. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol. 2005, 1, 259-263.
-
(2005)
Future Oncol.
, vol.1
, pp. 259-263
-
-
McFadyen, M.C.1
Murray, G.I.2
-
291
-
-
1542376883
-
Enzyme-catalyzed activation of anticancer prodrugs
-
Rooseboom, M.; Commandeur, J. N.; Vermeulen, N. P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
-
(2004)
Pharmacol. Rev.
, vol.56
, pp. 53-102
-
-
Rooseboom, M.1
Commandeur, J.N.2
Vermeulen, N.P.3
-
292
-
-
0034665390
-
Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells
-
Chua, M. S.; Kashiyama, E.; Bradshaw, T. D.; Stinson, S. F.; Brantley, E.; Sausville, E. A.; Stevens, M. F. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res. 2000, 60, 5196-5203.
-
(2000)
Cancer Res.
, vol.60
, pp. 5196-5203
-
-
Chua, M.S.1
Kashiyama, E.2
Bradshaw, T.D.3
Stinson, S.F.4
Brantley, E.5
Sausville, E.A.6
Stevens, M.F.7
-
293
-
-
9444263203
-
Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells
-
Brantley, E.; Trapani, V.; Alley, M. C.; Hose, C. D.; Bradshaw, T. D.; Stevens, M. F.; Sausville, E. A.; Stinson, S. F. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab. Dispos. 2004, 32, 1392-1401.
-
(2004)
Drug Metab. Dispos.
, vol.32
, pp. 1392-1401
-
-
Brantley, E.1
Trapani, V.2
Alley, M.C.3
Hose, C.D.4
Bradshaw, T.D.5
Stevens, M.F.6
Sausville, E.A.7
Stinson, S.F.8
-
294
-
-
41649109300
-
Gene directed enzyme prodrug therapy for ovarian cancer: Could GDEPT become a promising treatment against ovarian cancer?
-
DOI 10.2174/187152008783497000
-
Nawa, A.; Tanino, T.; Luo, C.; Iwaki, M.; Kajiyama, H.; Shibata, K.; Yamamoto, E.; Ino, K.; Nishiyama, Y.; Kikkawa, F. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer? Anti-Cancer Agents Med. Chem. 2008, 8, 232-239. (Pubitemid 351761446)
-
(2008)
Anti-Cancer Agents in Medicinal Chemistry
, vol.8
, Issue.2
, pp. 232-239
-
-
Nawa, A.1
Tanino, T.2
Luo, C.H.3
Iwaki, M.4
Kajiyama, H.5
Shibata, K.6
Yamamoto, E.7
Ino, K.8
Nishiyama, Y.9
Kikkawa, F.10
-
295
-
-
0035181464
-
Strategies for enzyme/prodrug cancer therapy
-
Xu, G.; McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001, 7, 3314-3324.
-
(2001)
Clin Cancer Res.
, vol.7
, pp. 3314-3324
-
-
Xu, G.1
McLeod, H.L.2
-
296
-
-
30644478786
-
Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer
-
Roy, P.; Waxman, D. J. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol. In Vitro 2006, 20, 176-186.
-
(2006)
Toxicol. in Vitro
, vol.20
, pp. 176-186
-
-
Roy, P.1
Waxman, D.J.2
-
297
-
-
41149146613
-
Improvement of cyclophosphamide activation by CYP2B6 mutants: From in silico to ex vivo
-
Nguyen, T. A.; Tychopoulos, M.; Bichat, F.; Zimmermann, C.; Flinois, J. P.; Diry, M.; Ahlberg, E.; Delaforge, M.; Corcos, L.; Beaune, P.; Dansette, P.; André, F.; de Waziers, I. Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. Mol. Pharmacol. 2008, 73, 1122-1133.
-
(2008)
Mol. Pharmacol.
, vol.73
, pp. 1122-1133
-
-
Nguyen, T.A.1
Tychopoulos, M.2
Bichat, F.3
Zimmermann, C.4
Flinois, J.P.5
Diry, M.6
Ahlberg, E.7
Delaforge, M.8
Corcos, L.9
Beaune, P.10
Dansette, P.11
André, F.12
De Waziers, I.13
-
298
-
-
33646779548
-
Tumor-selective drug activation: A GDEPT approach utilizing cytochrome P450 1A1 and AQ4N
-
DOI 10.1038/sj.cgt.7700933, PII 7700933
-
Yakkundi, A.; McErlane, V.; Murray, M.; McCarthy, H. O.; Ward, C.; Hughes, C. M.; Patterson, L. H.; Hirst, D. G.; McKeown, S. R.; Robson, T. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther. 2006, 13, 598-605. (Pubitemid 43756248)
-
(2006)
Cancer Gene Therapy
, vol.13
, Issue.6
, pp. 598-605
-
-
Yakkundi, A.1
McErlane, V.2
Murray, M.3
McCarthy, H.O.4
Ward, C.5
Hughes, C.M.6
Patterson, L.H.7
Hirst, D.G.8
McKeown, S.R.9
Robson, T.10
-
299
-
-
42949091356
-
Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo
-
DOI 10.1155/2008/683505, PII S1110724308683505
-
Klein, R.; Ruttkowski, B.; Schwab, S.; Peterbauer, T.; Salmons, B.; Günzburg, W. H.; Hohenadl, C. Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for genedirected enzyme prodrug therapy are functional in vitro and in vivo. J. Biomed. Biotechnol. 2008, 2008, 683505-683515. (Pubitemid 352000606)
-
(2008)
Journal of Biomedicine and Biotechnology
, vol.2008
, Issue.1
, pp. 683505
-
-
Klein, R.1
Ruttkowski, B.2
Schwab, S.3
Peterbauer, T.4
Salmons, B.5
Gunzburg, W.H.6
Hohenadl, C.7
-
300
-
-
34547135686
-
Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factoralpha via MAPK and PI3K/Akt signaling pathways
-
Yang, S.; Lin, L.; Chen, J. X.; Lee, C. R.; Seubert, J. M.; Wang, Y.; Wang, H.; Chao, Z. R.; Tao, D. D.; Gong, J. P.; Lu, Z. Y.; Wang, D. W.; Zeldin, D. C. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factoralpha via MAPK and PI3K/Akt signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, 142-151.
-
(2007)
Am. J. Physiol. Heart Circ. Physiol.
, vol.293
, pp. 142-151
-
-
Yang, S.1
Lin, L.2
Chen, J.X.3
Lee, C.R.4
Seubert, J.M.5
Wang, Y.6
Wang, H.7
Chao, Z.R.8
Tao, D.D.9
Gong, J.P.10
Lu, Z.Y.11
Wang, D.W.12
Zeldin, D.C.13
-
301
-
-
0036080081
-
P-450 metabolites of arachidonic acid in the control of cardiovascular function
-
Roman, R. J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002, 82, 131-185.
-
(2002)
Physiol. Rev.
, vol.82
, pp. 131-185
-
-
Roman, R.J.1
-
302
-
-
33845313333
-
Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids
-
Medhora, M.; Dhanasekaran, A.; Gruenloh, S. K.; Dunn, L. K.; Gabrilovich, M.; Falck, J. R.; Harder, D. R.; Jacobs, E. R.; Pratt, P. F. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat. 2007, 82, 19-29.
-
(2007)
Prostaglandins Other Lipid Mediat.
, vol.82
, pp. 19-29
-
-
Medhora, M.1
Dhanasekaran, A.2
Gruenloh, S.K.3
Dunn, L.K.4
Gabrilovich, M.5
Falck, J.R.6
Harder, D.R.7
Jacobs, E.R.8
Pratt, P.F.9
-
303
-
-
33845291121
-
Sphingolipids as modulators of cancer cell death: Potential therapeutic targets
-
DOI 10.1016/j.bbamem.2006.05.024, PII S0005273606002094, Sphingolipids, Apoptosis and Disease
-
Ségui, B.; Andrieu-Abadie, N.; Jaffrézou, J. P.; Benoist, H.; Levade, T. Sphingolipids as modulators of cancer cell death: potential therapeutic targets. Biochim. Biophys. Acta 2006, 1758, 2104-2120. (Pubitemid 44879359)
-
(2006)
Biochimica et Biophysica Acta - Biomembranes
, vol.1758
, Issue.12
, pp. 2104-2120
-
-
Segui, B.1
Andrieu-Abadie, N.2
Jaffrezou, J.-P.3
Benoist, H.4
Levade, T.5
-
304
-
-
2442679411
-
Expression of cytochrome P450 in tumor tissues and its association with cancer development
-
d1500-1993
-
Oyama, T.; Kagawa, N.; Kunugita, N.; Kitagawa, K.; Ogawa, M.; Yamaguchi, T.; Suzuki, R.; Kinaga, T.; Yashima, Y.; Ozaki, S.; Isse, T.; Kim, Y. D.; Kim, H.; Kawamoto, T. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci. 2004, 9, 1967-1976. (Pubitemid 38918646)
-
(2004)
Frontiers in Bioscience
, vol.9
, pp. 1967-1976
-
-
Oyama, T.1
Kagawa, N.2
Kunugita, N.3
Kitagawa, K.4
Ogawa, M.5
Yamaguchi, T.6
Suzuki, R.7
Kinaga, T.8
Yashima, Y.9
Ozaki, S.10
Isse, T.11
Kim, Y.-D.12
Kim, H.13
Kawamoto, T.14
-
305
-
-
23844451055
-
Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer
-
DOI 10.1158/1078-0432.CCR-04-2545
-
Tokizane, T.; Shiina, H.; Igawa, M.; Enokida, H.; Urakami, S.; Kawakami, T.; Ogishima, T.; Okino, S. T.; Li, L. C.; Tanaka, Y.; Nonomura, N.; Okuyama, A.; Dahiya, R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 2005, 11, 5793-5801. (Pubitemid 41170305)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.16
, pp. 5793-5801
-
-
Tokizane, T.1
Shiina, H.2
Igawa, M.3
Enokida, H.4
Urakami, S.5
Kawakami, T.6
Ogishima, T.7
Okino, S.T.8
Li, L.-C.9
Tanaka, Y.10
Nonomura, N.11
Okuyama, A.12
Dahiya, R.13
-
306
-
-
0030812372
-
Tumor-specific expression of cytochrome P450 CYP1B1
-
Murray, G. I.; Taylor, M. C.; McFadyen, M. C.; McKay, J. A.; Greenlee, W. F.; Burke, M. D.; Melvin, W. T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997, 57, 3026-3031. (Pubitemid 27315056)
-
(1997)
Cancer Research
, vol.57
, Issue.14
, pp. 3026-3031
-
-
Murray, G.I.1
Taylor, M.C.2
McFadyen, M.C.E.3
McKay, J.A.4
Greenlee, W.F.5
Burke, M.D.6
Melvin, W.T.7
-
307
-
-
0031772143
-
Cytochrome P450 1B1: A major P450 isoenzyme in human blood monocytes and macrophage subsets
-
Baron, J. M.; Zwadlo-Klarwasser, G.; Jugert, F.; Hamann, W.; Rubben, A.; Mukhtar, H.; Merk, H. F. Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem. Pharmacol. 1998, 56, 1105-1110.
-
(1998)
Biochem. Pharmacol.
, vol.56
, pp. 1105-1110
-
-
Baron, J.M.1
Zwadlo-Klarwasser, G.2
Jugert, F.3
Hamann, W.4
Rubben, A.5
Mukhtar, H.6
Merk, H.F.7
-
308
-
-
0036372506
-
Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes
-
DOI 10.1038/sj.tpj.6500086
-
Finnstrom, N.; Ask, B.; Dahl, M. L.; Gagg, M.; Rane, A. Intraindividual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes. Pharmacogenomics J. 2002, 2, 111-116. (Pubitemid 34982214)
-
(2002)
Pharmacogenomics Journal
, vol.2
, Issue.2
, pp. 111-116
-
-
Finnstrom, N.1
Ask, B.2
Dahl, M.-L.3
Gadd, M.4
Rane, A.5
-
309
-
-
0242418227
-
Immunochemical analysis of Cytochrome P450 variability in human leukapheresed samples and its consequences for the risk assessment process
-
DOI 10.1016/S0273-2300(03)00012-6
-
Bernauer, U.; Garritsen, H.; Heinrich-Hirsch, B.; Gundert-Remy, U. Immunochemical analysis of cytochrome P450 variability in human leukapheresed samples and its consequences for the risk assessment process. Regul. Toxicol. Pharmacol. 2003, 37, 318-327. (Pubitemid 36506584)
-
(2003)
Regulatory Toxicology and Pharmacology
, vol.37
, Issue.2
, pp. 318-327
-
-
Bernauer, U.1
Garritsen, H.2
Heinrich-Hirsch, B.3
Gundert-Remy, U.4
-
310
-
-
0035142865
-
Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation?
-
Rochat, B.; Morsman, J. M.; Murray, G. I.; Figg, W. D.; McLeod, H. L. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther. 2001, 296, 537-541.
-
(2001)
J. Pharmacol. Exp. Ther.
, vol.296
, pp. 537-541
-
-
Rochat, B.1
Morsman, J.M.2
Murray, G.I.3
Figg, W.D.4
McLeod, H.L.5
-
311
-
-
33645509358
-
Fragmentation Study of Imatinib and Characterization of New Imatinib Metabolites by Liquid Chromatography - Triple Quadrupole and Linear Ion Trap Mass Spectrometers
-
Marull, M.; Rochat, B. Fragmentation Study of Imatinib and Characterization of New Imatinib Metabolites by Liquid Chromatography - Triple Quadrupole and Linear Ion Trap Mass Spectrometers. J. Mass Spectrom. 2006, 41, 390-404.
-
(2006)
J. Mass Spectrom.
, vol.41
, pp. 390-404
-
-
Marull, M.1
Rochat, B.2
-
312
-
-
33845726062
-
Identification of a novel co-transcription of P450/1A1 with telomerase in A549
-
DOI 10.1016/j.gene.2006.10.010, PII S0378111906006627
-
Shervington, A.; Mohammed, K.; Patel, R.; Lea, R. Identification of a novel co-transcription of P450/1A1 with telomerase in A549. Gene 2007, 388, 110-116. (Pubitemid 46014019)
-
(2007)
Gene
, vol.388
, Issue.1-2
, pp. 110-116
-
-
Shervington, A.1
Mohammed, K.2
Patel, R.3
Lea, R.4
-
313
-
-
51549121877
-
Can CYP1A1 siRNA be an effective treatment for lung cancer?
-
Mohammed, K.; Shervington, A. Can CYP1A1 siRNA be an effective treatment for lung cancer? Cell. Mol Biol. Lett. 2008, 13, 240-249.
-
(2008)
Cell. Mol Biol. Lett.
, vol.13
, pp. 240-249
-
-
Mohammed, K.1
Shervington, A.2
-
314
-
-
0035965327
-
Epoxygenase Pathways of Arachidonic Acid Metabolism
-
DOI 10.1074/jbc.R100030200
-
Zeldin, D. C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 2001, 276, 36059-36062 (Pubitemid 37384204)
-
(2001)
Journal of Biological Chemistry
, vol.276
, Issue.39
, pp. 36059-36062
-
-
Zeldin, D.C.1
-
315
-
-
33845346159
-
Epoxyeicosatrienoic acids, cell signaling and angiogenesis
-
DOI 10.1016/j.prostaglandins.2006.05.003, PII S1098882306000529, Eicosanoid-Mediated Regulation of Vascular and Renal Function
-
Fleming, I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid. Mediat. 2007, 82, 60-67. (Pubitemid 44880162)
-
(2007)
Prostaglandins and Other Lipid Mediators
, vol.82
, Issue.1-4
, pp. 60-67
-
-
Fleming, I.1
-
316
-
-
22944448688
-
Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways
-
Wang, Y.; Wei, X.; Xiao, X.; Hui, R.; Card, J. W.; Carey, M. A.; Wang, D. W.; Zeldin, D. C. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J. Pharmacol. Exp. Ther. 2005, 314, 522-532.
-
(2005)
J. Pharmacol. Exp. Ther.
, vol.314
, pp. 522-532
-
-
Wang, Y.1
Wei, X.2
Xiao, X.3
Hui, R.4
Card, J.W.5
Carey, M.A.6
Wang, D.W.7
Zeldin, D.C.8
-
317
-
-
0035725998
-
Cytochrome P450 epoxygenase metabolism of arachidonic acid inhibits apoptosis
-
DOI 10.1128/MCB.21.18.6322-6331.2001
-
Chen, J. K.; Capdevila, J.; Harris R. C. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol. Cell Biol. 2001, 21, 6322-6331. (Pubitemid 34263530)
-
(2001)
Molecular and Cellular Biology
, vol.21
, Issue.18
, pp. 6322-6331
-
-
Chen, J.-K.1
Capdevila, J.2
Harris, R.C.3
-
318
-
-
33746716855
-
From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling
-
DOI 10.1016/j.pharmthera.2005.11.003, PII S0163725805002676
-
Michaelis, U. R.; Fleming, I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol. Ther. 2006, 111, 584-595. (Pubitemid 44160519)
-
(2006)
Pharmacology and Therapeutics
, vol.111
, Issue.3
, pp. 584-595
-
-
Michaelis, U.R.1
Fleming, I.2
-
319
-
-
33947389882
-
Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation
-
DOI 10.1124/jpet.106.115360
-
Guo, A. M.; Arbab, A. S.; Falck, J. R.; Chen, P.; Edwards, P. A.; Roman, R. J.; Scicli, A. G. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J. Pharmacol. Exp. Ther. 2007, 321, 18-27. (Pubitemid 46456964)
-
(2007)
Journal of Pharmacology and Experimental Therapeutics
, vol.321
, Issue.1
, pp. 18-27
-
-
Guo, A.M.1
Arbab, A.S.2
Falck, J.R.3
Chen, P.4
Edwards, P.A.5
Roman, R.J.6
Scicli, A.G.7
-
320
-
-
33746713687
-
CYP4B1: An enigmatic P450 at the interface between xenobiotic and endobiotic metabolism
-
Baer, B. R.; Rettie, A. E. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metab. Rev. 2006, 38, 451-457.
-
(2006)
Drug Metab. Rev.
, vol.38
, pp. 451-457
-
-
Baer, B.R.1
Rettie, A.E.2
-
321
-
-
33750000583
-
Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism
-
DOI 10.1016/j.pharmthera.2006.03.008, PII S0163725806001100
-
Kalsotra, A.; Strobel, H. W. Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol. Ther. 2006, 112, 589-611. (Pubitemid 44573491)
-
(2006)
Pharmacology and Therapeutics
, vol.112
, Issue.3
, pp. 589-611
-
-
Kalsotra, A.1
Strobel, H.W.2
-
322
-
-
0032997280
-
Kinetic profile of the rat CYP4A isoforms: Arachidonic acid metabolism and isoform-specific inhibitors
-
Nguyen, X.; Wang, M. H.; Reddy, K. M.; Falck, J. R.; Schwartzman, M. L. Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am. J. Physiol. 1999, 276, 1691-1700.
-
(1999)
Am. J. Physiol.
, vol.276
, pp. 1691-1700
-
-
Nguyen, X.1
Wang, M.H.2
Reddy, K.M.3
Falck, J.R.4
Schwartzman, M.L.5
-
323
-
-
0032403179
-
2
-
DOI 10.1006/abio.1998.2897
-
Bylund, J.; Ericsson, J.; Oliw, E. H. Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. Anal. Biochem. 1998, 265, 55-68. (Pubitemid 28541793)
-
(1998)
Analytical Biochemistry
, vol.265
, Issue.1
, pp. 55-68
-
-
Bylund, J.1
Ericsson, J.2
Oliw, E.H.3
-
324
-
-
0030063499
-
Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart
-
Wu, S.; Moomaw, C. R.; Tomer, K. B.; Falck, J. R.; Zeldin, D. C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 1996, 271, 3460-3468.
-
(1996)
J. Biol. Chem.
, vol.271
, pp. 3460-3468
-
-
Wu, S.1
Moomaw, C.R.2
Tomer, K.B.3
Falck, J.R.4
Zeldin, D.C.5
-
325
-
-
33751541195
-
Altering the sphingosine-1-phosphate/ceramide balance: A promising approach for tumor therapy
-
DOI 10.2174/138161206779010422
-
Huwiler, A.; Pfeilschifter, J. Altering the sphingosine-1-phosphate/ ceramide balance: a promising approach for tumor therapy. Curr. Pharm. Des. 2006, 12, 4625-4635. (Pubitemid 44835150)
-
(2006)
Current Pharmaceutical Design
, vol.12
, Issue.35
, pp. 4625-4635
-
-
Huwiler, A.1
Pfeilschifter, J.2
-
326
-
-
56649118965
-
New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development
-
Moreno, J. J. New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochem. Pharmacol. 2009, 77, 1-10.
-
(2009)
Biochem. Pharmacol.
, vol.77
, pp. 1-10
-
-
Moreno, J.J.1
-
327
-
-
33644977905
-
Sphingolipid targets in cancer therapy
-
Modrak, D. E.; Gold, D. V.; Goldenberg, D. M. Sphingolipid targets in cancer therapy. Mol.Cancer Ther. 2006, 5, 200-208.
-
(2006)
Mol.Cancer Ther.
, vol.5
, pp. 200-208
-
-
Modrak, D.E.1
Gold, D.V.2
Goldenberg, D.M.3
-
328
-
-
34548177098
-
Ceramide kinase uses ceramide provided by ceramide transport protein: Localization to organelles of eicosanoid synthesis
-
Lamour, N. F.; Stahelin, R. V.; Wijesinghe, D. S.; Maceyka, M.; Wang, E.; Allegood, J. C.; Merrill, A. H. Jr.; Cho, W.; Chalfant, C. E. Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis. J. Lipid Res. 2007, 48, 1293-1304.
-
(2007)
J. Lipid Res.
, vol.48
, pp. 1293-1304
-
-
Lamour, N.F.1
Stahelin, R.V.2
Wijesinghe, D.S.3
Maceyka, M.4
Wang, E.5
Allegood, J.C.6
Merrill Jr., A.H.7
Cho, W.8
Chalfant, C.E.9
-
329
-
-
0344898558
-
Regulation of cytochrome P450 expression by sphingolipids
-
DOI 10.1016/S0009-3084(99)00081-X, PII S000930849900081X
-
Merril, A. H. Jr.; Nikolova-Karakashian, M.; Schmelz, E. M.; Morgan, E. T.; Stewart, J. Regulation of cytochrome P450 expression by sphingolipids. Chem. Phys. Lipids 1999, 102, 131-139. (Pubitemid 29438665)
-
(1999)
Chemistry and Physics of Lipids
, vol.102
, Issue.1-2
, pp. 131-139
-
-
Merrill Jr., A.H.1
Nikolova-Karakashian, M.2
Schmelz, E.M.3
Morgan, E.T.4
Stewart, J.5
-
330
-
-
0036435599
-
Modulation of CYP3A4 expression by ceramide in human colon carcinoma HT-29 cells
-
DOI 10.1016/S0006-291X(02)02541-X, PII S0006291X0202541X
-
Chun, Y. J.; Lee, S.; Yang, S. A.; Park, S.; Kim, M. Y. Modulation of CYP3A4 expression by ceramide in human colon carcinoma HT-29 cells. Biochem. Biophys. Res. Commun. 2002, 298, 687-692. (Pubitemid 35356794)
-
(2002)
Biochemical and Biophysical Research Communications
, vol.298
, Issue.5
, pp. 687-692
-
-
Chun, Y.-J.1
Lee, S.2
Ae Yang, S.3
Park, S.4
Young Kim, M.5
-
331
-
-
38349045075
-
Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells
-
Gouazé-Andersson, V.; Yu, J. Y.; Kreitenberg, A. J.; Bielawska, A.; Giuliano, A. E.; Cabot, M. C. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim. Biophys. Acta 2007, 1771, 1407-1417.
-
(2007)
Biochim. Biophys. Acta
, vol.1771
, pp. 1407-1417
-
-
Gouazé-Andersson, V.1
Yu, J.Y.2
Kreitenberg, A.J.3
Bielawska, A.4
Giuliano, A.E.5
Cabot, M.C.6
-
332
-
-
32144447613
-
Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells
-
Sun, Y. L.; Zhou, G. Y.; Li, K. N.; Gao, P.; Zhang, Q. H.; Zhen, J. H.; Bai, Y. H.; Zhang, X. F. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma 2006, 53, 1-8. (Pubitemid 43206931)
-
(2006)
Neoplasma
, vol.53
, Issue.1
, pp. 1-8
-
-
Sun, Y.-L.1
Zhou, G.-Y.2
Li, K.-N.3
Gao, P.4
Zhang, Q.-H.5
Zhen, J.-H.6
Bai, Y.-H.7
Zhang, X.-F.8
-
333
-
-
1642453732
-
Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib
-
DOI 10.1158/1078-0432.CCR-0784-3
-
McLean, L. A.; Gathmann, I.; Capdeville, R.; Polymeropoulos, M. H.; Dressman, M. Pharmacogenomics analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin. Cancer Res. 2004, 10, 155-165. (Pubitemid 38114174)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.1 I
, pp. 155-165
-
-
McLean, L.A.1
Gathmann, I.2
Capdeville, R.3
Polymeropoulos, M.H.4
Dressman, M.5
-
334
-
-
0037988709
-
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy
-
Sparreboom, A.; Danesi, R.; Ando, Y.; Chan, J.; Figg, W. D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 2003, 6, 71-84.
-
(2003)
Drug Resist. Updat.
, vol.6
, pp. 71-84
-
-
Sparreboom, A.1
Danesi, R.2
Ando, Y.3
Chan, J.4
Figg, W.D.5
-
335
-
-
33745699234
-
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells
-
DOI 10.1016/j.canlet.2005.07.032, PII S0304383505007445
-
Huang, Y.; Sadee, W. Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett. 2005, 239, 168-182. (Pubitemid 43996825)
-
(2006)
Cancer Letters
, vol.239
, Issue.2
, pp. 168-182
-
-
Huang, Y.1
Sadee, W.2
-
336
-
-
16644379769
-
Tumoral drug metabolism: Overview and its implications for cancer therapy
-
DOI 10.1200/JCO.2005.02.120
-
Michael, M.; Doherty, M. M. Tumoral drug metabolism: overview and its implications for cancer therapy. J. Clin. Oncol. 2005, 23, 205-229. (Pubitemid 41702640)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.1
, pp. 205-229
-
-
Michael, M.1
Doherty, M.M.2
-
337
-
-
33947396419
-
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy
-
DOI 10.1007/s10555-007-9050-6, Special Issue on Transporters in Cancer
-
Huang, Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007, 26, 183-201. (Pubitemid 46452190)
-
(2007)
Cancer and Metastasis Reviews
, vol.26
, Issue.1
, pp. 183-201
-
-
Huang, Y.1
-
338
-
-
26444516024
-
Modulation of cytochrome P450 activity: Implications for cancer therapy
-
Scripture, C. D.; Sparreboom, A.; Figg, W. D. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005, 6, 780-789.
-
(2005)
Lancet Oncol.
, vol.6
, pp. 780-789
-
-
Scripture, C.D.1
Sparreboom, A.2
Figg, W.D.3
-
339
-
-
84934437989
-
Pharmacogenetics of membrane transporters: A review of current approaches
-
Sissung, T. M.; Gardner, E. R.; Gao, R.; Figg, W. D. Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol. Biol. 2008, 448, 41-62.
-
(2008)
Methods Mol. Biol.
, vol.448
, pp. 41-62
-
-
Sissung, T.M.1
Gardner, E.R.2
Gao, R.3
Figg, W.D.4
-
340
-
-
23844486685
-
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance
-
DOI 10.1158/0008-5472.CAN-04-4267
-
Huang, Y.; Dai, Z.; Barbacioru, C.; Sadée, W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005, 65, 7446-17445 (Pubitemid 41161279)
-
(2005)
Cancer Research
, vol.65
, Issue.16
, pp. 7446-7454
-
-
Huang, Y.1
Dai, Z.2
Barbacioru, C.3
Sadee, W.4
-
341
-
-
33748922789
-
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin
-
Holzer, A. K.; Manorek, G. H.; Howell, S. B. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 2006, 70, 1390-1394.
-
(2006)
Mol. Pharmacol.
, vol.70
, pp. 1390-1394
-
-
Holzer, A.K.1
Manorek, G.H.2
Howell, S.B.3
-
342
-
-
54049145153
-
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters
-
Okabe, M.; Szakács, G.; Reimers, M. A.; Suzuki, T.; Hall, M. D.; Abe, T.; Weinstein, J. N.; Gottesman, M. M. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol. Cancer Ther. 2008, 7, 3081-3091.
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 3081-3091
-
-
Okabe, M.1
Szakács, G.2
Reimers, M.A.3
Suzuki, T.4
Hall, M.D.5
Abe, T.6
Weinstein, J.N.7
Gottesman, M.M.8
-
343
-
-
49649092002
-
Interaction of imatinib with human organic ion carriers
-
Hu, S.; Franke, R. M.; Filipski, K. K.; Hu, C.; Orwick, S. J.; de Bruijn, E. A.; Burger, H.; Baker, S. D.; Sparreboom, A. Interaction of imatinib with human organic ion carriers. Clin. Cancer. Res. 2008, 14, 3141-3148
-
(2008)
Clin. Cancer. Res.
, vol.14
, pp. 3141-3148
-
-
Hu, S.1
Franke, R.M.2
Filipski, K.K.3
Hu, C.4
Orwick, S.J.5
De Bruijn, E.A.6
Burger, H.7
Baker, S.D.8
Sparreboom, A.9
-
344
-
-
33645746275
-
Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: Transcriptional silencing, inactivating mutations, and allele loss
-
Kaufman, Y.; Ifergan, I.; Rothem, L.; Jansen, G.; Assaraf, Y. G. Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss. Blood 2006, 107, 3288-3294.
-
(2006)
Blood
, vol.107
, pp. 3288-3294
-
-
Kaufman, Y.1
Ifergan, I.2
Rothem, L.3
Jansen, G.4
Assaraf, Y.G.5
-
345
-
-
10244250320
-
Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: Implications for efficacy of methotrexate therapy
-
DOI 10.1182/blood-2004-04-1493
-
Fotoohi, K.; Jansen, G.; Assaraf, Y. G.; Rothem, L.; Stark, M.; Kathmann, I.; Gregorczyk, J.; Peters, G. J.; Albertioni, F. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. Blood 2004, 104, 4194-4201. (Pubitemid 39620174)
-
(2004)
Blood
, vol.104
, Issue.13
, pp. 4194-4201
-
-
Fotoohi, K.1
Jansen, G.2
Assaraf, Y.G.3
Rothem, L.4
Stark, M.5
Kathmann, I.6
Gregorczyk, J.7
Peters, G.J.8
Albertioni, F.9
-
346
-
-
3843092833
-
Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library
-
Lee, D. K.; Kim, Y. H.; Kim, J. S.; Seol, W. Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library. Nucleic Acids Res. 2004, 32, 116-122.
-
(2004)
Nucleic Acids Res.
, vol.32
, pp. 116-122
-
-
Lee, D.K.1
Kim, Y.H.2
Kim, J.S.3
Seol, W.4
-
347
-
-
38349193809
-
Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia
-
Wang, L.; Giannoudis, A.; Lane, S.; Williamson, P.; Pirmohamed, M.; Clark, R. E. Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia. Clin. Pharmacol. Ther. 2008, 83, 258-264.
-
(2008)
Clin. Pharmacol. Ther.
, vol.83
, pp. 258-264
-
-
Wang, L.1
Giannoudis, A.2
Lane, S.3
Williamson, P.4
Pirmohamed, M.5
Clark, R.E.6
-
348
-
-
23044433630
-
hOCT 1 and resistance to imatinib
-
Crossman, L. C.; Druker, B. J.; Deininger, M. W.; Pirmohamed, M.; Wang, L.; Clark, R. E. hOCT 1 and resistance to imatinib. Blood 2005, 106, 1133-1134.
-
(2005)
Blood
, vol.106
, pp. 1133-1134
-
-
Crossman, L.C.1
Druker, B.J.2
Deininger, M.W.3
Pirmohamed, M.4
Wang, L.5
Clark, R.E.6
-
349
-
-
33745085275
-
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
-
White, D. L.; Saunders, V. A.; Dang, P.; Engler, J.; Zannettino, A. C.; Cambareri, A. C.; Quinn, S. R.; Manley, P. W.; Hughes, T. P. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108, 697-704.
-
(2006)
Blood
, vol.108
, pp. 697-704
-
-
White, D.L.1
Saunders, V.A.2
Dang, P.3
Engler, J.4
Zannettino, A.C.5
Cambareri, A.C.6
Quinn, S.R.7
Manley, P.W.8
Hughes, T.P.9
-
350
-
-
0345724797
-
Biotransformation of tamoxifen in a human endometrial explant culture model
-
Sharma, M.; Shubert, D. E.; Sharma, M.; Lewis, J.; McGarrigle, B. P.; Bofinger, D. P.; Olson, J. R. Biotransformation of tamoxifen in a human endometrial explant culture model. Chem. Biol. Interact. 2003, 146, 237-249.
-
(2003)
Chem. Biol. Interact.
, vol.146
, pp. 237-249
-
-
Sharma, M.1
Shubert, D.E.2
Sharma, M.3
Lewis, J.4
McGarrigle, B.P.5
Bofinger, D.P.6
Olson, J.R.7
-
351
-
-
0036132097
-
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues
-
Miyoshi, Y.; Ando, A.; Takamura, Y.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int. J. Cancer 2002, 97, 129-132.
-
(2002)
Int. J. Cancer
, vol.97
, pp. 129-132
-
-
Miyoshi, Y.1
Ando, A.2
Takamura, Y.3
Taguchi, T.4
Tamaki, Y.5
Noguchi, S.6
-
352
-
-
0038352146
-
Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma
-
Dhaini, H. R.; Thomas, D. G.; Giordano, T. J.; Johnson, T. D.; Biermann, J. S.; Leu, K.; Hollenberg, P. F.; Baker, L. H. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J. Clin. Oncol. 2003, 21, 2481-2485.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 2481-2485
-
-
Dhaini, H.R.1
Thomas, D.G.2
Giordano, T.J.3
Johnson, T.D.4
Biermann, J.S.5
Leu, K.6
Hollenberg, P.F.7
Baker, L.H.8
-
353
-
-
0036304753
-
Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia
-
Krajinovic, M.; Labuda, D.; Mathonnet, G.; Labuda, M.; Moghrabi, A.; Champagne, J.; Sinnett, D. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancer Res. 2002, 8, 802-810. (Pubitemid 34742111)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.3
, pp. 802-810
-
-
Krajinovic, M.1
Labuda, D.2
Mathonnet, G.3
Labuda, M.4
Moghrabi, A.5
Champagne, J.6
Sinnett, D.7
-
354
-
-
0038446667
-
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication
-
Bowen, D. T.; Frew, M. E.; Rollinson, S.; Roddam, P. L.; Dring, A.; Smith, M. T.; Langabeer, S. E.; Morgan, G. J. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood 2003, 101, 2770-2774.
-
(2003)
Blood
, vol.101
, pp. 2770-2774
-
-
Bowen, D.T.1
Frew, M.E.2
Rollinson, S.3
Roddam, P.L.4
Dring, A.5
Smith, M.T.6
Langabeer, S.E.7
Morgan, G.J.8
-
355
-
-
22544431983
-
The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia
-
Voso, M. T.; D'Alo', F.; Gumiero, D.; Guidi, F.; Hohaus, S.; Leone, G. The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 2005, 90, 982-984. (Pubitemid 41020304)
-
(2005)
Haematologica
, vol.90
, Issue.7
, pp. 982-984
-
-
Voso, M.T.1
D'Alo, F.2
Gumiero, D.3
Guidi, F.4
Hohaus, S.5
Leone, G.6
-
356
-
-
0035879957
-
Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance
-
McFadyen, M. C.; McLeod, H. L.; Jackson, F. C.; Melvin, W. T.; Doehmer, J.; Murray, G. I. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol. 2001, 62, 207-212.
-
(2001)
Biochem. Pharmacol.
, vol.62
, pp. 207-212
-
-
McFadyen, M.C.1
McLeod, H.L.2
Jackson, F.C.3
Melvin, W.T.4
Doehmer, J.5
Murray, G.I.6
-
357
-
-
38349148686
-
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
-
Sissung, T. M.; Danesi, R.; Price, D. K.; Steinberg, S. M.; de Wit, R.; Zahid, M.; Gaikwad, N.; Cavalieri, E.; Dahut, W. L.; Sackett, D. L.; Figg, W. D.; Sparreboom, A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 2008, 7, 19-26.
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 19-26
-
-
Sissung, T.M.1
Danesi, R.2
Price, D.K.3
Steinberg, S.M.4
De Wit, R.5
Zahid, M.6
Gaikwad, N.7
Cavalieri, E.8
Dahut, W.L.9
Sackett, D.L.10
Figg, W.D.11
Sparreboom, A.12
-
358
-
-
0036841719
-
Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme
-
Bournique, B.; Lemarié, A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. 2002, 30, 1149-1152.
-
(2002)
Drug Metab. Dispos.
, vol.30
, pp. 1149-1152
-
-
Bournique, B.1
Lemarié, A.2
-
359
-
-
34548081331
-
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
-
DOI 10.1038/sj.tpj.6500434, PII 6500434
-
Marsh, S.; Somlo, G.; Li, X.; Frankel, P.; King, C. R.; Shannon, W. D.; McLeod, H. L.; Synold, T. W. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007, 7, 362-365. (Pubitemid 47484774)
-
(2007)
Pharmacogenomics Journal
, vol.7
, Issue.5
, pp. 362-365
-
-
Marsh, S.1
Somlo, G.2
Li, X.3
Frankel, P.4
King, C.R.5
Shannon, W.D.6
McLeod, H.L.7
Synold, T.W.8
-
360
-
-
18844370604
-
Cytochrome P450 profile of colorectal cancer: Identification of markers of prognosis
-
DOI 10.1158/1078-0432.CCR-04-1848
-
Kumarakulasingham, M.; Rooney, P. H.; Dundas, S. R.; Telfer, C.; Melvin, W. T.; Curran, S.; Murray, G. I. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res. 2005, 11, 3758-3765. (Pubitemid 40685593)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.10
, pp. 3758-3765
-
-
Kumarakulasingham, M.1
Rooney, P.H.2
Dundas, S.R.3
Telfer, C.4
Melvin, W.T.5
Curran, S.6
Murray, G.I.7
-
361
-
-
27144434397
-
Profiling cytochrome P450 expression in ovarian cancer: Identification of prognostic markers
-
DOI 10.1158/1078-0432.CCR-05-0466
-
Downie, D.; McFadyen, M. C.; Rooney, P. H.; Cruickshank, M. E.; Parkin, D. E.; Miller, I. D.; Telfer, C.; Melvin, W. T.; Murray, G. I. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res. 2005, 11, 7369-7375. (Pubitemid 41507696)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.20
, pp. 7369-7375
-
-
Downie, D.1
McFadyen, M.C.E.2
Rooney, P.H.3
Cruickshank, M.E.4
Parkin, D.E.5
Miller, I.D.6
Telfer, C.7
Melvin, W.T.8
Murray, G.I.9
-
362
-
-
1942532186
-
Identification of a Novel Mammary-Restricted Cytochrome P450, CYP4Z1, with Overexpression in Breast Carcinoma
-
DOI 10.1158/0008-5472.CAN-03-0849
-
Rieger, M. A.; Ebner, R.; Bell, D. R.; Kiessling, A.; Rohayem, J.; Schmitz, M.; Temme, A.; Rieber, E. P.; Weigle, B. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 2004, 64, 2357-2364. (Pubitemid 38528668)
-
(2004)
Cancer Research
, vol.64
, Issue.7
, pp. 2357-2364
-
-
Rieger, M.A.1
Ebner, R.2
Bell, D.R.3
Kiessling, A.4
Rohayem, J.5
Schmitz, M.6
Temme, A.7
Rieber, E.P.8
Weigle, B.9
-
363
-
-
33745576138
-
Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon
-
Cummings, J.; Ethell, B. T.; Jardine, L.; Burchell, B. Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon. Anticancer Res. 2006, 26, 2189-2196. (Pubitemid 43980170)
-
(2006)
Anticancer Research
, vol.26
, Issue.3 B
, pp. 2189-2196
-
-
Cummings, J.1
Ethell, B.T.2
Jardine, L.3
Burchell, B.4
-
364
-
-
0034597678
-
CYP4B1 is a possible risk factor for bladder cancer in humans
-
DOI 10.1006/bbrc.2000.3740
-
Imaoka, S.; Yoneda, Y.; Sugimoto, T.; Hiroi, T.; Yamamoto, K.; Nakatani, T.; Funae, Y. CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem. Biophys. Res. Commun. 2000, 277, 776-780. (Pubitemid 30819754)
-
(2000)
Biochemical and Biophysical Research Communications
, vol.277
, Issue.3
, pp. 776-780
-
-
Imaoka, S.1
Yoneda, Y.2
Sugimoto, T.3
Hiroi, T.4
Yamamoto, K.5
Nakatani, T.6
Funae, Y.7
-
365
-
-
24944566839
-
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer
-
Petros, W. P.; Hopkins, P. J.; Spruill, S.; Broadwater, G.; Vredenburgh, J. J.; Colvin, O. M.; Peters, W. P.; Jones, R. B.; Hall, J.; Marks, J. R. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J. Clin. Oncol. 2005, 23, 6117-6125.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 6117-6125
-
-
Petros, W.P.1
Hopkins, P.J.2
Spruill, S.3
Broadwater, G.4
Vredenburgh, J.J.5
Colvin, O.M.6
Peters, W.P.7
Jones, R.B.8
Hall, J.9
Marks, J.R.10
-
366
-
-
24944544420
-
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort
-
DOI 10.1200/JCO.2005.06.208
-
DeMichele, A.; Aplenc, R.; Botbyl, J.; Colligan, T.; Wray, L.; Klein-Cabral, M.; Foulkes, A.; Gimotty, P.; Glick, J.; Weber, B.; Stadtmauer E.; Rebbeck T. R. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J. Clin. Oncol. 2005, 23, 5552-5559. (Pubitemid 46300149)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.24
, pp. 5552-5559
-
-
Demichele, A.1
Aplenc, R.2
Botbyl, J.3
Colligan, T.4
Wray, L.5
Klein-Cabral, M.6
Foulkes, A.7
Gimotty, P.8
Click, J.9
Weber, B.10
Stadtmauer, E.11
Rebbeck, T.R.12
-
367
-
-
33644639136
-
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
-
Goetz, M. P.; Rae, J. M.; Suman, V. J.; Safgren, S. L.; Ames, M. M.; Visscher, D. W.; Reynolds, C.; Couch, F. J.; Lingle, W. L.; Flockhart, D. A.; Desta, Z.; Perez, E. A.; Ingle, J. N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 2005, 23, 9312-9318.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 9312-9318
-
-
Goetz, M.P.1
Rae, J.M.2
Suman, V.J.3
Safgren, S.L.4
Ames, M.M.5
Visscher, D.W.6
Reynolds, C.7
Couch, F.J.8
Lingle, W.L.9
Flockhart, D.A.10
Desta, Z.11
Perez, E.A.12
Ingle, J.N.13
-
368
-
-
33751112296
-
Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: Major roles for CYP2J2 and CYP3A
-
Liu, K. H.; Kim, M. G.; Lee, D. J.; Yoon, Y. J.; Kim, M. J.; Shon, J. H.; Choi, C. S.; Choi, Y. K.; Desta, Z.; Shin, J. G. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab. Dispos. 2006, 34, 1793-1797.
-
(2006)
Drug Metab. Dispos.
, vol.34
, pp. 1793-1797
-
-
Liu, K.H.1
Kim, M.G.2
Lee, D.J.3
Yoon, Y.J.4
Kim, M.J.5
Shon, J.H.6
Choi, C.S.7
Choi, Y.K.8
Desta, Z.9
Shin, J.G.10
-
369
-
-
0036842039
-
Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole
-
DOI 10.1124/dmd.30.11.1240
-
Matsumoto, S.; Hirama, T.; Matsubara, T.; Nagata, K.; Yamazoe, Y. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos. 2002, 30, 1240-1245. (Pubitemid 35265831)
-
(2002)
Drug Metabolism and Disposition
, vol.30
, Issue.11
, pp. 1240-1245
-
-
Matsumoto, S.1
Hirama, T.2
Matsubara, T.3
Nagata, K.4
Yamazoe, Y.5
-
370
-
-
0036138172
-
Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes
-
DOI 10.1124/jpet.300.1.298
-
Hashizume, T.; Imaoka, S.; Mise, M.; Terauchi, Y.; Fujii, T.; Miyazaki, H.; Kamataki, T.; Funae, Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther. 2002, 300, 298-304. (Pubitemid 34028540)
-
(2002)
Journal of Pharmacology and Experimental Therapeutics
, vol.300
, Issue.1
, pp. 298-304
-
-
Hashizume, T.1
Imaoka, S.2
Mise, M.3
Terauchi, Y.4
Fujii, T.5
Miyazaki, H.6
Kamataki, T.7
Funae, Y.8
-
371
-
-
33751090675
-
CYP2J2 and CYP4F12 are active for the metabolism of nonsedating antihistamines: Terfenadine and astemizole
-
Parikh, S.; Gagne, P.; Miller, V.; Crespi, C.; Thummel, K.; Patten, C. CYP2J2 and CYP4F12 are active for the metabolism of nonsedating antihistamines: terfenadine and astemizole. Drug Metab. Rev. 2003, 35, 190-191.
-
(2003)
Drug Metab. Rev.
, vol.35
, pp. 190-191
-
-
Parikh, S.1
Gagne, P.2
Miller, V.3
Crespi, C.4
Thummel, K.5
Patten, C.6
-
372
-
-
35548936928
-
Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine
-
Wang, M. Z.; Wu, J. Q.; Bridges, A. S.; Zeldin, D. C.; Kornbluth, S.; Tidwell, R. R.; Hall, J. E.; Paine, M. F. Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab. Dispos. 2007, 35, 2067-2075.
-
(2007)
Drug Metab. Dispos.
, vol.35
, pp. 2067-2075
-
-
Wang, M.Z.1
Wu, J.Q.2
Bridges, A.S.3
Zeldin, D.C.4
Kornbluth, S.5
Tidwell, R.R.6
Hall, J.E.7
Paine, M.F.8
-
373
-
-
4444312707
-
Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids
-
Kalsotra, A.; Turman, C. M.; Kikuta, Y.; Strobel, H. W. Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol. Appl. Pharmacol. 2004, 199, 295-304.
-
(2004)
Toxicol. Appl. Pharmacol.
, vol.199
, pp. 295-304
-
-
Kalsotra, A.1
Turman, C.M.2
Kikuta, Y.3
Strobel, H.W.4
-
374
-
-
34548779111
-
Expression of Multidrug Resistance 1 (MDR1), Multidrug Resistance-related Protein 1 (MRP1), Lung Resistance Protein (LRP), and Breast Cancer Resistance Protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia
-
DOI 10.1532/IJH97.E0624
-
Kourti, M.; Vavatsi, N.; Gombakis, N.; Sidi, V.; Tzimagiorgis, G.; Papageorgiou, T.; Koliouskas, D.; Athanassiadou, F. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int. J. Hematol. 2007, 86, 166-173. (Pubitemid 47425197)
-
(2007)
International Journal of Hematology
, vol.86
, Issue.2
, pp. 166-173
-
-
Kourti, M.1
Vavatsi, N.2
Gombakis, N.3
Sidi, V.4
Tzimagiorgis, G.5
Papageorgiou, T.6
Koliouskas, D.7
Athanassiadou, F.8
-
375
-
-
33645747683
-
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma
-
Haber, M.; Smith, J.; Bordow, S. B.; Flemming, C.; Cohn, S. L.; London, W. B.; Marshall, G. M.; Norris, M. D. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J. Clin. Oncol. 2006, 24, 1546-1553.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1546-1553
-
-
Haber, M.1
Smith, J.2
Bordow, S.B.3
Flemming, C.4
Cohn, S.L.5
London, W.B.6
Marshall, G.M.7
Norris, M.D.8
-
376
-
-
34147156300
-
Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma
-
DOI 10.1182/blood-2006-09-047621
-
Andreadis, C.; Gimotty, P. A.; Wahl, P.; Hammond, R.; Houldsworth, J.; Schuster, S. J.; Rebbeck, T. R. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 2007, 109, 3409-3416. (Pubitemid 46572530)
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3409-3416
-
-
Andreadis, C.1
Gimotty, P.A.2
Wahl, P.3
Hammond, R.4
Houldsworth, J.5
Schuster, S.J.6
Rebbeck, T.R.7
-
377
-
-
0028242077
-
Immunocytochemical detection of P-Glycoprotein: Initial expression correlates with survival in renal cell carcinoma patients
-
Duensing, S.; Dallmann, I.; Grosse, J.; Buer, J.; Lopez Hänninen, E.; Deckert, M.; Störkel, S.; Kirchner, H.; Poliwoda, H.; Atzpodien, J. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 1994, 51, 309-313. (Pubitemid 24185128)
-
(1994)
Oncology
, vol.51
, Issue.4
, pp. 309-313
-
-
Duensing, S.1
Dallmann, I.2
Grosse, J.3
Buer, J.4
Hanninen, E.L.5
Deckert, M.6
Storkel, S.7
Kirchner, H.8
Poliwoda, H.9
Atzpodien, J.10
-
378
-
-
33947420385
-
Prognostic significance of multidrug-resistance protein (MDR-1) in renal cancer cell carcinomas: A five year follow-up analysis
-
DOI 10.1186/1471-2407-6-293
-
Mignogna, C.; Staibano, S.; Altieri, V.; De Rosa, G.; Pannone, G.; Santoro, A.; Zamparese, R.; D'Armiento, M.; Rocchetti, R.; Mezza, E.; Nasti, M.; Strazzullo, V.; Montanaro, V.; Mascolo, M.; Bufo, P. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 2006, 6, 293-303. (Pubitemid 46454535)
-
(2006)
BMC Cancer
, vol.6
, pp. 293
-
-
Mignogna, C.1
Staibano, S.2
Altieri, V.3
De Rosa, G.4
Pannone, G.5
Santoro, A.6
Zamparese, R.7
D'Armiento, M.8
Rocchetti, R.9
Mezza, E.10
Nasti, M.11
Strazzullo, V.12
Montanaro, V.13
Mascolo, M.14
Bufo, P.15
-
379
-
-
23844440902
-
Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes
-
Kim, D. H.; Lee, N. Y.; Sung, W. J.; Baek, J. H.; Kim, J. G.; Sohn, S. K.; Suh, J. S.; Lee, K. S.; Lee, K. B. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. Acta Haematol. 2005, 114, 78-83.
-
(2005)
Acta Haematol.
, vol.114
, pp. 78-83
-
-
Kim, D.H.1
Lee, N.Y.2
Sung, W.J.3
Baek, J.H.4
Kim, J.G.5
Sohn, S.K.6
Suh, J.S.7
Lee, K.S.8
Lee, K.B.9
-
380
-
-
0031936939
-
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin
-
Mechetner, E.; Kyshtoobayeva, A.; Zonis, S.; Kim, H.; Stroup, R.; Garcia, R.; Parker, R. J.; Fruehauf, J. P. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 1998, 4, 389-398.
-
(1998)
Clin. Cancer Res.
, vol.4
, pp. 389-398
-
-
Mechetner, E.1
Kyshtoobayeva, A.2
Zonis, S.3
Kim, H.4
Stroup, R.5
Garcia, R.6
Parker, R.J.7
Fruehauf, J.P.8
-
381
-
-
26944497848
-
Pharmacogenetics of folate-related drug targets in cancer treatment
-
DOI 10.2217/14622416.6.7.673
-
Robien, K.; Boynton, A.; Ulrich, C. M. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 2005, 6, 673-689. (Pubitemid 41479413)
-
(2005)
Pharmacogenomics
, vol.6
, Issue.7
, pp. 673-689
-
-
Robien, K.1
Boynton, A.2
Ulrich, C.M.3
-
382
-
-
25144450089
-
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
-
Burger, H.; van Tol, H.; Brok, M.; Wiemer, E. A.; de Bruijn, E. A.; Guetens, G.; de Boeck, G.; Sparreboom, A.; Verweij, J.; Nooter, K. Chronic Imatinib Mesylate Exposure Leads to Reduced Intracellular Drug Accumulation by Induction of the ABCG2 (BCRP) and ABCB1 (MDR1) Drug Transport Pumps. Cancer Biol. Ther. 2005, 4, 747-752. (Pubitemid 41351174)
-
(2005)
Cancer Biology and Therapy
, vol.4
, Issue.7
, pp. 747-752
-
-
Burger, H.1
Van Tol, H.2
Brok, M.3
Wiemer, E.A.C.4
De Bruijn, E.A.5
Guetens, G.6
De Boeck, G.7
Sparreboom, A.8
Verweij, J.9
Nooter, K.10
-
383
-
-
34249669336
-
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
-
DOI 10.1038/sj.leu.2404638, PII 2404638
-
Brendel, C.; Scharenberg, C.; Dohse, M.; Robey, R. W.; Bates, S.E.; Shukla, S.; Ambudkar, S. V.; Wang, Y.; Wennemuth, G.; Burchert, A.; Boudriot, U.; Neubauer, A. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21, 1267-1275. (Pubitemid 46831816)
-
(2007)
Leukemia
, vol.21
, Issue.6
, pp. 1267-1275
-
-
Brendel, C.1
Scharenberg, C.2
Dohse, M.3
Robey, R.W.4
Bates, S.E.5
Shukla, S.6
Ambudkar, S.V.7
Wang, Y.8
Wennemuth, G.9
Burchert, A.10
Boudriot, U.11
Neubauer, A.12
-
384
-
-
33746741049
-
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
-
DOI 10.1016/j.clpt.2006.05.003, PII S0009923606001731
-
Gardner, E. R.; Burger, H.; van Schaik, R. H.; van Oosterom, A. T.; de Bruijn, E. A.; Guetens, G.; Prenen, H.; de Jong, F. A.; Baker, S. D.; Bates, S. E.; Figg, W. D.; Verweij, J.; Sparreboom, A.; Nooter, K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther. 2006, 80, 192-201. (Pubitemid 44160695)
-
(2006)
Clinical Pharmacology and Therapeutics
, vol.80
, Issue.2
, pp. 192-201
-
-
Gardner, E.R.1
Burger, H.2
Van Schaik, R.H.3
Van Oosterom, A.T.4
De Bruijn, E.A.5
Guetens, G.6
Prenen, H.7
De Jong, F.A.8
Baker, S.D.9
Bates, S.E.10
Figg, W.D.11
Verweij, J.12
Sparreboom, A.13
Nooter, K.14
-
385
-
-
0344305459
-
Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro
-
Ferrao, P. T.; Frost, M. J.; Siah, S. P.; Ashman, L. K. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003, 102, 4499-4503.
-
(2003)
Blood
, vol.102
, pp. 4499-4503
-
-
Ferrao, P.T.1
Frost, M.J.2
Siah, S.P.3
Ashman, L.K.4
-
386
-
-
20144364602
-
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time
-
EORTC Soft Tissue and Bone Sarcoma Group
-
Judson, I.; Ma, P.; Peng, B.; Verweij, J.; Racine, A.; di Paola, E. D.; van Glabbeke, M.; Dimitrijevic, S.; Scurr, M.; Dumez, H.; van Oosterom, A. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 2005, 55, 379-386.
-
(2005)
Cancer Chemother. Pharmacol.
, vol.55
, pp. 379-386
-
-
Judson, I.1
Ma, P.2
Peng, B.3
Verweij, J.4
Racine, A.5
Di Paola, E.D.6
Van Glabbeke, M.7
Dimitrijevic, S.8
Scurr, M.9
Dumez, H.10
Van Oosterom, A.11
-
387
-
-
34250708413
-
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels
-
Widmer, N.; Rumpold, H.; Untergasser, G.; Fayet, A.; Buclin, T.; Decosterd, L. A. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 2007, 21, 1561-1562.
-
(2007)
Leukemia
, vol.21
, pp. 1561-1562
-
-
Widmer, N.1
Rumpold, H.2
Untergasser, G.3
Fayet, A.4
Buclin, T.5
Decosterd, L.A.6
-
388
-
-
34250727018
-
Reply to 'Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels' by Widmer et al. [2]
-
DOI 10.1038/sj.leu.2404672, PII 2404672
-
Zong, Y.; Zhou, S.; Sorrentino, B. P. Reply to 'Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels' by Widmer et al. Leukemia 2007, 21, 1562-1563. (Pubitemid 46965299)
-
(2007)
Leukemia
, vol.21
, Issue.7
, pp. 1562-1563
-
-
Zong, Y.1
Zhou, S.2
Sorrentino, B.P.3
-
389
-
-
55949092708
-
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
-
Rottenberg, S.; Jaspers, J. E.; Kersbergen, A.; van der Burg, E.; Nygren, A. O; Zander, S. A.; Derksen, P. W.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; Cranston, A.; O'Connor, M. J.; Martin, N. M.; Borst, P.; Jonkers, J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 2008, 105, 17079-17084.
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 17079-17084
-
-
Rottenberg, S.1
Jaspers, J.E.2
Kersbergen, A.3
Van Der Burg, E.4
Nygren, A.O.5
Zander, S.A.6
Derksen, P.W.7
De Bruin, M.8
Zevenhoven, J.9
Lau, A.10
Boulter, R.11
Cranston, A.12
O'Connor, M.J.13
Martin, N.M.14
Borst, P.15
Jonkers, J.16
-
390
-
-
37249061592
-
What makes tumors multidrug resistant?
-
Borst, P.; Jonkers, J.; Rottenberg, S. What makes tumors multidrug resistant? Cell Cycle 2007, 6, 2782-2787. (Pubitemid 350277170)
-
(2007)
Cell Cycle
, vol.6
, Issue.22
, pp. 2782-2787
-
-
Borst, P.1
Jonkers, J.2
Rottenberg, S.3
-
391
-
-
34547504504
-
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
-
DOI 10.1073/pnas.0702955104
-
Rottenberg, S.; Nygren, A. O.; Pajic, M.; van Leeuwen, F. W.; van der Heijden, I.; van de Wetering, K.; Liu, X.; de Visser, K. E.; Gilhuijs, K. G.; van Tellingen, O.; Schouten, J. P.; Jonkers, J.; Borst, P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 12117-12122. (Pubitemid 47185639)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.29
, pp. 12117-12122
-
-
Rottenberg, S.1
Nygren, A.O.H.2
Pajic, M.3
Van Leeuwen, F.W.B.4
Van Der Heijden, I.5
Van Wetering, K.D.6
Liu, X.7
De Visser, K.E.8
Gilhuijs, K.G.9
Van Tellingen, O.10
Schouten, J.P.11
Jonkers, J.12
Borst, P.13
-
392
-
-
3843082080
-
Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes
-
DOI 10.1002/ijc.20289
-
Tanaka, T.; Tanimoto, K.; Otani, K.; Satoh, K.; Ohtaki, M.; Yoshida, K.; Toge, T.; Yahata, H.; Tanaka, S.; Chayama, K.; Okazaki, Y.; Hayashizaki, Y.; Hiyama, K.; Nishiyama, M. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int. J. Cancer. 2004, 111, 617-626. (Pubitemid 39045331)
-
(2004)
International Journal of Cancer
, vol.111
, Issue.4
, pp. 617-626
-
-
Tanaka, T.1
Tanimoto, K.2
Otani, K.3
Satoh, K.4
Otaki, M.5
Yoshida, K.6
Toge, T.7
Yahata, H.8
Tanaka, S.9
Chayama, K.10
Okazaki, Y.11
Hayashizaki, Y.12
Hiyama, K.13
Nishiyama, M.14
-
393
-
-
0037015184
-
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: The panel on clinical practices for treatment of HIV
-
Dybul, M.; Fauci, A. S.; Bartlett, J. G.; Kaplan, J. E.; Pau, A. K.; Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 2002, 137, 381-433. (Pubitemid 34982041)
-
(2002)
Annals of Internal Medicine
, vol.137
, Issue.5 II
, pp. 381-433
-
-
Dybul, M.1
Fauci, A.S.2
Bartlett, J.G.3
Kaplan, J.E.4
Pau, A.K.5
-
394
-
-
12344322578
-
The intracellular pharmacology of antiretroviral protease inhibitors
-
Ford, J.; Khoo, S. H.; Back, D. J. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 2004, 54, 982-990.
-
(2004)
J. Antimicrob. Chemother.
, vol.54
, pp. 982-990
-
-
Ford, J.1
Khoo, S.H.2
Back, D.J.3
-
395
-
-
33747795961
-
What's new in antibiotic resistance? Focus on beta-lactamases
-
DOI 10.1016/j.drup.2006.05.005, PII S1368764606000446
-
Babic, M.; Hujer, A. M.; Bonomo, R. A. What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist. Updat. 2006, 9, 142-156. (Pubitemid 44279523)
-
(2006)
Drug Resistance Updates
, vol.9
, Issue.3
, pp. 142-156
-
-
Babic, M.1
Hujer, A.M.2
Bonomo, R.A.3
-
396
-
-
39049128343
-
Extended-spectrum beta-lactamase-producing Enterobacteriaceae: An emerging public-health concern
-
Pitout, J. D; Laupland, K. B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 2008, 8, 159-166.
-
(2008)
Lancet Infect. Dis.
, vol.8
, pp. 159-166
-
-
Pitout, J.D.1
Laupland, K.B.2
-
397
-
-
37249049746
-
Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: The role of piperacillin-tazobactam
-
Peterson, L. R. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin. Microbiol. Infect. 2008, 14, 181-184.
-
(2008)
Clin. Microbiol. Infect.
, vol.14
, pp. 181-184
-
-
Peterson, L.R.1
-
398
-
-
42049096412
-
Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia
-
Clark, R. E.; Davies, A.; Pirmohamed, M.; Giannoudis, A. Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk. Lymphoma 2008, 49, 639-642.
-
(2008)
Leuk. Lymphoma
, vol.49
, pp. 639-642
-
-
Clark, R.E.1
Davies, A.2
Pirmohamed, M.3
Giannoudis, A.4
|